Questions

1. Anatomical Site and Catheter Size:
   • Insertion Site: Midline infraumbilical (2 cm below the umbilicus in the linea alba) or either lower quadrant (right or left iliac fossa/lower quadrant, lateral to the rectus sheath to avoid the inferior epigastric vessels). The urinary bladder must be emptied via catheterization prior to puncture.
   • Catheter Size: 8.5 Fr to 12 Fr acute rigid/semi-rigid catheter (stylet catheter) or soft pediatric coiled/straight Tenckhoff catheter without cuff (commonly 9–11.5 Fr or 12 Fr, length 20 cm for young children).
2. Biophysical Transport Mechanisms:
   • Diffusion: Movement of solutes down their concentration gradient from mesenteric capillary blood across the semipermeable peritoneal membrane into the dialysate (primary mechanism for small solute clearance like urea, creatinine, and potassium).
   • Convection (Solute Drag): Movement of solutes dissolved in water carried across membrane pores along with the bulk fluid movement driven by hydrostatic or osmotic pressure gradients.
   • Osmotic Ultrafiltration: Transcapillary fluid movement driven by an osmotic gradient generated across the peritoneal membrane, primarily established by hypertonic dialysate dextrose.
3. Modifications to Increase Ultrafiltration:
   • Increase the dextrose concentration of the dialysate solution (e.g., step up from 1.5% or 2.5% to 4.25% dextrose).
   • Shorten the dwell time (e.g., reduce dwell to 30–45 minutes) to maintain a steep transperitoneal glucose concentration gradient before glucose absorption dissipates the osmotic drive.
   • Increase the fill volume cautiously (up to 30–40 mL/kg or 800–1000 mL/m$^2$ BSA) once tolerated, maximizing functional peritoneal surface contact area.
4. Troubleshooting Outflow Failure:
   • Positional and Mechanical Checks: Confirm all clamps are open, release kinks in external tubing, and change the child’s position (turn side-to-side, elevate the head of the bed, or ambulate if feasible) to dislodge catheter tip from peritoneal fold.
   • Rule Out Constipation: Relieve fecal impaction with glycerin suppositories or warm saline enemas, as distended bowel loops compress catheter drainage side-holes.
   • Flush Catheter: Perform gentle manual retrograde flush with 5–10 mL of sterile heparinized warm normal saline (500 units heparin/L) under strict aseptic technique to clear fibrin plugs or blood clots.
   • Imaging and Fibrinolytics: Obtain an abdominal radiograph (X-ray babygram/pelvis) to detect catheter migration, tip displacement out of the pouch of Douglas, or severe bowel distension; instill intra-catheter urokinase or alteplase (tPA) if occlusive fibrin thrombus is suspected.
5. Fill Volume Calculation and Initial Cycle Parameters:
   $$ > \begin{aligned} > \text{Initial Fill Volume} &= 10\text{ to }20\text{ mL/kg/cycle} \\ > &= 10\text{ to }20\text{ mL/kg} \times 14\text{ kg} \\ > &= \mathbf{140\text{ to }280\text{ mL/cycle}} \quad (\text{Target: } \approx 200\text{ mL initial run}) > \end{aligned} > $$
   • Initial Dwell Time: 30 to 45 minutes (total cycle time 60 minutes: 10 minutes inflow, 30–35 minutes dwell, 15–20 minutes outflow) to prevent rapid fluid shifts, peritoneal overdistension, and respiratory compromise.
6. Diagnostic Criteria for PD-Related Peritonitis:
   Diagnosis requires at least two of the following three features:
   • Clinical features consistent with peritonitis (cloudy/turbid peritoneal effluent, abdominal pain, fever, abdominal guarding/rebound).
   • Dialysate effluent white blood cell (WBC) count $>100/\mu\text{L}$ (after a minimum 2-hour dwell) with $>50\%$ polymorphonuclear leukocytes (neutrophils).
   • Positive effluent Gram stain or positive microbiological culture of dialysate effluent.

graph TD
    A[Acute Anuria / Fluid Overload / Refractory Hyperkalemia] --> B[Acute Peritoneal Dialysis Indication]
    B --> C[Bedside Percutaneous Insertion]
    C --> D{Site: Left / Right Iliac Fossa or Midline Infraumbilical}
    D --> E[Initial Volume: 10-20 mL/kg/cycle; Dwell 30-45 min]
    E --> F{Adequate Ultrafiltration & Drain?}
    F -- Yes --> G[Titrate to 30-40 mL/kg/cycle; Monitor Electrolytes]
    F -- Outflow Block --> H[Check Clamps / Turn Patient / Treat Constipation / Heparin Flush]
    F -- Poor UF --> I[Increase Dextrose to 2.5% or 4.25% / Shorten Dwell]

Acute Peritoneal Dialysis Prescription Nuances:

• Heparinization: Add 500 units of unfractionated heparin per liter of dialysate during initial runs to prevent fibrin clot formation within the small-bore catheter fenestrations.
• Potassium Addition: Standard commercial PD solutions are potassium-free. Potassium chloride (3.5–4.0 mEq/L) should only be supplemented into dialysate bags once serum potassium drops below 4.0 mEq/L to prevent rebound hypokalemia.
• Absolute Contraindications: Severe omphalocele, gastroschisis, diaphragmatic hernia, extensive intra-abdominal adhesions/peritoneal fibrosis, peritoneal membrane tears, and uncorrected abdominal wall cellulitis.

1. Neuroimaging Findings & Diagnosis:

   • Findings: Crescent-shaped (concave-convex) hyperdense extra-axial collection over the right cerebral convexity crossing cranial suture lines, causing significant mass effect, sulcal effacement, compression of the right lateral ventricle, and marked subfalcine midline shift to the left.
   • Definitive Diagnosis: Acute traumatic right hemispheric subdural hematoma (SDH) with life-threatening uncal / transtentorial herniation syndrome.

2. Vascular Anatomy & Radiologic Differences:

   • Vascular Origin: Laceration of bridging cortical veins traversing the subdural space to empty into the superior sagittal sinus or dural venous sinuses (shearing forces due to rotational acceleration-deceleration).
   • Subdural vs. Epidural Hematoma:
     • Subdural: Crescent-shaped, concave inner margin conforming to the brain contour; crosses cranial sutures but is limited by dural reflections (falx cerebri, tentorium cerebelli); located between dura mater and arachnoid mater.
     • Epidural: Biconvex/lentiform shaped, hyperdense collection; limited by cranial sutures (where dura is firmly adherent to the inner table of calvarium) but can cross the midline/dural attachments; classic arterial tear (middle meningeal artery).

3. Cerebral Perfusion Pressure (CPP) Derivation:
   

   $$ > \begin{aligned} > \text{CPP} &= \text{MAP} - \text{ICP} \\ > &= 103 \text{ mm Hg} - 28 \text{ mm Hg} \\ > &= \mathbf{75\text{ mm Hg}} \quad (\text{Target Goal: } \ge 60\text{ to } 70\text{ mm Hg}) > \end{aligned} > $$

   
   (Note: While CPP of 75 mm Hg is currently maintained due to Cushing-mediated hypertension, the ICP of 28 mm Hg is critically elevated above the treatment threshold of 20–22 mm Hg).

4. Emergency Osmotherapy Protocol:

   • First-line Option (3% Hypertonic Saline - preferred in acute trauma/hypovolemia):
     • Dose: $3\text{ to }5\text{ mL/kg}$ IV over $10\text{ to }20\text{ minutes}$.
     • For 38 kg: $\mathbf{114\text{ to }190\text{ mL}}$ of 3% NaCl bolus via central venous line or large-bore peripheral line (Target serum sodium: $145\text{--}155\text{ mEq/L}$, serum osmolarity $< 360\text{ mOsm/L}$).
   • Alternative (20% Mannitol):
     • Dose: $0.5\text{ to }1.0\text{ g/kg}$ ($2.5\text{ to }5.0\text{ mL/kg}$) IV over $20\text{ to }30\text{ minutes}$ using an inline filter (For 38 kg: $\mathbf{95\text{ to }190\text{ mL}}$ of 20% Mannitol); contraindicated if patient is hypotensive/hypovolemic.

5. Neurosurgical Indications for Operative Evacuation (Craniotomy/Craniectomy):

   • Clot thickness $> 10\text{ mm}$ on NCCT regardless of GCS.
   • Midline shift $> 5\text{ mm}$ on NCCT regardless of GCS.
   • GCS score $< 9$ with clot thickness $< 10\text{ mm}$ and midline shift $< 5\text{ mm}$ IF:
     • GCS drops by $\ge 2$ points from the time of injury to hospitalization.
     • Asymmetric, fixed, or dilated pupils are present (anisocoria).
     • Refractory Intracranial Pressure persistently exceeding $> 20\text{--}22\text{ mm Hg}$.

Algorithm for Acute Management of Severe Pediatric TBI (GCS $\le 8$)

graph TD
    A[Severe TBI: GCS <= 8] --> B[Immediate Resuscitation: Tier 0]
    B --> B1[RSI with in-line cervical stabilization]
    B --> B2[Maintain PaCO2 35-40 mmHg, PaO2 >= 100 mmHg]
    B --> B3[Target MAP > 50th centile for age; avoid hypotension]
    B --> C[Emergency Non-contrast Head CT]
    C --> D{Mass Lesion Criteria?}
    D -->|Thickness >10mm OR Midline Shift >5mm OR Herniation| E[Emergent Craniotomy / Evacuation]
    D -->|Non-surgical or Diffuse Injury| F[Place Invasive ICP Monitor]
    F --> G{ICP > 20-22 mmHg?}
    G -->|Yes| H[Tier 1: Head of bed 30°, Sedation, 3% Saline bolus]
    G -->|Refractory| I[Tier 2: Neuromuscular blockade, Mild Hypothermia, CSF drainage]
    G -->|Refractory| J[Tier 3: Decompressive Craniectomy, High-dose Barbiturates]

Key Pearls:

• Cushing Triad: The triad of systemic hypertension with widened pulse pressure, bradycardia, and irregular/agonal respirations indicates imminent or active brainstem herniation through the foramen magnum.
• Avoid Prophylactic Hyperventilation: Prophylactic hyperventilation ($PaCO_2 < 30\text{ mm Hg}$) in the first 24 hours induces severe cerebral vasoconstriction and worsens secondary cerebral ischemia. Hyperventilation is strictly reserved as a temporary temporizing measure for active uncal herniation while transitioning to the operating room.

1. Definitive Diagnosis & Classification:

   • Diagnosis: Acute Clinical Tumor Lysis Syndrome (TLS), Grade 3 (due to acute kidney injury / oliguria).
   • Standardized Classification: Cairo-Bishop Classification (or Howard Classification).

2. Cairo-Bishop Diagnostic Criteria:

   • Laboratory TLS (LTLS): Presence of $\ge 2$ of the following metabolic derangements occurring within 3 to 7 days after starting cytotoxic therapy:
     • Hyperuricemia: Uric acid $\ge 8.0\text{ mg/dL}$ ($\ge 476\ \mu\text{mol/L}$) or $25\%$ increase from baseline.
     • Hyperkalemia: Potassium $\ge 6.0\text{ mEq/L}$ ($\ge 6.0\text{ mmol/L}$) or $25\%$ increase from baseline.
     • Hyperphosphatemia: Phosphorus $\ge 6.5\text{ mg/dL}$ ($\ge 2.1\text{ mmol/L}$) in children or $25\%$ increase from baseline.
     • Hypocalcemia: Corrected serum calcium $\le 7.0\text{ mg/dL}$ ($\le 1.75\text{ mmol/L}$) or ionized calcium $< 1.12\text{ mg/dL}$ ($< 0.3\text{ mmol/L}$) or $25\%$ decrease from baseline.
   • Clinical TLS (CTLS): Presence of Laboratory TLS plus at least one of the following clinical complications not directly attributable to therapeutic agent:
     • Renal: Serum creatinine $\ge 1.5\times$ upper limit of normal for age (or oliguria/anuria).
     • Cardiac: Cardiac arrhythmia or sudden death.
     • Neurological: Seizure, tetany, or altered mental status.

3. Hyperhydration Strategy:

   • Fluid Volume / Rate:
     $$ > \begin{aligned} > \text{Rate} &= 3000\text{ mL/m}^2/\text{day} \quad (\text{or } 1.5\text{ to } 2\times \text{maintenance}) \\ > &= 3000 \times 0.68\text{ m}^2 = 2040\text{ mL/day} \approx \mathbf{85\text{ mL/hour}} > \end{aligned} > $$
   • Composition: $0.45\text{–}0.9\%$ Normal Saline in $5\%$ Dextrose. Strictly omit potassium and phosphate from intravenous fluids. Avoid urinary alkalinization (sodium bicarbonate is no longer recommended due to risk of calcium phosphate precipitation and worsened hypocalcemia).
   • Target Physiological Endpoints:
     • Urine output $\ge 2\text{ mL/kg/hour}$ (or $\ge 100\text{ mL/m}^2/\text{hour}$).
     • Urine specific gravity $\le 1.010$.

4. Hypouricemic Pharmacotherapy:

   • Rasburicase (Recombinant Urate Oxidase) — Drug of choice for established/high-risk TLS:
     • Mechanism: Converts insoluble uric acid into soluble allantoin, which is easily excreted by the kidneys.
     • Dose: $0.15\text{–}0.2\text{ mg/kg/dose}$ IV infusion in $50\text{ mL}$ $0.9\%$ NS over 30 minutes once daily for 1–3 days (or single fixed-dose $3\text{ mg}$ or $6\text{ mg}$).
     • Contraindication: Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency (risk of severe methemoglobinemia and hemolytic anemia).
   • Allopurinol (Used for low/intermediate risk or where rasburicase is contraindicated):
     • Mechanism: Competitive inhibitor of xanthine oxidase, preventing formation of new uric acid from xanthine and hypoxanthine (does not break down existing uric acid).
     • Dose: $10\text{ mg/kg/day}$ PO divided q8h (maximum $300\text{–}400\text{ mg/m}^2/\text{day}$ or $400\text{–}800\text{ mg/day}$).

5. Management of Severe Hyperkalemia and Hyperphosphatemia:

   • Hyperkalemia with ECG Changes:
     • Membrane Stabilization: Intravenous Calcium Gluconate $10\%$ at $0.5\text{–}1.0\text{ mL/kg}$ ($50\text{–}100\text{ mg/kg}$) slow IV over 5–10 minutes under continuous cardiac monitoring.
     • Intracellular Shift:
       • Regular Insulin ($0.1\text{ unit/kg}$) with $25\%$ Dextrose ($2\text{ mL/kg}$) IV over 30 minutes.
       • Nebulized Salbutamol ($2.5\text{ mg}$ if $<25\text{ kg}$, $5.0\text{ mg}$ if $>25\text{ kg}$) over 15 minutes.
     • Elimination: Loop diuretics (e.g., Furosemide $1\text{ mg/kg}$ IV) once intravascular volume is re-expanded; Potassium-binding resins (e.g., Sodium/Calcium Polystyrene Sulfonate $1\text{ g/kg}$ PO or PR).
   • Hyperphosphatemia:
     • Hyperhydration and forced diuresis.
     • Non-calcium, non-aluminum oral phosphate binders (e.g., Sevelamer carbonate $30\text{–}50\text{ mg/kg/dose}$ PO three times daily with meals).
     • Note on Hypocalcemia: Treat hypocalcemia only if symptomatic (tetany, seizures, QT prolongation) to avoid worsening calcium-phosphate metastatic soft tissue and renal tubular precipitation ($\text{Ca} \times \text{PO}_4\text{ product} > 60\text{ mg}^2/\text{dL}^2$).
     • Renal Replacement Therapy (Hemodialysis / CRRT): Indicated for refractory hyperkalemia ($>7.0\text{ mEq/L}$), rapid rise in potassium, refractory fluid overload, severe symptomatic hypocalcemia, or oliguria/anuria unresponsive to medical therapy.

graph TD
    A[Massive Tumor Cell Lysis] --> B[Intracellular Release]
    B --> C[Uric Acid]
    B --> D[Potassium]
    B --> E[Phosphorus]
    
    C --> F[Uric Acid Crystallization in Renal Tubules]
    D --> G[Cardiac Arrhythmias & Conduction Blocks]
    E --> H[Calcium Phosphate Precipitation]
    
    H --> I[Acute Tubular Obstruction]
    H --> J[Secondary Hypocalcemia]
    J --> K[Neuromuscular Tetany, Seizures, Prolonged QTc]
    
    F --> L[Acute Oliguric Kidney Injury]
    I --> L
    L --> M[Failure to Excrete K & P: Vicious Cycle]

Key Management Pitfalls in TLS:

1. Routine Alkalinization of Urine: Previously, intravenous sodium bicarbonate was administered to target a urine pH $> 7.0$. Current consensus guidelines strongly discourage this practice. Alkalinization decreases the solubility of calcium phosphate and hypoxanthine/xanthine (especially when allopurinol is used), precipitating obstructive nephropathy and worsening acute renal failure.
2. Aggressive Calcium Repletion: Exogenous calcium infusion combines rapidly with high serum phosphorus, forming insoluble calcium phosphate crystals ($\text{Ca} \times \text{P} > 60$). Only symptomatic hypocalcemia should receive minimum calcium gluconate to alleviate clinical tetany or arrhythmogenic QTc prolongation.
3. Rasburicase Blood Sampling Artifact: If blood drawn for uric acid testing is kept at room temperature, ex-vivo rasburicase continues to degrade uric acid in the tube, resulting in falsely low reported levels. Samples must be placed immediately on wet ice and analyzed within 4 hours.

1. Clinical Indications for Adrenaline:

   • Acute severe anaphylaxis (first-line therapy)
   • Pediatric cardiopulmonary arrest (asystole, pulseless electrical activity, or shock-refractory pulseless ventricular tachycardia / ventricular fibrillation)
   • Symptomatic bradycardia unresponsive to oxygenation, ventilation, and vagolytic therapy
   • Moderate-to-severe viral croup (laryngotracheobronchitis) or post-extubation subglottic edema
   • Fluid-refractory vasodilatory (warm) or cardiogenic (cold) septic shock
   • Life-threatening acute severe asthma exacerbation unresponsive to inhaled beta-2 agonists
   • Overdose/toxicity from beta-adrenergic antagonists or calcium channel blockers

2. Formulations, Routes, and Dosing:

   • Anaphylaxis: Intramuscular (IM) injection into the anterolateral mid-thigh; 1:1,000 solution ($1\text{ mg/mL}$); $0.01\text{ mg/kg}$ ($0.01\text{ mL/kg}$), maximum single dose $0.3\text{ mg}$ ($0.3\text{ mL}$) in prepubertal children ($0.5\text{ mg}$ in adolescents).
   • Cardiopulmonary Arrest: Intravenous/intraosseous (IV/IO); 1:10,000 solution ($0.1\text{ mg/mL}$); $0.01\text{ mg/kg}$ ($0.1\text{ mL/kg}$), maximum single dose $1\text{ mg}$ ($10\text{ mL}$), repeated every 3 to 5 minutes. (Endotracheal route if IV/IO unavailable: $0.1\text{ mg/kg}$ of 1:1,000 solution [$0.1\text{ mL/kg}$]).
   • Croup (Stridor at Rest): Nebulized via oxygen face mask; 1:1,000 standard L-adrenaline; $0.5\text{ mL/kg/dose}$ (maximum dose $5\text{ mL}$), diluted to a total volume of $3\text{ to }5\text{ mL}$ with normal saline.
   • Vasoactive Infusion for Shock: Continuous IV/IO infusion via central venous access preferred; $0.05\text{ to }1.0\text{ mcg/kg/min}$, titrated rapidly to mean arterial pressure and perfusion targets.

3. Mathematical Calculations (Child Weight = 15 kg):

   • Acute Anaphylaxis (IM):
     $$ > \begin{aligned} > \text{Target Dose} &= 15\text{ kg} \times 0.01\text{ mg/kg} = 0.15\text{ mg} \\ > \text{Concentration} &= 1:1,000 \equiv 1\text{ mg/mL} \\ > \text{Volume to Administer} &= \frac{0.15\text{ mg}}{1\text{ mg/mL}} = \mathbf{0.15\text{ mL}} \quad (\text{IM anterolateral thigh}) > \end{aligned} > $$
   • Cardiopulmonary Arrest (IV/IO):
     $$ > \begin{aligned} > \text{Target Dose} &= 15\text{ kg} \times 0.01\text{ mg/kg} = 0.15\text{ mg} \\ > \text{Concentration} &= 1:10,000 \equiv 0.1\text{ mg/mL} \\ > \text{Volume to Administer} &= \frac{0.15\text{ mg}}{0.1\text{ mg/mL}} = \mathbf{1.5\text{ mL}} \quad (\text{IV/IO push with flush}) > \end{aligned} > $$

4. Pharmacodynamics and Complications:

   • Receptor Affinity by Infusion Rate:
     • Low-to-moderate doses ($< 0.1\text{ mcg/kg/min}$): Predominant $\beta_1$ (increased myocardial inotropy, chronotropy) and $\beta_2$ adrenergic activation (bronchodilation, peripheral vasodilation).
     • High doses ($> 0.1\text{ mcg/kg/min}$): Predominant $\alpha_1$ adrenergic activation overrides $\beta_2$ effects, causing potent systemic and pulmonary vasoconstriction, increasing systemic vascular resistance and afterload.
   • Complications of Inadvertent Rapid IV Push:
     • Severe acute hypertensive crisis leading to intracerebral hemorrhage or acute left ventricular failure/pulmonary edema
     • Malignant tachyarrhythmias (sustained ventricular tachycardia, ventricular fibrillation) or myocardial ischemia

Practical Bedside Infusion Preparation

To prepare an epinephrine infusion without smart pumps using the Rule of 6:

• For this 15 kg child: $0.6 \times 15 = 9\text{ mg}$ of adrenaline in $100\text{ mL}$ $5\%$ Dextrose or Normal Saline.
• At this dilution: $1\text{ mL/hr}$ delivers precisely $0.1\text{ mcg/kg/min}$.

graph TD
    A[Adrenaline Concentration Selection] --> B{Clinical Scenario?}
    B -->|Anaphylaxis| C["1:1,000 (1 mg/mL)"]
    C --> D["0.01 mL/kg IM (Max 0.3-0.5 mL)"]
    B -->|Cardiac Arrest| E["1:10,000 (0.1 mg/mL)"]
    E --> F["0.1 mL/kg IV/IO (Max 10 mL)"]
    B -->|Croup / Airway Edema| G["1:1,000 (1 mg/mL)"]
    G --> H["0.5 mL/kg Nebulized (Max 5 mL)"]
    B -->|Septic / Cardiogenic Shock| I["Continuous Infusion"]
    I --> J["0.05 - 1.0 mcg/kg/min Central IV/IO"]

1. Alveolar Gas Equation and $P_A O_2$ Calculation:

   • Formula:
     $$P_A O_2 = \left[(P_B - P_{H_2O}) \times FiO_2\right] - \frac{PaCO_2}{R}$$
   • Mathematical derivation:
     $$ > \begin{aligned} > P_I O_2 &= (697 - 47) \times 0.21 = 650 \times 0.21 = 136.5\text{ mmHg} \\ > P_A O_2 &= 136.5 - \left(\frac{28}{0.8}\right) \\ > &= 136.5 - 35 \\ > &= \mathbf{101.5\text{ mmHg}} > \end{aligned} > $$

2. Alveolar-Arterial Oxygen Gradient ($P_{(A-a)}O_2$):
   

   $$ > \begin{aligned} > P_{(A-a)}O_2 &= P_A O_2 - PaO_2 \\ > &= 101.5 - 55 \\ > &= \mathbf{46.5\text{ mmHg}} > \end{aligned} > $$
   • Normal physiological limit: Typically $< 10\text{ to }15\text{ mmHg}$ in a healthy adolescent breathing room air (or predicted by $\frac{\text{Age}}{4} + 4 = \frac{16}{4} + 4 = 8\text{ mmHg}$).

3. Clinical Interpretation of Oxygenation Gradient:

   • Elevated Gradient: The $P_{(A-a)}O_2$ of $46.5\text{ mmHg}$ is markedly widened.
   • Physiological Deductions:
     • Hypoxemia caused solely by hypobaric altitude hypoxia (reduced $P_I O_2$) or primary alveolar hypoventilation produces a normal $P_{(A-a)}O_2$ gradient.
     • An elevated $P_{(A-a)}O_2$ gradient confirms an intrinsic intrapulmonary gas exchange abnormality, primarily ventilation-perfusion ($V/Q$) mismatch secondary to acute bronchospasm (exercise/cold air-induced asthma exacerbation), with or without early high-altitude pulmonary edema (HAPE).

4. Emergency Procedural Checklist and Pharmacotherapy:

   • Oxygenation: High-flow supplemental oxygen via non-rebreathing mask (NRBM) titrated to maintain $SpO_2 \ge 92\%$.
   • Inhaled Bronchodilators:
     • Nebulized Salbutamol: $2.5\text{ to }5\text{ mg}$ (or $0.15\text{ mg/kg}$) every 20 minutes for 3 doses, then hourly.
     • Nebulized Ipratropium bromide: $500\ \mu\text{g}$ added to salbutamol every 20 minutes for the first hour.
   • Systemic Corticosteroids:
     • Intravenous Methylprednisolone: $1\text{ to }2\text{ mg/kg}$ stat (or oral Prednisolone $1\text{ to }2\text{ mg/kg}$, maximum $60\text{ mg}$).
   • Altitude Management / Disposition:
     • Immediate cessation of physical exertion; keep warm.
     • Strict restriction against further ascent; arrange immediate descent of at least $500\text{ to }1,000\text{ meters}$ if clinical response to bronchodilators is incomplete or signs of HAPE (crackles, worsening tachypnea) develop.

Diagnostic Algorithm for Hypoxemia Based on Alveolar Gas Metrics

flowchart TD
    A[Hypoxemia: PaO2 < 60 mmHg or SpO2 < 90%] --> B[Calculate PAO2 using Alveolar Gas Equation]
    B --> C[Calculate A-a Gradient: PAO2 - PaO2]
    C --> D{A-a Gradient Normal?}
    D -- Yes (< 10-15 mmHg) --> E[Low Inspired FiO2 / High Altitude OR Alveolar Hypoventilation]
    E --> E1[Hypoventilation: High PaCO2]
    E --> E2[High Altitude: Normal or Low PaCO2]
    D -- No (Elevated > 15-20 mmHg) --> F[Intrinsic Lung Pathology]
    F --> G[V/Q Mismatch: Responds to 100% O2 e.g., Asthma, COPD, Mild PE]
    F --> H[Right-to-Left Shunt: Poor response to 100% O2 e.g., Cyanotic Heart Disease, Severe ARDS]
    F --> I[Diffusion Impairment: e.g., Interstitial Lung Disease]

Key Clinical Nuance

Cold, dry air at high altitudes combined with strenuous hyperpnea regularly precipitates acute bronchospasm in individuals with bronchial hyperreactivity. Recognizing that the alveolar-arterial gradient is elevated prevents clinicians from erroneously attributing the entire hypoxemia to altitude exposure alone, thereby expediting lifesaving bronchodilator and anti-inflammatory administration.

1. Radiological Abnormality & Clinical Diagnosis:
   • Bilateral, diffuse, non-cardiogenic alveolar and interstitial infiltrates ("white-out" appearance) sparing the cardiothoracic ratio.
   • Pediatric Acute Respiratory Distress Syndrome (PARDS).
2. PALICC-2 Diagnostic Criteria:
   • Timing: Onset within 7 days of a known clinical insult or new/worsening respiratory symptoms.
   • Origin of Edema: Respiratory failure not fully explained by cardiac dysfunction, heart failure, or fluid overload.
   • Radiographic Imaging: Bilateral infiltrates on chest radiograph or computed tomography (or bilateral B-lines/consolidations on lung ultrasound) consistent with acute pulmonary parenchymal disease.
   • Oxygenation Deficit (Invasive Mechanical Ventilation):
     • Mild PARDS: $4 \le \text{OI} < 8$ (or $5 \le \text{OSI} < 7.5$)
     • Moderate PARDS: $8 \le \text{OI} < 16$ (or $7.5 \le \text{OSI} < 12.3$)
     • Severe PARDS: $\text{OI} \ge 16$ (or $\text{OSI} \ge 12.3$)
3. Mathematical Calculation:
   $$ > \begin{aligned} > \text{Oxygenation Index (OI)} &= \frac{\text{MAP } (\text{cmH}_2\text{O}) \times \text{FiO}_2 \times 100}{\text{PaO}_2\ (\text{mmHg})} \\ > &= \frac{12 \times 0.60 \times 100}{60} \\ > &= \frac{720}{60} \\ > &= \mathbf{12} \quad (\text{Moderate PARDS: } 8 \le \text{OI} < 16) > \end{aligned} > $$
4. Lung-Protective Mechanical Ventilation Strategy:
   • Tidal Volume ($\text{V}_t$): Low tidal volume ventilation at $4\text{ to }6\text{ mL/kg}$ of predicted body weight ($64\text{--}96\text{ mL}$ for this 16 kg child).
   • Inspiratory Pressure Limits: Maintain plateau pressure ($\text{P}_{\text{plat}}$) $\le 28\text{ cmH}_2\text{O}$ (or up to $32\text{ cmH}_2\text{O}$ if chest wall elastance is increased).
   • Positive End-Expiratory Pressure (PEEP): Moderate to high PEEP titrated according to the ARDS Network PEEP/$\text{FiO}_2$ titration table (typically $10\text{--}14\text{ cmH}_2\text{O}$ for moderate PARDS) to achieve recruitment while monitoring driving pressure ($\Delta P = \text{P}_{\text{plat}} - \text{PEEP} \le 15\text{ cmH}_2\text{O}$).
   • Gas Exchange Targets: Permissive hypercapnia ($\text{pH } 7.20\text{--}7.30$) and target $\text{SpO}_2\ 92\text{--}97\%$ (or $88\text{--}92\%$ on PEEP $\ge 10\text{ cmH}_2\text{O}$).

1. Waveform Identification:
   • A: End-diastolic arterial pressure
   • B: Peak systolic arterial pressure
   • C: Dicrotic notch (incisura)
   • D: Systolic ejection phase (anacrotic limb)
   • E: Diastolic runoff phase (catacrotic limb)
2. Physiologic Significance of Marker C:
   • Closure of the aortic valve marking the transition from mechanical ventricular systole to diastole.
   • A dicrotic notch positioned low on the downstroke indicates low systemic vascular resistance (vasodilatory/warm shock), whereas a high notch indicates elevated systemic vascular resistance (cold shock/vasoconstriction).
3. Preferred Pediatric Arterial Cannulation Sites:
   • Radial artery (first choice; non-dominant hand preferred)
   • Femoral artery
   • Posterior tibial artery
   • Dorsalis pedis artery (alternative: axillary or brachial artery when distal access is unavailable)
4. Damping Characteristics & Evaluation:
   • Underdamping: System oscillation produces false elevation of systolic pressure and falsely decreased diastolic pressure (mean arterial pressure remains accurate); associated with ringing/excessive resonance.
   • Overdamping: High-frequency components are lost due to compliant tubing, blood clots, or air bubbles, producing a blunted peak systolic pressure and falsely elevated diastolic pressure.
   • Bedside Test: Fast-flush test (square-wave test) evaluating dynamic response via natural frequency and damping coefficient.

1. Formula for Total Arterial Oxygen Content ($\text{CaO}_2$):
   $$ > \text{CaO}_2 = (1.34 \times \text{Hb} \times \text{SaO}_2) + (0.0031 \times \text{PaO}_2) > $$
   • Where $\text{Hb}$ is in $\text{g/dL}$, $\text{SaO}_2$ is a fraction ($0\text{ to }1.0$), $\text{PaO}_2$ is in $\text{mmHg}$, and the result is expressed in $\text{mL O}_2/\text{dL}$ (or $\text{vol}\%$).
2. Calculations:
   • Patient A:
     $$ > \begin{aligned} > \text{Bound } \text{O}_2 &= 1.34 \times 6.0 \times 0.96 = 7.718\text{ mL/dL} \\ > \text{Dissolved } \text{O}_2 &= 0.0031 \times 85 = 0.264\text{ mL/dL} \\ > \mathbf{\text{CaO}_2\ (\text{Patient A})} &= 7.718 + 0.264 = \mathbf{7.98\text{ mL/dL}} > \end{aligned} > $$
   • Patient B:
     $$ > \begin{aligned} > \text{Bound } \text{O}_2 &= 1.34 \times 14.0 \times 0.86 = 16.134\text{ mL/dL} \\ > \text{Dissolved } \text{O}_2 &= 0.0031 \times 55 = 0.171\text{ mL/dL} \\ > \mathbf{\text{CaO}_2\ (\text{Patient B})} &= 16.134 + 0.171 = \mathbf{16.31\text{ mL/dL}} > \end{aligned} > $$
3. Comparison & Physiological Interpretation:
   • Patient A is significantly more hypoxemic despite having a normal $\text{PaO}_2$ ($85\text{ mmHg}$) and satisfactory $\text{SaO}_2$ ($96\%$).
   • Physiological Basis: Over $98\%$ of circulating oxygen is bound to hemoglobin. Severe anemia ($\text{Hb } 6.0\text{ g/dL}$) halves the total oxygen-carrying capacity. Dissolved oxygen contributes minimally ($< 2\%$). Therefore, Patient A delivers less than half the oxygen per deciliter of blood compared to Patient B ($\text{CaO}_2\ 7.98\text{ vs } 16.31\text{ mL/dL}$).
4. Management Priorities:
   • Patient A: Emergency packed red blood cell transfusion ($10\text{--}15\text{ mL/kg}$) to directly raise hemoglobin concentration and restore arterial oxygen content; optimize cardiac output.
   • Patient B: Correct acute hypoventilation/hypercapnic respiratory failure via non-invasive or invasive positive pressure ventilation, optimize lung recruitment, and augment $\text{FiO}_2$ to improve $\text{SaO}_2$ and $\text{PaO}_2$.

1. SAAG Calculation & Interpretation:
   $$ > \begin{aligned} > \text{SAAG} &= \text{Serum Albumin} - \text{Ascitic Fluid Albumin} \\ > &= 3.2\text{ g/dL} - 1.1\text{ g/dL} \\ > &= \mathbf{2.1\text{ g/dL}} > \end{aligned} > $$
   • Interpretation: $\text{SAAG} \ge 1.1\text{ g/dL}$ establishes transudative ascites driven by portal hypertension with $> 97\%$ diagnostic accuracy. Combined with an ascitic total protein $< 2.5\text{ g/dL}$, it indicates sinusoidal/presinusoidal portal hypertension (e.g., cirrhosis or extrahepatic portal vein obstruction).
2. Classification & Pediatric Causes:
   • High SAAG ($\ge 1.1\text{ g/dL}$):
     • Extrahepatic portal venous obstruction (EHPVO) / Banti syndrome
     • Cirrhosis (biliary atresia, Wilson disease, autoimmune hepatitis)
     • Budd-Chiari syndrome / hepatic vein thrombosis
     • Right-sided congestive heart failure / constrictive pericarditis
   • Low SAAG ($< 1.1\text{ g/dL}$):
     • Nephrotic syndrome (hypoalbuminemia without portal hypertension)
     • Peritoneal tuberculosis
     • Peritoneal carcinomatosis / lymphoma
     • Pancreatic ascites
3. Chylous Ascites Criteria & Surgical Causes:
   • Diagnostic Cutoff: Peritoneal fluid triglyceride concentration $> 110\text{ mg/dL}$ (or $> 1.2\text{ mmol/L}$) with milky gross appearance.
   • Associated Procedures:
     • Fontan procedure or bidirectional Glenn shunt (due to elevated central venous pressure)
     • Surgical repair of congenital diaphragmatic hernia, retroperitoneal tumor resection (neuroblastoma), or mesenteric lymphangioma excision disrupting the cisterna chyli.
4. Spontaneous Bacterial Peritonitis (SBP) & Treatment:
   • Diagnostic Threshold: Ascitic fluid absolute neutrophil count (ANC) $\ge 250\text{ cells}/\mu\text{L}$ ($\ge 0.25 \times 10^9/\text{L}$), calculated as $\text{Total WBC} \times \% \text{neutrophils}$.
   • Empirical Regimen: IV Cefotaxime ($150\text{ mg/kg/day}$ divided q8h) OR IV Ceftriaxone ($75\text{--}100\text{ mg/kg/day}$ single daily dose or divided q12h) for $5\text{--}7$ days, plus IV Albumin ($1.5\text{ g/kg}$ on day 1, followed by $1.0\text{ g/kg}$ on day 3) to prevent hepatorenal syndrome.

1. Herniation Patterns:
   • 1: Cingulate (subfalcine) herniation
   • 2: Central (transtentorial) herniation
   • 3: Uncal (lateral transtentorial) herniation
   • 4: Transcalvarial (external) herniation
   • 5: Upward (ascending transtentorial/cerebellar) herniation
   • 6: Tonsillar herniation (foramen magnum impaction)
2. Uncal Herniation Clinical Manifestations & Mechanisms:
   • Ipsilateral Pupillary Dilation (Mydriasis): Medial compression of the oculomotor nerve (cranial nerve III) parasympathetic fibers against the tentorial notch, leading to loss of parasympathetic pupilloconstriction.
   • Contralateral Hemiparesis: Compression of the descending ipsilateral corticospinal tract within the cerebral peduncle (or paradoxical ipsilateral hemiparesis via Kernohan's notch phenomenon compressing the opposite peduncle).
   • Progressive Depressed Sensorium: Compression of the midbrain ascending reticular activating system (ARAS).
3. Acute Medical ICP Reduction Bundle:
   • Positioning & Drainage: Head midline, elevated $30^\circ$; avoid tight endotracheal tube ties restricting internal jugular venous drainage.
   • Hyperosmolar Therapy:
     • Hypertonic Saline ($3\%$ NaCl): $3\text{--}5\text{ mL/kg}$ IV bolus over $10\text{--}15\text{ minutes}$ (target serum sodium $145\text{--}155\text{ mEq/L}$, serum osmolality $< 360\text{ mOsm/kg}$).
     • OR Mannitol ($20\%$): $0.5\text{--}1.0\text{ g/kg}$ ($2.5\text{--}5\text{ mL/kg}$) IV over 20 minutes (provided systolic blood pressure is normovolemic; target osmolality $< 320\text{ mOsm/kg}$).
   • Ventilation & Temperature: Endotracheal intubation with rapid sequence induction; mild hyperventilation to target $\text{PaCO}_2\ 30\text{--}35\text{ mmHg}$ as a temporary rescue; avoid hypoxemia ($\text{PaO}_2 \ge 80\text{ mmHg}$); maintain strict normothermia ($36.0\text{--}37.0^\circ\text{C}$).
   • Sedation & Analgesia: Continuous infusions of fentanyl and midazolam or propofol (avoiding hypotension) with neuromuscular blockade if patient-ventilator dyssynchrony raises intrathoracic/intracranial pressure.
4. Cushing Triad & Significance:
   • Components:
     • Systemic hypertension (with widened pulse pressure)
     • Bradycardia
     • Irregular or depressed respirations (Cheyne-Stokes or ataxic breathing)
   • Pathophysiology & Significance: Life-threatening sign of imminent brainstem herniation and terminal cerebral hypoperfusion. Ischemia of the medullary vasomotor center triggers massive sympathetic outflow causing vasoconstriction/hypertension, which activates baroreceptors inducing reflex parasympathetic bradycardia, while medullary respiratory center distortion disrupts normal respiratory rhythm.

1. Immediate Life-Threatening Complication & Indications for Intubation:
   • Primary Complication: Acute upper airway obstruction secondary to thermal and inhalational injury with progressive mucosal edema.
   • Clinical Indications for Urgent Intubation:
     • Stridor, hoarseness, or brassy cough
     • Singed nasal hairs, facial burns, soot or carbonaceous debris in the oropharynx
     • Tachypnea, intercostal/subcostal retractions, or hypoxemia ($\text{SpO}_2 < 94\%$ on room air)
     • Extensive full-thickness burns involving the face and circumferential neck burns
2. Fluid Requirement Calculations:
   • Parkland Resuscitation Fluid (Ringers Lactate):
     $$ > \begin{aligned} > \text{Fluid Volume} &= 4\text{ mL} \times \text{Weight (kg)} \times \text{\% TBSA burned} \\ > &= 4\text{ mL} \times 16\text{ kg} \times 60 \\ > &= \mathbf{3840\text{ mL}} \quad (\text{over first 24 hours}) > \end{aligned} > $$
   • Maintenance Fluid (Holliday-Segar Formula):
     $$ > \begin{aligned} > \text{Maintenance Volume} &= 1000\text{ mL (first 10 kg)} + 50\text{ mL/kg} \times 6\text{ kg} \\ > &= 1000 + 300 \\ > &= \mathbf{1300\text{ mL/24 hours}} \quad (\approx 54\text{ mL/hour}) > \end{aligned} > $$
3. Administration Schedule and Fluid Selection:
   • Crystalloid Selection: Resuscitation requires balanced salt crystalloid (Ringer's Lactate or Plasmalyte). Maintenance in young children requires dextrose-containing fluid (e.g., D5 0.45% Normal Saline with 20 mEq/L KCl) to prevent hypoglycemia.
   • Infusion Schedule (Parkland):
     • First 8 hours (calculated from the exact time of the burn, not emergency department arrival): Administer half of the total resuscitation volume ($1920\text{ mL}$) plus maintenance ($433\text{ mL}$) = $\mathbf{294\text{ mL/hour}}$.
     • Next 16 hours: Administer the remaining half ($1920\text{ mL}$) plus maintenance ($867\text{ mL}$) = $\mathbf{174\text{ mL/hour}}$.
   • Titration Endpoint: Titrate fluid rates targeting a pediatric urine output of $1.0\text{ to }1.5\text{ mL/kg/hour}$.
4. Causes of Burn Mortality:
   • Early Mortality (<72 hours):
     • Acute asphyxia and carbon monoxide (CO) / hydrogen cyanide poisoning
     • Acute upper airway obstruction from progressive edema
     • Refractory burn hypovolemic/distributive shock
   • Late Mortality (>72 hours):
     • Systemic sepsis (most commonly Pseudomonas aeruginosa, Staphylococcus aureus, or invasive fungal infection)
     • Multi-Organ Dysfunction Syndrome (MODS)
     • Acute Respiratory Distress Syndrome (ARDS) and ventilator-associated pneumonia

1. Phases of a Normal Capnogram:
   • Phase I (Inspiratory Baseline): Exhalation of $\text{CO}_2$-free gas from the anatomical dead space (trachea, large bronchi, and ventilator circuit). The baseline should remain at $0\text{ mmHg}$.
   • Phase II (Expiratory Upstroke): Rapid rise in $\text{PCO}_2$ representing a mixed transition of anatomical dead space gas and alveolar gas.
   • Phase III (Alveolar Plateau): Exhalation of purely alveolar gas. The slope is slightly upward owing to uneven alveolar emptying; the peak value at the end of this phase represents end-tidal $\text{CO}_2$ ($\text{EtCO}_2$).
   • Phase 0 / IV (Inspiratory Downstroke): Rapid downward deflection to baseline as fresh, $\text{CO}_2$-free inspiratory gas washes over the sensor during inhalation.
2. Abnormal Capnographic Waveforms:
   • Curare Cleft:
     • Appearance: A dip or cleft occurring in the latter third of the Phase III alveolar plateau.
     • Significance: Indicates diaphragmatic contraction against the ventilator, signaling recovery/wearing off of neuromuscular blockade or patient-ventilator dyssynchrony.
   • "Shark-Fin" Contour:
     • Appearance: Slanted, prolonged Phase II upstroke with an increased Phase III slope lacking a flat plateau.
     • Significance: Expiratory airflow obstruction, typical of acute severe asthma, bronchospasm, or mechanical endotracheal tube kinking.
3. Differentials for Sudden Loss of $\text{EtCO}_2$ ($\text{EtCO}_2 = 0\text{ mmHg}$):
   • Accidental extubation or displacement into the pharynx
   • Complete endotracheal tube obstruction (mucus plug, kinking)
   • Ventilator circuit disconnection or catastrophic ventilator failure
   • Sudden circulatory arrest / pulseless cardiac arrest (loss of pulmonary perfusion)
   • Esophageal intubation (if immediately following intubation attempts)
4. Mainstream vs Sidestream Capnometers:
   • Mainstream: Sensor placed directly between endotracheal tube and breathing circuit. Rapid real-time response time with no sampling line delay; cannot be occluded by secretions, but adds mechanical dead space and weight, increasing accidental extubation risk.
   • Sidestream: Aspirates gas via a small capillary tube to a console sensor. Allows use in non-intubated patients (via nasal prongs), introduces a transit time delay ($1\text{ to }2\text{ seconds}$), and is prone to moisture/secretions blocking the sampling line.

1. Core Cardiac Arrest Rhythms:
   • Shockable Rhythms:
     • Ventricular Fibrillation (VF)
     • Pulseless Ventricular Tachycardia (pVT)
   • Non-Shockable Rhythms:
     • Asystole
     • Pulseless Electrical Activity (PEA) / Electromechanical Dissociation
2. PALS Defibrillation Energy Dosing:
   $$ > \begin{aligned} > \text{Initial Shock Dose} &= \mathbf{2\text{ J/kg}} \\ > \text{Second Shock Dose} &= \mathbf{4\text{ J/kg}} \\ > \text{Subsequent Shock Doses} &\ge \mathbf{4\text{ J/kg}} \quad (\text{titrate to max } 10\text{ J/kg or adult dose: } 200\text{ J}) > \end{aligned} > $$
3. Epinephrine Administration in Pediatric Cardiac Arrest:
   • Dose: $0.01\text{ mg/kg}$ ($0.1\text{ mL/kg}$ of the $1:10,000$ concentration; $0.1\text{ mg/mL}$).
   • Route: Intravenous (IV) or Intraosseous (IO), followed by a $5\text{ mL}$ normal saline flush.
   • Frequency: Every $3\text{ to }5\text{ minutes}$ during continuous resuscitation.
   • Timing:
     • Non-shockable (Asystole/PEA): Administer as soon as vascular access is established.
     • Shockable (VF/pVT): Administer after the second unsuccessful defibrillation shock.
4. Reversible Causes ("H's and T's"):
   • The H's:
     • Hypovolemia
     • Hypoxia
     • Hydrogen ion (Acidosis)
     • Hypoglycemia
     • Hypokalemia / Hyperkalemia
     • Hypothermia
   • The T's:
     • Tension pneumothorax
     • Tamponade (cardiac)
     • Toxins / toxic ingestions
     • Thrombosis (pulmonary embolism)
     • Thrombosis (coronary)

1. Indication and Clinical Objectives:
   • Validated scoring system for assessing distress, pain, and sedation levels in critically ill, mechanically ventilated pediatric patients from neonates up to adolescence.
   • Prevents under-sedation (ventilator dyssynchrony, accidental extubation, hypercatabolism) and over-sedation (prolonged mechanical ventilation, delirium, tolerance, withdrawal, hemodynamic instability).
   • Facilitates objective nurse-driven titration protocols for sedative and opioid infusions.
2. Items of the Original COMFORT Scale:
   • The score evaluates 8 distinct parameters (each scored 1 to 5):
     • Behavioral Dimensions (6 items):
       • Alertness
       • Calmness / Agitation
       • Respiratory response (in ventilated children) / Crying (in non-ventilated children)
       • Physical movement
       • Muscle tone
       • Facial tension
     • Physiological Dimensions (2 items):
       • Baseline heart rate change
       • Baseline mean arterial blood pressure (MAP) change
         (Note: The COMFORT-Behavior [COMFORT-B] scale excludes the two physiological parameters due to confounding by hemodynamic shifts and inotropic support).
3. Score Interpretation and Thresholds:
   • Total Score Range: $8\text{ to }40$ points.
   • Clinical Interpretation:
     • Score < 17: Over-sedation (excess sedation depth; decrease or wean infusion rate).
     • Score 17 – 26: Optimal sedation / adequate comfort (target maintenance range).
     • Score > 26: Under-sedation / distress / inadequate analgesia (requires assessment for pain/anxiety and consideration of bolus or dose escalation).
4. Alternative Pediatric Sedation Scores:
   • State Behavioral Scale (SBS)
   • Richmond Agitation-Sedation Scale (RASS) / Pediatric RASS (p-RASS)
   • University of Michigan Sedation Scale (UMSS)

1. Definitions and Distinctions:
   • $\text{PaO}_2$ (Partial Pressure of Oxygen): Measure of physically dissolved oxygen in arterial plasma (expressed in $\text{mmHg}$ or $\text{kPa}$). It represents only $1\text{ to }2\%$ of total blood oxygen and is determined by alveolar gas exchange ($\text{PAO}_2$), ventilation-perfusion matching, and diffusion.
   • $\text{SaO}_2$ (Oxygen Saturation): The percentage of available hemoglobin binding sites occupied by oxygen:
     $$\text{SaO}_2 = \frac{[\text{HbO}_2]}{[\text{HbO}_2] + [\text{Deoxy-Hb}]} \times 100$$
   • $\text{CaO}_2$ (Arterial Oxygen Content): The total volume of oxygen carried in $100\text{ mL}$ ($1\text{ dL}$) of whole blood, combining hemoglobin-bound oxygen and dissolved oxygen.
2. Effect on Arterial $\text{PaO}_2$:
   • Severe iron deficiency anemia: Normal (oxygen dissolved in plasma depends on alveolar-capillary exchange, not hemoglobin concentration; though $\text{CaO}_2$ is markedly reduced).
   • Acute carbon monoxide poisoning: Normal (CO binds competitively to hemoglobin; dissolved oxygen tension in plasma remains unaltered).
   • Acquired methemoglobinemia: Normal (ferric $\text{Fe}^{3+}$ heme impairs $\text{O}_2$ binding to hemoglobin; dissolved plasma $\text{PaO}_2$ is unaffected).
   • Cyanotic congenital heart disease: Decreased (anatomical right-to-left mixing of deoxygenated systemic venous blood directly into the systemic arterial circulation).
   • Severe ARDS: Decreased (severe intrapulmonary shunting and ventilation-perfusion mismatch caused by alveolar collapse and flooding).
3. Calculation of Arterial Oxygen Content ($\text{CaO}_2$):
   $$ > \begin{aligned} > \text{CaO}_2 &= (1.34 \times \text{Hb} \times \frac{\text{SaO}_2}{100}) + (0.003 \times \text{PaO}_2) \\ > &= (1.34 \times 10 \times 0.90) + (0.003 \times 60) \\ > &= 12.06 + 0.18 \\ > &= \mathbf{12.24\text{ mL O}_2/\text{dL}} \quad (\text{Reference normal: } 17\text{ to }20\text{ mL/dL}) > \end{aligned} > $$
4. Mechanism of Refractory Shunt Hypoxemia:
   • In a true right-to-left shunt (fraction $Q_s/Q_t$), shunted blood bypasses ventilated alveoli entirely and enters the left heart completely deoxygenated.
   • Non-shunted blood traversing ventilated alveoli exposed to $100\%\ \text{O}_2$ already reaches near-maximal hemoglobin saturation ($\approx 100\%$). Because the oxygen-hemoglobin dissociation curve is flat at high $\text{PaO}_2$, this blood cannot bind additional hemoglobin-bound oxygen.
   • The only additional oxygen carried by non-shunted blood is a minuscule increase in dissolved oxygen ($0.003\text{ mL/dL/mmHg}$). When this mixes downstream with the deoxygenated shunted blood, the resulting mixed arterial $\text{PaO}_2$ remains low, producing the hallmark "oxygen-refractory hypoxemia."

1. Physiologically Difficult Airway:
   • Definition: An airway where physiological derangements (hemodynamic instability, hypoxemia, acidosis, or ventricular dysfunction) markedly increase the risk of peri-intubation cardiovascular collapse, arrest, or secondary brain injury, despite normal craniofacial anatomy.
   • Predisposing conditions in this patient:
     • Severe refractory hypoxemia (ARDS with intrapulmonary shunting; rapid desaturation during apnea)
     • Hypotensive septic shock (loss of endogenous sympathetic tone upon sedation leading to severe hypotension)
     • Severe metabolic/respiratory acidosis (apnea causes acute PaCO2 elevation and catastrophic pH drop)
     • Right ventricular dysfunction / pulmonary arterial hypertension (sudden rise in RV afterload with positive pressure ventilation)
2. Bedside Assessment Tools:
   • LEMON Mnemonic: Look externally, Evaluate 3-3-2 rule, Mallampati score, Obstruction, Neck mobility
   • HEAVEN Criteria: Hypoxemia, Extremes of size, Anatomical challenges, Vomit/blood/fluid, Exsanguination/anemia, Neck mobility
3. Immediate Airway Rescue Adjunct:
   • Second-generation Supraglottic Airway Device (SAD) / Laryngeal Mask Airway (LMA) (e.g., LMA ProSeal, LMA Supreme, or i-gel size 2.0 or 2.5).
4. Definitive CICO Management:
   • Emergency Front-of-Neck Access (eFONA): Needle cricothyroidotomy with transtracheal jet ventilation (TTJV) or scalpel-bougie-tube cricothyroidotomy.

flowchart TD
    A[Failed Direct Laryngoscopy Attempt 1 & 2] --> B[Optimize Head Position / Video Laryngoscopy / Bougie]
    B -->|Failed Intubation & Desaturation| C[Insert 2nd Generation LMA / Supraglottic Airway]
    C -->|Successful Ventilation| D[Oxygenate & Awaken / Plan Fiberoptic Intubation]
    C -->|Failed Oxygenation: CICO State| E[Declare Emergency CICO]
    E --> F[Emergency Front of Neck Access - eFONA]
    F --> G[Scalpel Cricothyroidotomy or Needle Cannula Ventilation]

1. WHO Consensus Definitions:
   • Drowning: The process of experiencing respiratory impairment from submersion/immersion in liquid, resulting in death, morbidity, or no morbidity. (Terms like "dry", "wet", "secondary", or "near-drowning" are obsolete).
   • Non-fatal Drowning: The process of experiencing respiratory impairment from submersion/immersion in liquid where the victim survives the initial incident (at least 24 hours post-event).
2. Predisposing Risk Factors:
   • Inadequate adult supervision / momentary lapse of attention
   • Lack of physical isolation barriers (e.g., absence of four-sided pool fencing with self-closing/self-latching gates)
   • Inability to swim or lack of water safety education
   • Underlying medical triggers (e.g., unprovoked seizure disorder, long QT syndrome [LQTS Type 2/3 triggered by immersion/swimming])
3. Laboratory Derangements:
   • Electrolyte abnormalities: Hyperkalemia (secondary to tissue hypoxia, acidosis, or hemolysis); Hyponatremia (secondary to large-volume hypotonic water ingestion/absorption or SIADH)
   • Hematological complication: Disseminated intravascular coagulation (DIC) or intravascular hemolysis
4. Most Common Initial Pulseless Rhythm:
   • Asystole (followed by Pulseless Electrical Activity [PEA]; ventricular fibrillation is rare unless profound hypothermia or underlying channelopathy exists).
5. Respiratory Strategy & Empirical Pharmacotherapy:
   • Ventilatory strategy: Immediate endotracheal intubation, lung-protective ventilation ($V_T$ 6 mL/kg), high Positive End-Expiratory Pressure (PEEP $8\text{--}12\text{ cmH}_2\text{O}$) to recruit fluid-filled, surfactant-depleted alveoli, targeting $\text{SpO}_2\ 94\%\text{--}98\%$ and normocapnia ($\text{PaCO}_2\ 35\text{--}45\text{ mmHg}$).
   • Prophylactic antibiotics: Not recommended routinely. Indicated only if submersion occurred in grossly contaminated/sewage water or if clinical/microbiological evidence of pneumonia emerges after 48–72 hours.
   • Corticosteroids: Not recommended; no proven benefit in improving pulmonary mechanics or survival in drowning-associated ARDS and increases secondary nosocomial infection risks.

1. Device Identification and Components:
   • Device: Cuffed Endotracheal Tube (ETT)
   • A: 15 mm standard machine connector
   • B: Depth markings (in centimeters) along the radiopaque longitudinal line
   • C: Low-pressure, high-volume micro-cuff
   • D: Murphy's eye (bevel side hole preventing total occlusion)
2. Internal Diameter (ID) Calculations:
   $$ > \begin{aligned} > \text{Uncuffed ETT Size (mm ID)} &= \frac{\text{Age (years)}}{4} + 4 \\ > &= \frac{6}{4} + 4 = 1.5 + 4 \\ > &= \mathbf{5.5\text{ mm}} > \end{aligned} > $$
   $$ > \begin{aligned} > \text{Cuffed ETT Size (mm ID) [Khine / Motoyama formula]} &= \frac{\text{Age (years)}}{4} + 3.5 \\ > &= \frac{6}{4} + 3.5 = 1.5 + 3.5 \\ > &= \mathbf{5.0\text{ mm}} > \end{aligned} > $$
   (Note: Always keep one size smaller [4.5 mm] and one size larger [5.5 mm] immediately available).
3. Insertion Depth Calculation:
   $$ > \begin{aligned} > \text{Depth at lips (cm)} &= \frac{\text{Age (years)}}{2} + 12 \quad \left(\text{or } \text{Internal Diameter} \times 3\right) \\ > &= \frac{6}{2} + 12 = 3 + 12 = \mathbf{15\text{ cm}} \\ > &= 5.0 \times 3 = \mathbf{15\text{ cm}} > \end{aligned} > $$
4. Hemodynamic / Autonomic Responses:
   • Marked vagal stimulation resulting in severe sinus bradycardia or sinus arrest (particularly in infants and young children).
   • Sympathetic discharge causing reflex systemic hypertension, tachycardia, and increased intracranial / intraocular pressure.
5. Cuff Pressure Target and Complication:
   • Maximum safe cuff pressure: $\mathbf{< 20\text{--}25\text{ cmH}_2\text{O}}$ (monitored continuously or intermittently with an aneroid manometer).
   • Complication of excessive pressure: Mucosal capillary ischemia of the subglottic tracheal lining ($>30\text{ cmH}_2\text{O}$ exceeds capillary perfusion pressure) leading to ulceration, mucosal necrosis, and long-term subglottic stenosis.

1. Definition & Severity Classification of Neutropenia:
   • Definition: Absolute Neutrophil Count (ANC) $< 1500/\text{mm}^3$ (or $< 1000/\text{mm}^3$ in infants under 1 year).
   • Mild Neutropenia: ANC $1000\text{--}1500/\text{mm}^3$
   • Moderate Neutropenia: ANC $500\text{--}999/\text{mm}^3$
   • Severe Neutropenia: ANC $< 500/\text{mm}^3$
   • (Profound / Deep Neutropenia: ANC $< 100/\text{mm}^3$)
2. ANC Calculation:
   $$ > \begin{aligned} > \text{ANC} &= \text{Total Leukocyte Count (TLC)} \times \frac{\% \text{Polymorphs (Neutrophils)} + \% \text{Bands}}{100} \\ > &= 800 \times \frac{8 + 4}{100} \\ > &= 800 \times 0.12 \\ > &= \mathbf{96/\text{mm}^3} > \end{aligned} > $$
   • Severity: Profound / Severe Neutropenia ($\text{ANC} < 500/\text{mm}^3$, specifically $<100/\text{mm}^3$).
3. Definition of Febrile Neutropenia:
   • A single oral/core temperature $\ge 38.3^\circ\text{C}$ ($101^\circ\text{F}$) OR a sustained temperature $\ge 38.0^\circ\text{C}$ ($100.4^\circ\text{F}$) over a 1-hour period, IN A PATIENT WITH an $\text{ANC} < 500/\text{mm}^3$ OR an ANC predicted to decline to $< 500/\text{mm}^3$ within 48 hours.
4. Empirical First-line Antibiotic Monotherapy:
   • Cefepime: $50\text{ mg/kg/dose}$ IV every 8 hours (maximum $2\text{ g/dose}$), OR
   • Piperacillin-Tazobactam: $75\text{--}100\text{ mg/kg/dose}$ (of piperacillin component) IV every 6 hours (maximum $4\text{ g/dose}$ infused over 30 minutes to 3 hours).
5. Indications for Upfront Vancomycin:
   • Hemodynamic instability / septic shock
   • Catheter-site infection (erythema, tenderness, purulent tunnel drainage)
   • Known colonization with Methicillin-Resistant Staphylococcus aureus (MRSA) or Penicillin-resistant Streptococcus pneumoniae
   • Suspected serious catheter-related bloodstream infection (e.g., chills/rigors following central line flush)
   • Apparent skin or soft tissue infection (e.g., cellulitis, ecthyma gangrenosum)

1. Mechanism of Action & Relative Potency:
   • Mechanism: Selective, high-affinity synthetic phenylpiperidine agonist at the $\mu$ (mu)-opioid G-protein coupled receptor. Binding inhibits adenylyl cyclase, closes voltage-gated calcium channels, and opens inwardly rectifying potassium channels, hyperpolarizing ascending pain transmission pathways.
   • Potency: Approximately 50 to 100 times more potent than parenteral morphine (due to high lipophilicity enabling rapid crossing of the blood-brain barrier).
2. Pharmacokinetics:
   • Metabolism: Extensive hepatic metabolism via cytochrome P450 enzymes (specifically CYP3A4) via N-dealkylation.
   • Metabolites: Forms norfentanyl (along with hydroxyfentanyl and hydroxynorfentanyl), which is biologically inactive and non-toxic.
   • Excretion: Primarily renal ($>70\%$ excreted in urine as inactive metabolites; $<10\%$ excreted unchanged).
   • Terminal Half-life ($t_{1/2}$): Approximately 2 to 4 hours (prolonged significantly up to 8–12 hours with prolonged continuous infusions due to high volume of distribution and context-sensitive half-time).
3. Alternative Routes of Administration:
   • Intranasal (IN) (mucosal atomizer device)
   • Transdermal (continuous release matrix patch for chronic cancer pain)
   • Oral transmucosal / Sublingual / Buccal (fentanyl lollipop/lozenge/tablets)
   • Epidural / Intrathecal (neuraxial analgesia)
4. Intravenous Dosing:
   • Dose: $1\text{ to }2\ \mu\text{g/kg/dose}$ IV slowly over 3 to 5 minutes (For this 25 kg child: $25\text{ to }50\ \mu\text{g}$ per dose).
5. Severe Adverse Effect & Antidote:
   • Complication: Wooden Chest Syndrome (Acute Thoracoabdominal Muscle Rigidity / Glottic Rigidity) causing impossible bag-mask ventilation and rapid asphyxiation.
   • Antidote: Naloxone ($0.01\text{ to }0.1\text{ mg/kg}$ IV; up to $2\text{ mg}$) to reverse opioid receptor binding; or a rapid-acting neuromuscular blocking agent (e.g., Succinylcholine $1\text{--}2\text{ mg/kg}$ IV or Rocuronium $1\text{ mg/kg}$ IV) with definitive endotracheal intubation.

1. Diagnosis and Definition:
   • Diagnosis: Food-induced Anaphylactic Shock (severe Type I IgE-mediated hypersensitivity reaction with cardiovascular collapse).
   • Clinical Definition: A severe, life-threatening, generalized or systemic hypersensitivity reaction characterized by rapid onset of potentially fatal airway, breathing, or circulatory compromise, typically associated with mucocutaneous manifestations.
2. Immediate First-Line Drug:
   • Drug: Epinephrine (Adrenaline).
   • Concentration: 1:1,000 aqueous solution ($1\text{ mg/mL}$).
   • Dose: $0.01\text{ mg/kg}$ ($0.01\text{ mL/kg}$ of 1:1,000 solution; maximum single dose $0.3\text{ mg}$ in children $<12$ years). For a $14\text{ kg}$ child: $0.14\text{ mg}$ ($0.14\text{ mL}$).
   • Route & Site: Deep Intramuscular (IM) injection into the anterolateral aspect of the middle third of the thigh (vastus lateralis). May repeat every 5 to 15 minutes if symptoms persist.
3. Immediate Resuscitation Protocol:
   • Airway & Breathing: High-flow oxygen ($10\text{--}15\text{ L/min}$) via non-rebreathing mask with reservoir bag; prepare for early endotracheal intubation if stridor or severe angioedema progresses.
   • Circulation & Positioning: Place child in supine position with legs elevated (Trendelenburg/passive leg raise); avoid sudden sitting or upright standing.
   • Fluid Resuscitation: Rapid intravenous (IV) or intraosseous (IO) infusion of isotonic crystalloid (Normal Saline or Ringer's Lactate) at $20\text{ mL/kg}$ ($280\text{ mL}$ in this child) over 5 to 10 minutes using the push-pull syringe-stopcock technique; repeat boluses up to $40\text{--}60\text{ mL/kg}$ guided by perfusion markers.
4. Refractory Shock & Adjuvants:
   • Refractory Hypotension: Continuous intravenous infusion of Epinephrine at $0.05\text{--}0.3\text{ mcg/kg/min}$ (titrated up to $1\text{ mcg/kg/min}$) or Norepinephrine ($0.05\text{--}0.5\text{ mcg/kg/min}$) via infusion pump.
   • Secondary Adjuvant Medications:
     • H1-antihistamine: Chlorpheniramine ($0.1\text{ mg/kg}$ IV/IM) or Cetirizine/Diphenhydramine.
     • H2-antagonist: Ranitidine ($1\text{ mg/kg}$ IV) or Famotidine ($0.5\text{ mg/kg}$ IV).
     • Systemic Corticosteroids (to prevent biphasic reactions): Hydrocortisone ($4\text{--}5\text{ mg/kg}$ IV stat) or Methylprednisolone ($1\text{--}2\text{ mg/kg}$ IV).
     • Inhaled Beta-2 Agonist: Nebulized Salbutamol ($2.5\text{ mg}$) for bronchospasm.

1. Identification and Structural Components:
   • Device: Heated Humidified High-Flow Nasal Cannula (HHHFNC) system.
   • Components:
     • Air-oxygen blender with integrated flow meter ($0\text{--}60\text{ L/min}$).
     • Heated active humidification base unit with chamber (e.g., Fisher & Paykel MR850/AIRVO).
     • Heated inspiratory delivery circuit with internal heating wire.
     • Sterile water bag for continuous chamber feed.
     • Soft, flexible, wide-bore pediatric nasal prongs (sized to occlude $\le 50\%$ of the internal nares).
2. Physiological Mechanisms:
   • Dead space washout: Continuous high wash-out of anatomical nasopharyngeal dead space, eliminating expired $CO_2$ and providing a pharyngeal oxygen reservoir.
   • Positive distending airway pressure: Generates dynamic positive end-expiratory pressure (PEEP) of approximately $2\text{--}5\text{ cmH}_2\text{O}$, improving functional residual capacity (FRC) and staving off microatelectasis.
   • Reduction of airway resistance: Matches or exceeds the patient's peak inspiratory flow, diminishing inspiratory resistive work of breathing.
   • Mucociliary preservation: Optimal conditioning ($37^\circ\text{C}$ with $100\%$ relative humidity, $44\text{ mg }H_2O\text{/L}$) preserves mucociliary escalator clearance and decreases metabolic expenditure for gas conditioning.
3. Pediatric Clinical Indications:
   • Moderate-to-severe acute viral bronchiolitis.
   • Severe acute viral or bacterial pneumonia.
   • Post-extubation respiratory failure support / prevention of extubation failure.
   • Acute moderate asthma refractory to initial nebulization therapy.
   • Non-cardiogenic pulmonary edema or early mild pediatric acute respiratory distress syndrome (PARDS).
4. Settings and Monitoring Index:
   • Flow Rate:
     $$ > \begin{aligned} > \text{Initial Flow Rate} &= 2\text{ L/kg/min for first } 10\text{ kg} \\ > &= 8.5\text{ kg} \times 2\text{ L/kg/min} = \mathbf{17\text{ L/min}} \quad (\text{Range: } 1.5\text{--}2\text{ L/kg/min}) > \end{aligned} > $$
   • Temperature & $FiO_2$: Set temperature to $37^\circ\text{C}$ (invasive mode); titrate $FiO_2$ ($0.40\text{--}0.60$) to target $SpO_2$ $92\text{--}96\%$.
   • Bedside Failure Predictor: ROX Index (or pediatric ROX-p):
     $$ > \text{ROX Index} = \frac{SpO_2\text{ (\%)} / FiO_2\text{ (fractional)}}{RR\text{ (breaths/min)}} > $$
     A low or declining ROX index at 2, 6, and 12 hours predicts failure and mandates timely escalation to CPAP/BiPAP or invasive mechanical ventilation.

1. Principal Differential Diagnoses:
   • Atypical Hemolytic Uremic Syndrome (aHUS) / Thrombotic Microangiopathy (TMA).
   • Systemic Lupus Erythematosus (SLE) with active Lupus Nephritis (Class III/IV) and secondary thrombotic microangiopathy or autoimmune cytopenia.
2. Peripheral Smear and Hemolysis Markers:
   • Smear Finding: Schistocytes (fragmented RBCs, helmet cells, keratocytes) $\ge 1\%$ on peripheral smear, accompanied by thrombocytopenia without alternative causes.
   • Biochemical Confirmation:
     • Markedly elevated Serum Lactate Dehydrogenase (LDH).
     • Undetectable or severely reduced Serum Haptoglobin.
     • Elevated unconjugated (indirect) serum bilirubin.
     • Negative Direct Coombs Test (DAT) in aHUS (DAT may be positive in autoimmune hemolysis of SLE).
3. Differentiating Laboratory Workup:
   • For Lupus Nephritis / SLE:
     • Antinuclear Antibodies (ANA) by indirect immunofluorescence.
     • Anti-double-stranded DNA (anti-dsDNA) antibodies.
     • Anti-Smith (anti-Sm) antibodies.
     • Serum Complement C3 and C4 (both typically depressed in active lupus nephritis).
   • For aHUS:
     • Complement factor H (CFH), factor I (CFI), and factor B levels; Anti-CFH autoantibodies.
     • ADAMTS13 activity (must be $>10\%$ to rule out Thrombotic Thrombocytopenic Purpura [TTP]).
     • Serum C3 may be low in alternative complement pathway dysregulation, but C4 is usually normal.
4. Blood Pressure Classification and Emergency Pharmacotherapy:
   • Classification: Hypertensive Emergency (Stage 2 severe hypertension with end-organ involvement: acute kidney injury and pulmonary congestion).
   • Immediate Pharmacotherapy:
     • Continuous IV infusion of Nicardipine ($0.5\text{--}1\text{ mcg/kg/min}$, titrated up to $4\text{ mcg/kg/min}$) OR Labetalol ($0.25\text{--}1\text{ mg/kg}$ IV bolus over 2–5 min, or infusion at $0.25\text{--}3\text{ mg/kg/hour}$).
     • Add IV Furosemide ($1\text{--}2\text{ mg/kg/dose}$) to treat hypervolemia and pulmonary congestion.
     • Avoid precipitous drops: reduce BP by no more than $25\%$ over the first 6–8 hours, normalizing over the next 24–48 hours.

1. Definitions:
   • Hypertensive Emergency: Severe elevation in blood pressure ($>99\text{th}\text{ percentile} + 5\text{ mmHg}$) accompanied by acute, progressive end-organ damage (central nervous system, eyes, cardiovascular system, or kidneys).
   • Hypertensive Urgency: Severe elevation in blood pressure ($>99\text{th}\text{ percentile} + 5\text{ mmHg}$) without acute, life-threatening end-organ damage, where BP can be lowered gradually over 24–48 hours with oral medications.
2. Target Organs and Manifestations:
   • Central Nervous System: Hypertensive encephalopathy, seizures, visual loss/cortical blindness, intracerebral hemorrhage, posterior reversible encephalopathy syndrome (PRES).
   • Ocular: Grade III/IV hypertensive retinopathy (papilledema, retinal exudates, flame hemorrhages).
   • Cardiovascular: Acute left ventricular failure, pulmonary edema, myocardial ischemia, aortic dissection (rare in children).
   • Renal: Acute kidney injury, hematuria, rapidly progressive azotemia.
3. Management Goals & Contraindication to Rapid Normalization:
   • Reduction Timeline:
     • First 6 to 8 hours: Reduce blood pressure by a maximum of $20\text{--}25\%$ of the planned reduction (or to the 99th percentile).
     • Next 24 to 36 hours: Gradual reduction over the subsequent 24 hours to the 95th percentile.
     • Final normalization: Gradual return toward the 90th percentile over the following 48 hours.
   • Pathophysiological Risk of Rapid Drop: Autoregulatory curves of cerebral, coronary, and renal beds are shifted to the right in chronic or severe hypertension. A precipitous reduction induces critical hypoperfusion, resulting in watershed cerebral infarction, optic nerve ischemia (anterior ischemic optic neuropathy), or acute tubular necrosis.
4. First-Line Intravenous Pharmacotherapy:
   • Labetalol (Combined $\alpha$- and $\beta$-blocker):
     • Dose: $0.2\text{--}1.0\text{ mg/kg}$ slow IV push over 2 minutes (maximum single dose $20\text{ mg}$); OR continuous IV infusion at $0.25\text{--}3.0\text{ mg/kg/hour}$ titrated to response.
   • Nicardipine (Dihydropyridine calcium channel blocker):
     • Dose: Continuous IV infusion starting at $0.5\text{--}1.0\text{ mcg/kg/min}$; titrate every 15–30 minutes up to a maximum of $4.0\text{ mcg/kg/min}$.
   • Alternative: Sodium Nitroprusside ($0.5\text{--}8.0\text{ mcg/kg/min}$) with continuous arterial line monitoring (monitor thiocyanate levels if used $>48\text{ hours}$).

1. Differentiating Neurogenic Causes of Hyponatremia:

   Parameter	Syndrome of Inappropriate ADH (SIADH)	Cerebral Salt Wasting (CSW)
   Extracellular Fluid Volume	Euvolemic or mildly hypervolemic	Hypovolemic (signs of clinical dehydration)
   Urine Output	Low to normal (oliguria / concentrated)	Markedly increased (polyuria: $>4\text{ mL/kg/hr}$)
   Urine Sodium ($U_{Na}$)	Elevated ($>20\text{--}40\text{ mEq/L}$), matches intake	Excessively elevated (typically $>80\text{--}100\text{ mEq/L}$)
   Serum Uric Acid & BUN	Low serum uric acid, low/normal BUN	Normal to elevated BUN, low/normal uric acid
   Primary Management	Fluid restriction	Volume replacement with isotonic/hypertonic saline

2. Diagnosis and Pathophysiology:

   • Diagnosis: Cerebral Salt Wasting (CSW) Syndrome (evidenced by severe polyuria [$5.5\text{ mL/kg/hr}$], high urine specific gravity, and progressive volume contraction in a central nervous system pathology).
   • Pathophysiological Mechanism: CNS injury stimulates excessive release of natriuretic peptides (Brain Natriuretic Peptide [BNP] and Atrial Natriuretic Peptide [ANP]) into the circulation, and/or impairs central sympathetic neural tone to the proximal renal tubules. This inhibits proximal tubular sodium reabsorption and aldosterone responsiveness, causing primary renal natriuresis followed by osmotic diuresis and intravascular hypovolemia.

3. Mathematical Calculation:
   

   $$ > \begin{aligned} > \text{Total Body Water (TBW)} &= 0.6 \times \text{Body Weight (kg)} \\ > &= 0.6 \times 20\text{ kg} = \mathbf{12\text{ Liters}} \\ > \text{Sodium Deficit (mEq)} &= \text{TBW} \times (\text{Desired } Na - \text{Current } Na) \\ > &= 12 \times 5 = \mathbf{60\text{ mEq}} \\ > \text{Volume of 3\% NaCl } (0.513\text{ mEq/mL}) &= \frac{60\text{ mEq}}{0.513\text{ mEq/mL}} = \mathbf{116.9\text{ mL}} > \end{aligned} > $$

   
   Rapid Bedside Emergency Rule: $3\text{ mL/kg}$ of $3\%\text{ NaCl} = 3 \times 20 = \mathbf{60\text{ mL}}$ infused over 10–20 minutes raises serum sodium by approximately $2.5\text{--}3\text{ mEq/L}$; infusing $100\text{--}120\text{ mL}$ over 1–2 hours achieves the desired $5\text{ mEq/L}$ elevation to control acute neurological symptoms. Maximum correction rate should not exceed $8\text{--}10\text{ mEq/L}$ in 24 hours to prevent osmotic demyelination syndrome.

1. Pharmacological Class and Mechanism of Action:
   • Class: Calcium sensitizer / Inodilator.
   • Mechanism of Action:
     • Positive Inotropy: Binds selectively to the calcium-saturated N-terminal domain of cardiac troponin C (cTnC) during systole, stabilizing the active conformation and prolonging actin-myosin cross-bridge kinetics without increasing intracellular calcium concentration or cyclic adenosine monophosphate (cAMP).
     • Vasodilatation (Inodilator effect): Opens adenosine triphosphate-sensitive potassium channels ($K_{\text{ATP}}$) in vascular smooth muscle cells, leading to systemic, pulmonary, and coronary arterial and venous vasodilation (reducing both afterload and preload).
     • Cardioprotection: Opens mitochondrial $K_{\text{ATP}}$ channels in cardiomyocytes, conferring protection against ischemia-reperfusion injury and apoptosis.
2. Other Inodilators:
   • Pimobendan (calcium sensitizer and PDE-3 inhibitor).
   • Alternative inodilator category: Milrinone or Enoximone (phosphodiesterase-3 inhibitors).
3. Clinical Indications in Pediatric Critical Care:
   • Decompensated acute or chronic heart failure refractory to conventional inotropes (e.g., dilated cardiomyopathy).
   • Low cardiac output syndrome (LCOS) following congenital heart surgery / cardiopulmonary bypass.
   • Acute fulminant myocarditis with severe systolic dysfunction.
   • Pulmonary arterial hypertension with associated right ventricular failure.
   • Weaning bridge from mechanical circulatory support (e.g., ECMO or VAD).
4. Advantages over Conventional Adrenergic Inotropes / PDE-3 Inhibitors:
   • Neutral Myocardial Oxygen Consumption ($MVO_2$): Increases contractility without increasing intracellular calcium flux, avoiding excess myocardial oxygen demand and intracellular calcium overload.
   • Preserved Diastolic Relaxation (Lusitropy): Does not impair diastole because calcium dissociation from troponin C proceeds normally during diastole when intracellular calcium drops.
   • Independent of Beta-Adrenergic Signaling: Effective in patients receiving beta-blockers or those with downregulated/desensitized beta-1 adrenergic receptors due to chronic heart failure.
   • Sustained Hemodynamic Effect via Active Metabolite: Its active metabolite, OR-1896, has an elimination half-life of 70 to 80 hours, providing sustained clinical benefits (vasodilation and inotropy) for 7 to 10 days after a 24-hour infusion.
   • Lower Arrhythmogenic Potential: Considerably lower incidence of tachyarrhythmias compared to catecholamines (epinephrine/dopamine) and PDE-3 inhibitors.

1. "Bat Sign" on Lung Ultrasound:
   • Description: The fundamental reference landmark in lung ultrasonography identifying the pleural line in the longitudinal axis.
   • Anatomy:
     • The upper and lower rib margins with their posterior acoustic shadowing represent the "wings" of the bat.
     • The hyperechoic, horizontal pleural line (located approximately 0.5 cm deep to the ribs in children) between the two acoustic shadows represents the "body" of the bat.
2. B-Lines and Diagnostic Criteria:
   • Definition: Discrete laser-like hyperechoic vertical reverberation artifacts that arise from the pleural line and extend to the bottom of the screen.
   • Seven Defining Criteria:
     • 1. Hyperechoic vertical comet-tail artifact.
     • 2. Arises strictly from the pleural line.
     • 3. Moves synchronously with lung sliding.
     • 4. Well-defined, laser-like beam.
     • 5. Extends completely to the bottom of the screen without fading.
     • 6. Erases horizontal A-lines.
     • 7. Disappears or changes with movement of the transducer.
3. Clinical Significance:
   • Isolated B-lines (1–2 per space): Physiologic finding, frequently observed in gravity-dependent posterior and inferior lung zones.
   • B-profile (>3 B-lines per intercostal space): Indicates an alveolar-interstitial syndrome caused by loss of lung aeration and fluid accumulation in the interlobular septa.
   • Confluent B-lines ("Ground glass" or "White lung"): Represents severe interstitial and alveolar flooding (pulmonary edema, diffuse alveolar damage, or interstitial pneumonia).
4. Sonographic Differentiation: Cardiogenic Edema vs. PARDS:
   • Pleural Line Characteristics:
     • Cardiogenic Edema: Thin, regular, smooth, and intact pleural line with normal lung sliding.
     • PARDS: Thickened (>2 mm), irregular, fragmented, or coarse pleural line with reduced or absent lung sliding.
   • Distribution of B-lines:
     • Cardiogenic Edema: Homogeneous, symmetric, gravity-dependent distribution without spared areas.
     • PARDS: Patchy, heterogeneous, asymmetric distribution with alternating normal areas ("spared areas").
   • Subpleural Consolidations:
     • Cardiogenic Edema: Usually absent (except pleural effusions).
     • PARDS: Frequent small subpleural consolidations (micro-consolidations) with lung pulse.

1. Team Preparation and Pre-Resuscitation Briefing:
   • Team Composition: Minimum of two to three qualified providers skilled in advanced neonatal resuscitation (endotracheal intubation, vascular access, chest compressions).
   • Role Allocation: Designated team leader, airway management provider, circulation/compressions provider, and equipment/medication documenter.
   • Anticipated Complications: Preterm hypothermia, meconium aspiration syndrome, persistent pulmonary hypertension of the newborn (PPHN), perinatal asphyxia/hypoxic-ischemic encephalopathy, and respiratory distress syndrome.
2. Equipment and Environmental Preparation Checklist:
   • Thermal Care: Radiant warmer pre-warmed to 100% manual mode, room temperature 23–25°C, warm towels, plastic wrap/bag (if <1.5 kg, optional at 35 weeks), thermal mattress.
   • Airway & Suction: Mechanical suction set at 80–100 mmHg with 10 Fr and 12 Fr suction catheters, Yankauer sucker, meconium aspirator adapter.
   • Intubation Equipment: Laryngoscope with functional light and Miller size 0 and 1 straight blades; cuffed/uncuffed endotracheal tubes (size 3.0 mm and 3.5 mm ID); stylet; commercial tube securement device; colorimetric $CO_2$ detector.
   • Ventilation: T-piece resuscitator or flow-inflating bag connected to compressed air/oxygen blender with flow set to 10 L/min; PIP set at 20–25 $\text{cmH}_2\text{O}$ and PEEP at 5 $\text{cmH}_2\text{O}$; appropriate-sized cushioned anatomical face masks (preterm and term sizes).
   • Monitoring & Access: Pre-ductal pulse oximeter probe with monitor, 3-lead ECG monitor; umbilical venous catheterization tray with 3.5 Fr and 5.0 Fr catheters, 1:10,000 epinephrine, normal saline flush.
3. Immediate Management at Birth (NRP Guidelines):
   • A. Vigorous Infant (crying/active, good tone, HR >100 bpm):
     • Bring to radiant warmer or skin-to-skin (if stable).
     • Dry, warm, position airway, and clear secretions from mouth and nose with bulb syringe only if secretions obstruct the airway.
     • Routine routine suctioning (including tracheal suctioning) is not indicated.
     • Continue ongoing assessment of breathing, heart rate, and color.
   • B. Non-Vigorous Infant (apnea, gasping, or HR <100 bpm):
     • Immediately bring to radiant warmer.
     • Dry, position airway sniff position, stimulate, and suction mouth then nose.
     • Do not perform routine direct laryngoscopic tracheal suctioning.
     • Initiate Positive Pressure Ventilation (PPV) within the first 60 seconds of life ("Golden Minute") if the infant remains apneic, gasping, or has a heart rate <100 bpm.
     • Tracheal intubation is reserved for ineffective bag-mask ventilation or if the airway is anatomically obstructed by thick particulate meconium preventing effective PPV.
4. Target Pre-Ductal Saturations and Initial Gas Delivery:
   • Initial Gas Mixture: Begin PPV for $\ge 35$ weeks with $21\%\ \text{FiO}_2$ (room air), blended with medical air and titrated using a pulse oximeter.
   • Pre-Ductal Target $SpO_2$ (Right Wrist):
     • 1 minute: 60% – 65%
     • 2 minutes: 65% – 70%
     • 3 minutes: 70% – 75%
     • 4 minutes: 75% – 80%
     • 5 minutes: 80% – 85%
     • 10 minutes: 85% – 95%

1. Pharmacokinetic Model and Equation:
   • Model: Michaelis-Menten kinetics (also known as capacity-limited, nonlinear, or saturation pharmacokinetics).
   • Equation:
     $$ > V = \frac{V_{\max} \cdot C}{K_m + C} > $$
     Where:
     • $V$ = Rate of drug elimination (metabolic velocity)
     • $V_{\max}$ = Maximum elimination velocity (metabolic capacity of liver enzymes)
     • $C$ = Plasma drug concentration
     • $K_m$ = Michaelis constant (drug concentration at which elimination rate is half of $V_{\max}$)
2. Comparison: First-Order vs. Zero-Order Kinetics:
   • First-Order Kinetics ($C \ll K_m$):
     • Elimination Rate: Directly proportional to plasma drug concentration; a constant fraction or percentage of drug is eliminated per unit time.
     • Clearance: Constant and independent of drug concentration.
     • Half-Life ($t_{1/2}$): Constant ($t_{1/2} = \frac{0.693}{k_e}$).
   • Zero-Order Kinetics ($C \gg K_m$):
     • Elimination Rate: Constant and independent of drug concentration because metabolic pathways/enzymes are fully saturated; a constant amount of drug is eliminated per unit time.
     • Clearance: Decreases as drug concentration increases ($\text{Clearance} = \frac{V_{\max}}{C}$).
     • Half-Life ($t_{1/2}$): Increases progressively as drug concentration increases.
3. Pediatric Drugs Demonstrating Michaelis-Menten Kinetics:
   • Phenytoin (via CYP2C9 and CYP2C19 saturation).
   • Aspirin / Salicylates (saturation of glycine and glucuronide conjugation pathways).
   • Other examples: Ethanol, Voriconazole, Theophylline (at toxic concentrations).
4. Mathematical Calculation:
   $$ > \begin{aligned} > V &= \frac{V_{\max} \cdot C}{K_m + C} \\ > &= \frac{8\ \text{mg/kg/day} \times 15\ \mu\text{g/mL}}{5\ \mu\text{g/mL} + 15\ \mu\text{g/mL}} \\ > &= \frac{120}{20} \\ > &= \mathbf{6.0\ \text{mg/kg/day}} > \end{aligned} > $$

1. Definitions and Anatomical Sampling Sites:
   • Mixed Venous Oxygen Saturation ($S_vO_2$): Represents the weighted average oxygen saturation of blood returning from all systemic capillary beds after complete mixing in the right ventricle.
     • Sampling Site: Main pulmonary artery (sampled via the distal port of a pulmonary artery / Swan-Ganz catheter).
   • Central Venous Oxygen Saturation ($S_{cv}O_2$): Represents the oxygen saturation of venous blood returning primarily from the head, neck, upper extremities, and upper trunk.
     • Sampling Site: Superior vena cava (SVC) at or just above the cavoatrial junction (sampled via an internal jugular or subclavian central venous catheter).
2. Normal Range and Relationship:
   • Normal Reference Range:
     • $S_vO_2$: 65% to 75% (average ~70%).
     • $S_{cv}O_2$: 70% to 80% (typically 3% to 5% higher than true $S_vO_2$ under normal physiological conditions).
   • Reason for Difference:
     • Normal cerebral blood flow has lower oxygen extraction compared to splanchnic and renal circulations; blood from the inferior vena cava (IVC) has higher oxygen content due to renal venous blood ($S_{\text{renal}}O_2 \approx 85\%$). However, during critical illness or shock, renal and mesenteric vasoconstriction decreases IVC saturation, making $S_{cv}O_2$ approximately 5% higher than true $S_vO_2$.
3. Mechanisms Causing Low $S_vO_2$ / $S_{cv}O_2$ (<65%):
   • Based on the relationship:
     $$ > S_vO_2 \approx S_aO_2 - \frac{VO_2}{CO \times Hb \times 1.34} > $$
   • Decreased Cardiac Output ($CO$): Cardiogenic shock, hypovolemic shock, obstructive shock (cardiac tamponade, tension pneumothorax).
   • Decreased Arterial Oxygen Saturation ($S_aO_2$): Severe hypoxemic respiratory failure, PARDS, right-to-left intracardiac shunts.
   • Decreased Hemoglobin Concentration ($Hb$): Severe anemia, acute hemorrhage, hemodilution.
   • Increased Oxygen Consumption ($VO_2$): Hyperthermia/fever, shivering, seizures, agitation/pain, severe work of breathing, thyroid storm.
4. Conditions Causing Paradoxically Normal or Elevated $S_vO_2$ / $S_{cv}O_2$ (>75%–80%) in Shock:
   • Severe Cytopathic Hypoxia / Cellular Dysoxia: Inability of mitochondria to utilize oxygen despite adequate delivery (e.g., late septic shock with mitochondrial dysfunction, cyanide poisoning).
   • Microvascular Shunting: Pathological opening of physiological arteriovenous channels with peripheral bypass of nutritive capillary beds (severe distributive/hyperdynamic septic shock).
   • Left-to-Right Intracardiac or Extracardiac Shunts: Ventricular septal defect (VSD), patent ductus arteriosus (PDA) contaminating the right-heart blood with oxygenated left-heart blood.
   • Severe Hypothermia: Markedly reduced tissue oxygen demand and metabolic rate ($VO_2$) with shift of the oxyhemoglobin dissociation curve to the left.
   • Extensive Tissue Necrosis / Brain Death: Total cessation of cellular metabolic extraction in non-viable organs.

1. Reactive Non-Stress Test (NST) Criteria:
   • Gestational age $\ge 32$ weeks:
     • Baseline fetal heart rate (FHR): 110–160 beats/min with moderate baseline variability (amplitude 6–25 beats/min).
     • Presence of $\ge 2$ FHR accelerations peaking $\ge 15\text{ beats/min}$ above baseline and lasting $\ge 15\text{ seconds}$ from onset to return over a 20-minute recording window.
   • Gestational age $< 32$ weeks:
     • Presence of $\ge 2$ FHR accelerations peaking $\ge 10\text{ beats/min}$ above baseline and lasting $\ge 10\text{ seconds}$ over a 20-minute window.
2. NICHD/NIH Consensus Definition of BPD (Infants $< 32$ Weeks Gestation):
   • Baseline requirement: Treatment with supplemental oxygen $> 21\%$ for $\ge 28$ cumulative days.
   • Assessment timepoint: Evaluated at 36 weeks post-menstrual age (PMA) or at discharge home (whichever comes first):
     • Mild BPD: Breathing ambient room air ($21\% \text{ O}_2$).
     • Moderate BPD: Requirement for supplemental $\text{FiO}_2 < 0.30$.
     • Severe BPD: Requirement for $\text{FiO}_2 \ge 0.30$ and/or positive pressure support (mechanical ventilation or continuous positive airway pressure [CPAP] / high-flow nasal cannula).
3. Walsh Physiological Oxygen Challenge Test:
   • Performed in clinically stable infants receiving effective $\text{FiO}_2 < 0.30$ or supplemental flow $\le 2\text{ L/min}$ to confirm true oxygen dependency.
   • Supplemental oxygen is stepwise weaned by $2\%$ to $5\%$ every 10–15 minutes until room air is reached while continuously monitoring pre-ductal pulse oximetry ($\text{SpO}_2$).
   • Failure criteria (confirms BPD):
     • Sustained $\text{SpO}_2 < 90\%$ for $\ge 5$ continuous minutes.
     • Any single desaturation $< 80\%$ lasting $\ge 15$ seconds.
     • Persistent bradycardia ($< 100\text{ beats/min}$) or significant apnea ($> 20\text{ seconds}$).
4. Evidence-Based Interventions to Reduce BPD:
   • Antenatal corticosteroids: Complete course of intramuscular betamethasone (12 mg q24h $\times$ 2 doses) or dexamethasone (6 mg q12h $\times$ 4 doses).
   • Early non-invasive respiratory support: Delivery room stabilization with bubble CPAP (5–7 cm $\text{H}_2\text{O}$) avoiding unnecessary endotracheal intubation.
   • Early selective surfactant with rapid extubation: InSurE (Intubation-Surfactant-Extubation) or LISA/MIST (Less Invasive / Minimally Invasive Surfactant Administration).
   • Early prophylactic/therapeutic caffeine citrate: Loading dose 20 mg/kg IV/oral followed by 5–10 mg/kg/day maintenance started within the first 72 hours of life.

1. Three Rapid Assessment Questions (NRP 8th Edition):
   • Is the baby born at term gestation?
   • Does the baby have good muscle tone?
   • Is the baby breathing or crying?
2. Routine Care (All Questions Answered "Yes"):
   • Place the vigorous infant directly on the mother's bare chest or abdomen for immediate skin-to-skin contact.
   • Provide continuous warmth using maternal body heat covered with a warm, dry linen and a cap on the head.
   • Dry the infant thoroughly with a clean warm towel and discard damp linen.
   • Maintain a clear airway by positioning the head in the "sniffing" position; clear secretions from the mouth and then nose with a bulb syringe or cloth only if obstructed.
   • Continue uninterrupted observation of breathing, tone, activity, and color while initiating early breastfeeding within the first hour.
3. Initial Resuscitation Steps & Targeted Pre-Ductal $\text{SpO}_2$ Values:
   • Initial steps (completed within 30 seconds of birth):
     • Place under a pre-heated radiant warmer.
     • Position the head and neck in a neutral/sniffing position to open the airway.
     • Clear secretions from mouth then nose only if airway is obstructed or if PPV is required.
     • Dry the neonate thoroughly and remove wet linen.
     • Provide tactile stimulation by gently rubbing the back or flicking the soles of the feet.
   • Targeted Pre-Ductal $\text{SpO}_2$ (Right Wrist/Palm):
     • 1 minute: $60\% - 65\%$
     • 3 minutes: $70\% - 75\%$
     • 5 minutes: $80\% - 85\%$
     • 10 minutes: $85\% - 95\%$
4. Positive Pressure Ventilation (PPV) Specifications:
   • Interface/Device: T-piece resuscitator (preferred) or self-inflating bag with PEEP valve attached to an anatomical cushioned face mask.
   • Initial Pressures:
     • Peak Inspiratory Pressure (PIP): $20 - 25\text{ cm }\text{H}_2\text{O}$.
     • Positive End-Expiratory Pressure (PEEP): $5\text{ cm }\text{H}_2\text{O}$.
   • Ventilatory Rate: $40 - 60\text{ breaths/minute}$ (cadence: "Breathe, two, three, breathe...").
   • Initial $\text{FiO}_2$: $21\%\text{ O}_2$ (room air) for term neonates ($\ge 35$ weeks); blended oxygen titrated against pre-ductal pulse oximetry targets.

1. Radiant Warmer Operation & Probe Placement:
   • Servo (Skin) Mode vs Manual Mode:
     • Servo (Skin) Mode: Automatic microcomputer-controlled closed loop where heater output modulates dynamically based on the neonate's skin temperature relative to a set-point. This is the mandatory standard mode for continuous patient care.
     • Manual Mode: Fixed, non-regulated heater output (percentage of maximal power) without feedback control. Reserved exclusively for pre-warming the mattress before delivery or brief acute resuscitation; carries a high risk of lethal hyperthermia or hypothermia if left unmonitored.
   • Probe Placement & Settings:
     • Anatomical site: Anterior abdominal wall over the right hypochondrium (over the liver) in the supine position, or over the flank in the prone position. Avoid bony prominences, bruised tissue, and areas overlying brown fat (interscapular zone).
     • Fixation: Attached securely using an insulated reflective foil patch (e.g., hydrogel adhesive patch) to reflect radiant heat away from the probe sensor.
     • Target Set-Point: $36.5^\circ\text{C} - 37.5^\circ\text{C}$ (typically set at $36.8^\circ\text{C} - 37.0^\circ\text{C}$).
2. Bubble CPAP Mechanics & Circuit Parameters:
   • PEEP Generation: The expiratory limb of the circuit is submerged underwater in a pressure generator column. The depth of submersion (in centimeters) directly determines the positive end-expiratory pressure generated in $\text{cm }\text{H}_2\text{O}$ (e.g., 5 cm submersion = $5\text{ cm }\text{H}_2\text{O}$ CPAP). Bubbling produces high-frequency oscillatory pressure waveforms that enhance gas mixing and work of breathing.
   • Bias Flow Rate: $6 - 8\text{ L/min}$ (ensures continuous bubbling throughout both inspiration and expiration without excessive resistance).
   • Humidification Settings: Heated-wire humidifier set to invasive/CPAP mode delivering gas at $37^\circ\text{C}$ with $100\%$ relative humidity ($44\text{ mg }\text{H}_2\text{O/L}$) at the airway interface.
3. Binasal Prong Selection & Injury Prevention:
   • Prong Size Selection: Prongs should fully occlude $80\% - 100\%$ of the nares diameter without stretching the alar cartilage or causing tissue blanching.
   • Columellar Protection:
     • Leave a minimum gap of $2\text{ mm}$ between the base of the prongs and the nasal columella.
     • Prongs must never exert downward pressure on the philtrum or backward pressure on the septum.
     • Apply a barrier hydrocolloid dressing over the columella and nasal bridge.
     • Secure the tubing symmetrically using an appropriately fitted cap and safety clips/elastic loops to prevent prong rotation.
4. Bedside Clinical Monitoring Routine:
   • Respiratory Assessment: Evaluate work of breathing hourly using the Silverman-Anderson Retraction Score (evaluating upper chest retraction, lower chest indrawing, xiphoid retraction, nares dilation, and expiratory grunt).
   • Circuit Integrity Verification: Confirm continuous, vigorous bubbling in the water chamber at all times during both phases of respiration. Loss of bubbling indicates airway displacement, mouth opening, prong dislodgement, or inadequate bias flow.
   • Gastric Decompression: Insert an orogastric feeding tube (size 5–6 Fr), aspirate air, and leave the tube vented/open to air above patient level (or connect to a syringe barrel without plunger) to prevent gastric overdistension ("CPAP belly") and splinting of the diaphragm.

1. Mechanism of Action:
   • Paracetamol (Acetaminophen): Acts primarily within the central nervous system by inhibiting prostaglandin synthesis via inhibition of peroxidase function of cyclooxygenase (COX-1, COX-2, and putative central COX-3/splice variants). It also stimulates descending inhibitory serotonergic pain pathways and produces active metabolites (AM404) that act on cannabinoid type 1 ($\text{CB}_1$) and vanilloid ($\text{TRPV}_1$) receptors. It possesses negligible peripheral anti-inflammatory activity.
   • Traditional NSAIDs (e.g., Ketorolac, Ibuprofen): Non-selectively and competitively inhibit peripheral and central cyclooxygenase enzymes ($\text{COX-1}$ and $\text{COX-2}$), preventing the conversion of arachidonic acid to prostaglandin $\text{H}_2$ ($\text{PGH}_2$), thereby blocking the downstream synthesis of inflammatory prostanoids ($\text{PGE}_2, \text{PGI}_2$) and thromboxane $\text{A}_2$.
2. Rectal Paracetamol Dosing Regimens:
   • Loading Dose: $30 - 40\text{ mg/kg}$ per rectum single dose (erratic and slower rectal bioavailability compared to oral route necessitates a higher loading dose).
   • Maintenance Dose: $15 - 20\text{ mg/kg}$ per rectum every 6 to 8 hours as needed.
   • Maximum Daily Limits:
     • Preterm infants ($< 32$ weeks PMA): $60\text{ mg/kg/day}$.
     • Term neonates ($0 - 28$ days): $60 - 80\text{ mg/kg/day}$.
     • Infants and older children: $90\text{ mg/kg/day}$ (not to exceed $4000\text{ mg/day}$).
3. Intravenous NSAID (Ketorolac Tromethamine):
   • Dose: $0.5\text{ mg/kg/dose}$ IV (maximum single dose: $15\text{ mg}$).
   • Frequency: Every 6 to 8 hours.
   • Duration: Maximum duration $\le 48 - 72\text{ hours}$ (not to exceed 5 days) to minimize nephrotoxicity and gastrointestinal bleeding.
   • Contraindications:
     • Active gastrointestinal ulceration or bleeding.
     • Renal impairment or significant uncorrected hypovolemia/dehydration.
     • Coagulopathy, active thrombocytopenia, or high risk of postoperative surgical site hemorrhage.
     • Aspirin-exacerbated respiratory disease (aspirin-induced asthma triad).
4. Paracetamol Toxicity Threshold & NAC Regimen:
   • Toxic Ingestion Threshold:
     $$ > \begin{aligned} > \text{Threshold Dose} &= 150 - 200\text{ mg/kg} \\ > \text{For 16 kg Child} &= 16 \times 150\text{ mg} \text{ to } 16 \times 200\text{ mg} \\ > &= \mathbf{2400\text{ to }3200\text{ mg}} > \end{aligned} > $$
   • Intravenous N-Acetylcysteine (NAC) Regimen (Modified 2-Bag / Standard 3-Bag):
     • Standard 3-Bag Infusion:
       • Loading infusion: $150\text{ mg/kg}$ in $5\%\text{ Dextrose}$ over 60 minutes.
       • Second infusion: $50\text{ mg/kg}$ in $5\%\text{ Dextrose}$ over 4 hours.
       • Third infusion: $100\text{ mg/kg}$ in $5\%\text{ Dextrose}$ over 16 hours.
       • Total dose: $300\text{ mg/kg}$ over 21 hours.

1. Relative Potency of Parenteral Opioid Analgesics:

   Opioid Agent	Relative Potency (Relative to IV Morphine = 1)
   **Peth

1. Stoichiometric and Physiological Derivation:

   • Constant 2: Sodium is the dominant extracellular cation; multiplying by 2 accounts for electrical neutrality provided by the accompanying univalent extracellular anions (principally chloride [$\text{Cl}^-$] and bicarbonate [$\text{HCO}_3^-$]).
   • Constant 18: Converts glucose concentration from $\text{mg/dL}$ to $\text{mmol/L}$ ($\text{mOsm/L}$). The molecular weight of glucose ($\text{C}_6\text{H}_{12}\text{O}_6$) is $180\text{ g/mol}$. Converting $\text{mg/dL}$ to $\text{mg/L}$ ($\times 10$) and dividing by $180$ yields: $\frac{10}{180} = \frac{1}{18}$.
   • Constant 2.8: Converts Blood Urea Nitrogen ($\text{BUN}$) from $\text{mg/dL}$ to $\text{mmol/L}$. Urea ($\text{CH}_4\text{N}_2\text{O}$) contains two nitrogen atoms with an atomic mass of $28\text{ g/mol of nitrogen}$ ($2 \times 14$). Converting $\text{mg/dL}$ to $\text{mg/L}$ ($\times 10$) and dividing by $28$ yields: $\frac{10}{28} = \frac{1}{2.8}$.

2. Calculation and Clinical Interpretation:
   

   $$ > \begin{aligned} > \text{Calculated Osmolality} &= 2 \times [\text{Na}^+] + \frac{[\text{Glucose}]}{18} + \frac{[\text{BUN}]}{2.8} \\ > &= 2 \times 140 + \frac{180}{18} + \frac{28}{2.8} \\ > &= 280 + 10 + 10 = \mathbf{300\text{ mOsm/kg H}_2\text{O}} \quad (275\text{--}295\text{ mOsm/kg H}_2\text{O}) \\ > \text{Osmolar Gap} &= \text{Measured Osmolality} - \text{Calculated Osmolality} \\ > &= 320 - 300 = \mathbf{20\text{ mOsm/kg H}_2\text{O}} \quad (< 10\text{ mOsm/kg H}_2\text{O}) > \end{aligned} > $$
   • Interpretation: An elevated osmolar gap ($> 10\text{ mOsm/kg H}_2\text{O}$) confirms the presence of an unmeasured low-molecular-weight exogenous osmotically active solute in the extracellular fluid.
   • Etiologies: Toxic alcohol ingestion (methanol, ethylene glycol, isopropanol, or propylene glycol).

3. Effective vs. Ineffective Osmoles:

   • Effective Osmoles (Tonicity Determinants): Solutes restricted to a specific fluid compartment by an impermeable membrane; they create a sustained transcellular osmotic pressure gradient driving water movement. Examples: Sodium ($\text{Na}^+$), Mannitol, Glucose (in the absence of insulin).
   • Ineffective Osmoles: Solutes that cross cell membranes freely via diffusion or facilitated transporters; they equilibrate across compartments without creating a sustained transcellular osmotic pressure gradient. Examples: Urea, Ethanol.

4. Dialysis Disequilibrium Syndrome (DDS):

   • Clinical Setting: Occurs during or within 24 hours of initiating rapid hemodialysis, particularly in children with severe, chronic azotemia ($\text{BUN} > 100\text{ mg/dL}$).
   • Pathophysiology: Rapid clearance of urea from the intravascular space creates a steep transient urea concentration gradient because urea clearance from brain tissue across the blood-brain barrier is delayed (downregulation of urea transporters and delayed efflux). This produces an intracerebral hyperosmolar state relative to plasma, drawing water into brain parenchyma and precipitating acute cerebral edema and increased intracranial pressure.
   • Preventive Strategies:
     • Initiate hemodialysis with low blood flow rates ($1.5\text{--}2.0\text{ mL/kg/min}$) and shorter dialyzer session durations ($1.5\text{--}2\text{ hours}$).
     • Concurrent infusion of osmotic agents (e.g., hypertonic saline or mannitol $0.5\text{--}1.0\text{ g/kg}$) or using a dialysate with elevated sodium or higher glucose concentration to maintain serum osmolality during urea reduction.

1. Classification of Oxygen Delivery Systems:

   • Variable-Performance (Low-Flow) Systems: Deliver gas flow rates below the patient's peak inspiratory flow demand (normal pediatric peak inspiratory flow is $3\text{--}4$ times minute ventilation, approximately $1\text{--}2\text{ L/kg/min}$). The patient entrains ambient room air to meet total inspiratory demand; delivered $\text{FiO}_2$ fluctuates with tidal volume, respiratory rate, and peak flow.
   • Fixed-Performance (High-Flow) Systems: Deliver total gas flow that meets or exceeds the patient’s peak inspiratory flow rate. The patient breathes only the gas mixture supplied by the device, guaranteeing a precise, constant $\text{FiO}_2$ independent of patient ventilatory patterns.

2. Device Identification and Working Principle:

   • Device: Air-entrainment mask (Venturi mask).
   • Principle: Bernoulli principle and jet-entrainment (often termed the Venturi effect).
   • Mechanism: Oxygen enters through a constricted orifice at high velocity, producing a drop in lateral pressure at the nozzle aperture. This localized pressure differential draws in ambient room air through calibrated side entrainment ports. Regulating the orifice size and entrainment window area fixes the ratio of entrained air to source oxygen, delivering a precise $\text{FiO}_2$ ($0.24\text{--}0.50$).

3. Mathematical Derivations:
   

   $$ > \begin{aligned} > \text{Air-to-Oxygen Ratio} &= \frac{1.00 - \text{FiO}_2}{\text{FiO}_2 - 0.21} \\ > &= \frac{1.00 - 0.40}{0.40 - 0.21} \\ > &= \frac{0.60}{0.19} \approx \mathbf{3.16 : 1} \quad (\approx 3.16\text{ parts air to } 1\text{ part } \text{O}_2) \\ > \text{Total Flow Factor} &= 3.16 + 1 = 4.16 \\ > \text{Total Gas Flow} &= \text{Oxygen Flow} \times \text{Total Flow Factor} \\ > &= 8\text{ L/min} \times 4.16 = \mathbf{33.3\text{ L/min}} > \end{aligned} > $$

4. Comparison of Nasal Cannula vs. Non-Rebreathing Reservoir Mask (NRBM):

   • Low-Flow Nasal Cannula:
     • Operational Flow Rates: $0.5\text{--}4\text{ L/min}$ (in neonates/infants $\le 2\text{ L/min}$; flows $> 4\text{ L/min}$ cause mucosal drying and epistaxis).
     • Delivered $\text{FiO}_2$ Range: $0.24\text{--}0.44$ (rule of thumb: adds $\approx 3\text{--}4\%$ per $1\text{ L/min}$).
     • Clinical Limitations: Unreliable $\text{FiO}_2$ in mouth-breathers; high flows cause drying, discomfort, and crusting without warm humidification.
   • Non-Rebreathing Reservoir Mask (NRBM):
     • Operational Flow Rates: $10\text{--}15\text{ L/min}$ (flow must prevent reservoir bag collapse during inspiration).
     • Delivered $\text{FiO}_2$ Range: $0.80\text{--}0.95$ (does not deliver true $100\%$ due to mask seal leaks).
     • Clinical Limitations: Risk of asphyxiation and $\text{CO}_2$ rebreathing if source oxygen fails or if flow drops below $10\text{ L/min}$; ill-fitting masks lead to significant air dilution.

1. Neurobiological Pain Categories:

   • Somatic Nociceptive Pain: Arises from direct activation of peripheral nociceptors in cutaneous, subcutaneous, or musculoskeletal tissue; described as sharp, localized, or aching. Example: Lacerations, acute bone fractures, post-surgical incisional wounds.
   • Visceral Nociceptive Pain: Arises from stretch, ischemia, or inflammation of internal thoracic, abdominal, or pelvic organs; poorly localized, dull, crampy, often accompanied by autonomic symptoms. Example: Acute appendicitis, intussusception, renal colic.
   • Neuropathic Pain: Arises as a direct consequence of a lesion or disease affecting the peripheral or central somatosensory nervous system; characterized by burning, shooting, paresthesias, or allodynia. Example: Vincristine-induced peripheral neuropathy, phantom limb pain, complex regional pain syndrome (CRPS).

2. FLACC Behavioral Pain Assessment Tool:

   • Parameters (0, 1, or 2 points each):
     • F – Face (0 = smile/no expression; 1 = occasional grimace/frown; 2 = frequent/constant quivering chin, clenched jaw).
     • L – Legs (0 = normal/relaxed; 1 = uneasy/restless/tense; 2 = kicking/legs drawn up).
     • A – Activity (0 = lying quietly/normal movement; 1 = squirming/shifting/tense; 2 = arched/rigid/jerking).
     • C – Cry (0 = no cry; 1 = moans/whimpers/occasional complaint; 2 = continuous crying/screaming/sobbing).
     • C – Consolability (0 = content/relaxed; 1 = reassured by touching/hugging/talking; 2 = difficult to console or comfort).
   • Total Score Range: $0\text{--}10$ ($0 = \text{relaxed/comfortable}$, $1\text{--}3 = \text{mild pain}$, $4\text{--}6 = \text{moderate pain}$, $7\text{--}10 = \text{severe pain}$).
   • Validated Patient Populations: Children aged 2 months to 7 years, non-verbal or pre-verbal children, mechanically ventilated pediatric patients, and children with severe cognitive or developmental impairment (FLACC Revised).

3. Classification of Local Anesthetics:

   • Amino-Esters:
     • Agents: Procaine, Tetracaine, Chloroprocaine, Benzocaine.
     • Metabolism: Rapidly hydrolyzed in plasma by pseudocholinesterase (butyrylcholinesterase); metabolite para-aminobenzoic acid (PABA) carries high risk of allergic reactions.
   • Amino-Amides:
     • Agents: Lidocaine, Bupivacaine, Ropivacaine, Prilocaine.
     • Metabolism: Metabolized by hepatic cytochrome P450 microsomal enzymes; excreted renally. Hepatic dysfunction or cardiac failure prolongs half-life and increases toxicity risk.

4. Dosing and Toxicity Management:

   • Maximum Safe Dosage Calculations:
     $$ > \begin{aligned} > \text{Plain Lidocaine Maximum Dose} &= 4.5\text{ mg/kg} \quad (\text{some guidelines } 3\text{--}5\text{ mg/kg}) \\ > &= 14\text{ kg} \times 4.5\text{ mg/kg} = \mathbf{63\text{ mg}} \\ > \text{Volume of } 1\% \text{ Lidocaine} &= \frac{63\text{ mg}}{10\text{ mg/mL}} = \mathbf{6.3\text{ mL}} \\ > \text{Lidocaine with Epinephrine Maximum Dose} &= 7.0\text{ mg/kg} \\ > &= 14\text{ kg} \times 7.0\text{ mg/kg} = \mathbf{98\text{ mg}} \\ > \text{Volume of } 1\% \text{ with Epinephrine} &= \frac{98\text{ mg}}{10\text{ mg/mL}} = \mathbf{9.8\text{ mL}} > \end{aligned} > $$
   • LAST Rescue Antidote:
     • Intravenous Lipid Emulsion ($20\%$ Intralipid): Initial bolus of $1.5\text{ mL/kg}$ IV over $2\text{--}3\text{ minutes}$, followed by a continuous infusion at $0.25\text{ mL/kg/min}$ (up to $0.5\text{ mL/kg/min}$ if refractory).

1. Rhythm Identification and Classification:

   • Rhythm: Asystole (ventricular standstill / flat line).
   • Classification: Non-shockable cardiac arrest rhythm (defibrillation/cardioversion is strictly contraindicated).

2. Immediate PALS Resuscitation Protocol:

   • High-Quality Chest Compressions:
     • Rate: $100\text{--}120\text{ compressions/min}$.
     • Depth: At least one-third the anteroposterior diameter of the chest (approximately $5\text{ cm}$ or $2\text{ inches}$).
     • Technique: Allow full chest recoil after each compression; minimize interruptions to $< 10\text{ seconds}$.
   • Ventilation:
     • Compression-to-ventilation ratio of $15:2$ (two-rescuer pediatric cardiac arrest) with bag-mask ventilation.
     • Connect bag-valve-mask to $100\%$ supplemental oxygen with an oxygen reservoir at $15\text{ L/min}$.
   • Vascular Access: Rapidly establish IV access; if unsuccessful within 60 seconds, place an intraosseous (IO) needle (proximal tibia).

3. Pharmacotherapy Dosing & Administration:
   

   $$ > \begin{aligned} > \text{Drug} &= \mathbf{\text{Epinephrine (Adrenaline)}} \\ > \text{Route} &= \text{Intravenous (IV) or Intraosseous (IO)} \\ > \text{Dose} &= 0.01\text{ mg/kg} \quad (10\ \mu\text{g/kg}) \\ > \text{Concentration} &= 1:10,000 \quad (0.1\text{ mg/mL}) \\ > \text{Calculated Dose} &= 18\text{ kg} \times 0.01\text{ mg/kg} = \mathbf{0.18\text{ mg}} \\ > \text{Calculated Volume} &= 18\text{ kg} \times 0.1\text{ mL/kg} = \mathbf{1.8\text{ mL of } 1:10,000 \text{ solution}} \\ > \text{Frequency} &= \text{Every } 3\text{--}5\text{ minutes during active resuscitation} > \end{aligned} > $$
   • Flush each dose with $5\text{ mL}$ of normal saline to ensure central circulation entry.

4

1. Defibrillation Energy Dosing:
   • Initial shock energy: $2\text{ J/kg}$
   • Subsequent shock energy: $4\text{ J/kg}$ (subsequent shocks may escalate to $\ge 4\text{--}10\text{ J/kg}$, not to exceed the maximum standard adult dose of $200\text{ J}$ biphasic or $360\text{ J}$ monophasic).
   • Dose Calculation for 16-kg Patient:
     $$ > \begin{aligned} > \text{Initial Shock} &= 2\text{ J/kg} \times 16\text{ kg} = \mathbf{32\text{ J}} \quad (\text{deliver 30--35 J on manual defibrillator}) \\ > \text{Second Shock} &= 4\text{ J/kg} \times 16\text{ kg} = \mathbf{64\text{ J}} \quad (\text{deliver 60--70 J on manual defibrillator}) > \end{aligned} > $$
2. PALS Guidelines Statements (True / False):
   • (i) False: Cuffed endotracheal tubes are safe and preferred across all pediatric ages (including infants), as they reduce the need for tube exchanges, improve ventilation accuracy, and decrease aspiration risk without increasing subglottic injury when cuff pressure is properly monitored.
   • (ii) False: Routine premedication with atropine prior to emergency tracheal intubation is not recommended by AHA/ILCOR guidelines; it may be considered only in selected high-risk scenarios (e.g., when using succinylcholine or in patients with pre-existing bradycardia).
   • (iii) True: Continuous quantitative waveform capnography is strongly recommended during CPR; an $ETCO_2 < 10\text{--}15\text{ mm Hg}$ reflects suboptimal compressions, whereas a sudden, sustained rise in $ETCO_2$ ($\ge 35\text{--}40\text{ mm Hg}$) is an early indicator of ROSC.
   • (iv) True: Both amiodarone and lidocaine are equally recommended Class IIb options for shock-refractory VF/pVT; pediatric trials demonstrate equivalent rates of ROSC and survival to hospital discharge.
3. Endotracheal Tube Sizing & Cuff Pressure:
   $$ > \begin{aligned} > \text{Cuffed ETT ID (mm)} &= \frac{\text{Age in years}}{4} + 3.5 \\ > &= \frac{4}{4} + 3.5 \\ > &= \mathbf{4.5\text{ mm ID}} \quad (\text{keep 4.0 mm and 5.0 mm readily available}) > \end{aligned} > $$
   • Safe Cuff Pressure Limit: $\le \mathbf{20\text{--}25\text{ cm H}_2\text{O}}$ (measured with a calibrated manometer to avoid capillary hypoperfusion and mucosal necrosis of the subglottic tracheal wall).
4. Resuscitation Pharmacotherapy (Shock-Refractory Rhythm):
   • Adrenaline (Epinephrine):
     • Dose & Formulation: $0.01\text{ mg/kg}$ IV/IO ($0.1\text{ mL/kg}$ of $1:10,000$ [$0.1\text{ mg/mL}$] concentration). For this 16-kg child = $\mathbf{0.16\text{ mg}}$ ($1.6\text{ mL}$).
     • Timing: Administer after the 2nd defibrillation attempt during CPR; repeat every 3 to 5 minutes thereafter.
   • Antiarrhythmic Agent (Either Amiodarone OR Lidocaine):
     • Amiodarone: $\mathbf{5\text{ mg/kg}}$ IV/IO rapid bolus (For 16 kg = $\mathbf{80\text{ mg}}$, maximum single dose $300\text{ mg}$); can repeat up to 2 times for refractory VF/pVT.
     • OR Lidocaine: $\mathbf{1\text{ mg/kg}}$ IV/IO loading bolus (For 16 kg = $\mathbf{16\text{ mg}}$, maximum single dose $100\text{ mg}$); followed by continuous infusion ($20\text{--}50\text{ mcg/kg/min}$) if ROSC is achieved.

PALS Shockable Rhythm Algorithm (VF / Pulseless VT)

graph TD
    A[VF / Pulseless VT Identified] --> B[Shock 1: 2 J/kg]
    B --> C[Immediate CPR for 2 minutes<br/>Obtain IV/IO access]
    C --> D{Rhythm Check: Shockable?}
    D -- Yes --> E[Shock 2: 4 J/kg]
    E --> F[Immediate CPR for 2 minutes<br/>Administer Epinephrine 0.01 mg/kg IV/IO<br/>Consider Advanced Airway / Capnography]
    F --> G{Rhythm Check: Shockable?}
    G -- Yes --> H[Shock 3: >= 4 J/kg up to 10 J/kg]
    H --> I[Immediate CPR for 2 minutes<br/>Administer Amiodarone 5 mg/kg OR Lidocaine 1 mg/kg<br/>Treat Reversible Causes: 5 Hs & 5 Ts]
    D -- No --> J[Asystole / PEA Protocol or ROSC Care]
    G -- No --> J

Key Practical Reminders for Postgraduate Examinations

• Endotracheal Formulas:
  • Uncuffed ETT ID (mm): $\frac{\text{Age}}{4} + 4.0$
  • Cuffed ETT ID (mm): $\frac{\text{Age}}{4} + 3.5$
  • Tube Depth at Lip (cm): $\text{Tube ID (mm)} \times 3$ OR $\frac{\text{Age in years}}{2} + 12\text{ cm}$.
• Energy Progression: Current ILCOR/AHA consensus permits subsequent energy escalation beyond $4\text{ J/kg}$ up to $10\text{ J/kg}$ (or adult maximum) if ventricular fibrillation persists after consecutive shocks.
• Minimizing Interruptions: Defibrillator charging must occur during ongoing chest compressions; compressions are paused solely for rhythm check and the brief shock discharge ($<5\text{ seconds}$). CPR resumes immediately after shock discharge without waiting for post-shock rhythm or pulse check.

1. Resuscitation Fluid Calculation (ATLS 10th/11th Edition):
   $$ > \begin{aligned} > \text{Resuscitation Volume} &= 3 \text{ mL} \times \text{Body Weight (kg)} \times \text{TBSA Burnt (\%)} \\ > &= 3 \text{ mL} \times 12 \text{ kg} \times 25 \\ > &= \mathbf{900 \text{ mL of Ringer's Lactate (Hartmann's Solution)}} > \end{aligned} > $$
2. Administration Schedule (from time of burn injury):
   • First 8 hours: Administer $50\%$ of calculated volume ($450\text{ mL}$) minus any pre-hospital fluid given. Since 1 hour has elapsed, $450\text{ mL}$ is infused over the remaining 7 hours ($\approx 64\text{ mL/hr}$).
   • Next 16 hours: Administer remaining $50\%$ ($450\text{ mL}$) over 16 hours ($\approx 28\text{ mL/hr}$).
3. Concurrent Maintenance Fluid Rationale and Calculation:
   • Rationale: Children $<30\text{ kg}$ have low hepatic glycogen reserves and are prone to severe hypoglycemia; the burn formula replaces only translocated intravascular volume, not baseline metabolic requirements.
   • Composition: $5\%$ Dextrose in $0.45\%$ Normal Saline with $20\text{ mEq/L}$ Potassium Chloride (once adequate urine output is documented).
     $$ > \begin{aligned} > \text{Maintenance (Holliday-Segar)} &= 100 \text{ mL/kg for first 10 kg} + 50 \text{ mL/kg for next 2 kg} \\ > &= 1000 \text{ mL} + (2 \times 50 \text{ mL}) \\ > &= \mathbf{1100 \text{ mL/24 hours}} \quad (\approx 46 \text{ mL/hr}) > \end{aligned} > $$
   • Administered through a separate infusion line or piggybacked concurrently with Ringer's Lactate.
4. Colloid Administration Guidelines:
   • Timing: Not indicated during the initial 8–12 hours due to generalized capillary leak ("burn shock").
   • Indications: Indicated after 18–24 hours post-burn when capillary permeability normalizes, particularly if resuscitation fluid requirements exceed $150\%$ of predicted Parkland volume, or serum albumin falls below $2.0\text{ g/dL}$.
   • Agent & Dose: $5\%$ Albumin at $0.5–1.0\text{ mL/kg/\% TBSA}$ over 24 hours.
5. Endpoints of Resuscitation:
   • Urine output target: $1.0–1.5\text{ mL/kg/hr}$ in children $<30\text{ kg}$ via indwelling Foley catheter.
   • Capillary refill time $<2$ seconds, normal age-appropriate heart rate and blood pressure.
   • Clearing mental status / sensorium.
   • Resolution of base deficit and normalization of serum lactate ($<2\text{ mmol/L}$).

1. Initial Assessment & Team Activation Sequence:
   • Verify scene safety; check responsiveness by tapping shoulders and shouting ("Are you okay?").
   • Shout for immediate resuscitation assistance and activate "Code Blue" / Pediatric Crash Team.
   • Simultaneously assess breathing (apnea or agonal gasps) and check carotid or femoral pulse for $\ge 5$ but $\le 10$ seconds.
   • If no pulse or pulse is uncertain within 10 seconds: Immediately initiate chest compressions ($C \to A \to B$ sequence).
2. High-Quality CPR Parameters:
   • Compression rate: $100–120\text{ compressions/minute}$.
   • Compression depth: At least one-third the anteroposterior diameter of the chest (approximately $2\text{ inches} / 5\text{ cm}$).
   • Chest recoil: Allow complete elastic chest recoil after each compression; avoid leaning on the chest.
   • Compression-to-ventilation ratio:
     • Single rescuer: $30:2$.
     • Two or more healthcare rescuers: $15:2$.
     • With advanced airway: Continuous compressions at $100–120/\text{min}$ with 1 breath every $2–3\text{ seconds}$ ($20–30\text{ breaths/min}$).
   • Minimize interruptions in compressions to $<10$ seconds; rotate compressors every 2 minutes.
3. Rhythm-Specific Algorithms:
   • Shockable Rhythms (Ventricular Fibrillation / Pulseless Ventricular Tachycardia):
     • Deliver initial asynchronous shock: $2\text{ J/kg}$ ($50\text{ J}$).
     • Immediately resume CPR for 2 minutes without checking pulse/rhythm.
     • Second shock: $4\text{ J/kg}$ ($100\text{ J}$); subsequent shocks $\ge 4\text{ J/kg}$ (up to $10\text{ J/kg}$ or adult maximum $200\text{ J}$).
     • Administer Epinephrine after 2nd shock; Amiodarone or Lidocaine after 3rd shock.
   • Non-Shockable Rhythms (Asystole / Pulseless Electrical Activity):
     • Resume CPR immediately; establish IV/IO access.
     • Administer Epinephrine as early as possible.
     • Reassess rhythm and pulse every 2 minutes; aggressively identify and treat reversible causes ($H\text{'s and }T\text{'s}$).
4. Emergency Resuscitation Pharmacotherapy (Weight = 25 kg):
   • Epinephrine: $0.01\text{ mg/kg}$ ($0.1\text{ mL/kg}$ of $1:10,000$ concentration) IV/IO = $\mathbf{0.25\text{ mg} \ (2.5\text{ mL of } 1:10,000)}$, repeated every $3–5$ minutes.
   • Amiodarone (refractory VF/pVT): $5\text{ mg/kg}$ IV/IO bolus = $\mathbf{125\text{ mg}}$ rapid bolus; can repeat up to 2 times (maximum total cumulative dose $15\text{ mg/kg}$).
   • Lidocaine (alternative to Amiodarone): Initial bolus of $1\text{ mg/kg}$ IV/IO = $\mathbf{25\text{ mg}}$.

1. Severity Classification & Blind Sweep Contraindication:
   • Classification: Severe / Complete Foreign Body Airway Obstruction (indicated by silent/ineffective cough, inability to vocalize, severe retractions, and central cyanosis).
   • Contraindication to Blind Finger Sweeps: Blind sweeps risk pushing a supraglottic or pharyngeal foreign body further down into the subglottic space or larynx, precipitating complete, irreversible airway obstruction and vocal cord trauma.
2. Physical Dislodgement Maneuvers by Age:
   • Infant ($<1\text{ year old}$):
     • Prone position: Straddle infant facedown along rescuer's forearm, supporting head/mandible with hand, head lower than trunk.
     • Deliver 5 firm back slaps/blows between scapulae with heel of hand.
     • Turn infant supine onto opposite forearm, maintaining head-down position.
     • Deliver 5 quick downward chest thrusts in midline over lower half of sternum (similar to CPR compressions).
     • Repeat cycles of 5 back blows and 5 chest thrusts until dislodged or infant becomes unresponsive. (Abdominal thrusts are avoided due to risk of liver/splenic laceration).
   • Child $>1\text{ year old}$ (Index patient, 14 months):
     • Deliver subdiaphragmatic abdominal thrusts (Heimlich maneuver): Stand or kneel behind child, wrap arms around waist.
     • Place thumb-side of fist against mid-abdomen (between umbilicus and xiphoid process).
     • Grasp fist with other hand and deliver quick, inward, and upward thrusts until foreign object is expelled or child loses consciousness.
3. Management if Child Becomes Unresponsive:
   • Ease child gently onto a firm, flat surface and immediately call for advanced airway support.
   • Initiate cardiopulmonary resuscitation starting with 30 chest compressions (or 15 if 2 rescuers).
   • Open airway: Look into oropharynx; if a foreign body is clearly visible, perform a careful finger sweep to remove it. If nothing is visualized, do not sweep.
   • Attempt 2 rescue breaths; if chest does not rise, reposition head and re-attempt.
   • Continue CPR cycles ($15:2$ or $30:2$), checking oral cavity before each series of ventilations.
4. Definitive Procedure & Late Complications:
   • Definitive Procedure: Rigid bronchoscopy under general anesthesia in an operating room suite.
   • Late Complications:
     • Bronchiectasis.
     • Recurrent or non-resolving post-obstructive atelectasis/pneumonia.
     • Lung abscess or bronchial granulation tissue with airway stenosis.

1. Pediatric Trauma Score (PTS) Matrix & Patient Calculation:

2. Prognostic Significance & Cutoff:
   • Threshold Score $\le 8$: Indicates major polytrauma requiring immediate transfer to a Level-1 Pediatric Trauma Center; associated with significantly higher morbidity and mortality.
   • Mortality correlation: Scores $>8$ carry near $0\%$ mortality; scores $\le 0$ carry $>80\%$ mortality. A score of $+2$ denotes high risk of mortality.
3. Pediatric-Specific Primary Survey ($A-B-C-D-E$):
   • A (Airway with Cervical Spine Protection): Neutral in-line immobilization using age-appropriate rigid collar; avoid neck hyperextension (large occiput causes airway buckling; place thoracic elevation padding).
   • B (Breathing & Ventilation): High-flow $100\%$ oxygen via non-rebreather mask; assess for tension pneumothorax, flail chest, or hemothorax; thoracostomy decompression if indicated.
   • C (Circulation & Hemorrhage Control): Direct pressure over bleeding sites; establish two large-bore peripheral IV lines ($18–20\text{ G}$) or intraosseous (IO) access if IV failed within 90 seconds.
   • D (Disability): Rapid AVPU score or Pediatric Glasgow Coma Scale; assess pupillary size and reactivity; check point-of-care blood glucose.
   • E (Exposure & Environmental Control): Full exposure to examine hidden injuries; aggressively prevent hypothermia using warm blankets and fluid warmers.
4. Fluid & Blood Transfusion Protocol in Hemorrhagic Shock:
   • Initial bolus: Balanced crystalloid (Ringer's Lactate or Plasmalyte) $20\text{ mL/kg}$ ($360\text{ mL}$) rapid IV push over $5–10$ minutes.
   • If non-responsive or transiently responsive: Administer packed red blood cells (PRBCs) at $10–20\text{ mL/kg}$ ($180–360\text{ mL}$) (O-negative or type-specific).
   • Massive Transfusion Protocol (MTP): If ongoing hemorrhage persists, initiate a balanced 1:1:1 ratio of PRBCs ($10\text{ mL/kg}$), Fresh Frozen Plasma ($10\text{ mL/kg}$), and Platelets ($10\text{ mL/kg}$).

1. Radiographic Finding & Clinical Triad:
   • Radiographic abnormality: Massive cardiomegaly with a symmetric globular or "water-bottle" / "flask-shaped" cardiac silhouette, sharp cardiophrenic angles, and clear lung fields, characteristic of massive pericardial effusion.
   • Clinical triad: Beck's Triad (manifestation of cardiac tamponade):
     • Hypotension with narrowed pulse pressure ($80/62\text{ mmHg}$).
     • Distended neck veins / elevated jugular venous pressure.
     • Muffled / distant heart sounds.
2. Emergency Procedure & Hemodynamic Indications:
   • Procedure: Emergency Pericardiocentesis (preferably ultrasound-guided).
   • Indications:
     • Hemodynamic instability / decompensated cardiac tamponade (hypotension, pulsus paradoxus $>10–12\text{ mmHg}$, shock).
     • Suspected purulent/pyogenic pericarditis for immediate source control and microbiological identification.
3. Step-by-Step Pericardiocentesis Technique:
   • Patient position: Semi-recumbent position at $30–45^\circ$ angle (brings heart closer to anterior chest wall).
   • Asepsis & Local Anesthesia: Full surgical scrub, drape, and local infiltration with $1–2\%$ Lignocaine.
   • Anatomical Landmark: Subxiphoid approach — insert needle in the angle between the left costal margin and the xiphoid process (infrasternal notch).
   • Needle Trajectory: 18–20 gauge spinal needle or needle with cannula attached to a 20 mL syringe; advance at a $30–45^\circ$ angle to the abdominal skin, aiming toward the left shoulder.
   • Guidance / Monitoring:
     • Direct real-time ultrasound guidance (ideal): visualize the needle entering the hypoechoic pericardial space.
     • ECG monitoring: Attach alligator clip from chest lead (V-lead) to needle hub; ST-segment elevation or ventricular ectopy signals contact with epicardium (prompting immediate slight withdrawal).
   • Aspirate fluid smoothly; advance a guidewire using Seldinger technique and place a pigtail catheter for sustained drainage.
4. Complications & Fluid Analysis:
   • Complications:
     • Right ventricular or atrial wall puncture/laceration.
     • Coronary artery laceration or hemopericardium.
     • Pneumothorax / tension pneumothorax.
     • Fatal cardiac arrhythmias (ventricular fibrillation, sustained VT).
     • Liver laceration / peritoneal perforation.
   • Diagnostic investigations on aspirate: Cytology (malignancy), Gram stain, bacterial culture, acid-fast bacilli (AFB) stain, GeneXpert / CBNAAT for Mycobacterium tuberculosis, protein, LDH, and glucose.

1. Substance-Toxicity Matching:
   • Substance 1 (Kerosene): B (Chemical pneumonitis and acute lung injury due to low viscosity, high volatility, and low surface tension).
   • Substance 2 (Chloroquine): D (Severe hypokalemia via inward potassium current inhibition, QTc prolongation, and ventricular tachyarrhythmias).
   • Substance 3 (Camphor): A (Severe early-onset neurotoxicity, intractable seizures within 5–90 minutes, and rapid CNS depression).
   • Substance 4 (Methyl salicylate): E (Mixed high anion gap metabolic acidosis and respiratory alkalosis via direct respiratory center stimulation and uncoupling of oxidative phosphorylation).
   • Substance 5 (Amitriptyline): C (Hypotension, intraventricular conduction delay [QRS widening $\ge 100\text{ ms}$], and malignant ventricular dysrhythmias via fast inward myocardial sodium channel blockade).
2. Tricyclic Antidepressant (TCA) Cardiotoxicity & Antidote:
   • Mechanism: Blockade of phase 0 fast myocardial sodium channels (causes QRS prolongation and right bundle branch pattern), peripheral $\alpha_1$-adrenergic receptor antagonism (causes refractory hypotension), and myocardial $I_{Kr}$ potassium channel blockade (causes QTc prolongation).
   • Antidote / Therapy: Intravenous Sodium Bicarbonate ($8.4\%$ solution).
   • Indication: QRS duration $>100\text{ ms}$, ventricular arrhythmias, or hypotension refractory to fluid resuscitation.
   • Dose: $1\text{ to }2\text{ mEq/kg}$ IV bolus over 2–3 minutes; repeat until QRS narrows and arterial pH achieves $7.45–7.55$, followed by continuous infusion ($150\text{ mEq } \text{NaHCO}_3$ in $1\text{ L } \text{D5W}$ at $1.5–2\times$ maintenance).
3. Mathematical Derivation of Salicylate Equivalent:
   $$ > \begin{aligned} > \text{Mass of Solution} &= \text{Volume} \times \text{Density} = 10\text{ mL} \times 1.18\text{ g/mL} = 11.8\text{ g} \\ > \text{Mass of Methyl Salicylate} &= 11.8\text{ g} \times 0.98 = 11.564\text{ g} = 11,564\text{ mg} \\ > \text{Aspirin Equivalent Factor} &\approx 1.4\text{ (due to molecular weight conversion: } 1\text{ mL of oil of wintergreen } \approx 1.4\text{ g aspirin)} \\ > \text{Total Aspirin Equivalent} &\approx 11.564\text{ g} \times 1.4 = \mathbf{16.19\text{ g}}\text{ (or } 16,190\text{ mg}) \\ > \text{Equivalent Standard Tablets} &= \frac{16,190\text{ mg}}{325\text{ mg/tablet}} \approx \mathbf{49.8\text{ tablets}} \quad (\approx 50\text{ adult tablets}) > \end{aligned} > $$
4. Contraindication to Decontamination in Hydrocarbon Ingestion:
   • Contraindication: Induction of emesis (e.g., syrup of ipecac) and routine gastric lavage are strictly contraindicated.
   • Physiological Rationale: Hydrocarbons have low surface tension and low viscosity, conferring extreme volatility. Emesis or tube manipulation triggers retrograde aspiration into the trachea, causing surfactant destruction, capillary endothelial necrosis, chemical pneumonitis, and severe ventilation-perfusion mismatch. Gastric lavage is considered only if the hydrocarbon serves as a vehicle for a highly lethal co-ingestant (e.g., organophosphates, carbamates, camphor, or heavy metals) and airway is secured with a cuffed endotracheal tube.

1. Immediate Intervention:
   • Immediate initiation of Positive Pressure Ventilation (PPV) within the "Golden Minute" (30–60 seconds of life) because the infant remains bradycardic ($\text{HR} < 100\text{ bpm}$) and gasping/apneic despite initial stabilization.
2. Technical Parameters for Initial PPV:
   • Interface: Proper-sized anatomical or round cushioned face mask covering the chin, mouth, and nose without covering the eyes or extending beyond the chin.
   • Seal Technique: Single-handed "C-clamp" or "E-C" technique (thumb and index finger forming a "C" pressing mask downward; 3rd, 4th, and 5th fingers forming an "E" lifting the bony mandible forward) or two-handed jaw thrust technique.
   • Ventilation Device & Pressures: T-piece resuscitator or flow-inflating bag preferred; initial Peak Inspiratory Pressure (PIP) of $20–25\text{ cmH}_2\text{O}$ and Positive End-Expiratory Pressure (PEEP) of $5\text{ cmH}_2\text{O}$.
   • Ventilation Rate: 40 to 60 breaths per minute (cadence: "Breathe—two—three—Breathe—two—three").
   • Inspired Oxygen Concentration ($\text{FiO}_2$): Start at $21\%$ room air for neonates $\ge 35$ weeks of gestation (avoiding hyperoxic pulmonary and cerebral injury).
3. MR. SOPA Ventilation Corrective Steps:
   • M - Mask adjustment: Reapply mask to ensure an airtight seal.
   • R - Reposition airway: Place head in neutral or slightly extended "sniffing" position.
     (Provide 5 breaths and assess chest movement; if no rise, proceed:)
   • S - Suction mouth and nose: Suction secretions using a bulb syringe or $8\text{F}–10\text{F}$ suction catheter (negative pressure $80–100\text{ mmHg}$).
   • O - Open mouth: Gently open mouth and lift jaw forward.
     (Provide 5 breaths and assess chest movement; if no rise, proceed:)
   • P - Pressure increase: Increase PIP in increments of $5\text{ cmH}_2\text{O}$ up to a maximum of $30–40\text{ cmH}_2\text{O}$ until bilateral chest expansion is visible.
     (Provide 5 breaths; if no chest rise, proceed:)
   • A - Alternative airway: Insert an endotracheal tube (ETT) or laryngeal mask airway (LMA).
4. Endotracheal Intubation Parameters:
   • Indications: If PPV does not achieve chest movement after MR. SOPA; prior to initiating chest compressions (if $\text{HR} < 60\text{ bpm}$ despite 30 seconds of effective PPV that moves the chest); or in suspected congenital diaphragmatic hernia.
   • Laryngoscope Blade: Size 1 straight (Miller) blade.
   • Endotracheal Tube Size: $3.5\text{ mm}$ internal diameter (ID) uncuffed tube (for weight $>2000\text{ g}$ or gestational age $>34$ weeks).

1. Four Pre-Birth Questions (NRP 8th Edition):
   • 1. What is the expected gestational age?
   • 2. Is the amniotic fluid clear (or stained with meconium/blood)?
   • 3. Are there any additional maternal or fetal risk factors (e.g., maternal infections, antenatal steroids, abnormal fetal heart tracing, oligohydramnios/polyhydramnios)?
   • 4. What is our umbilical cord management plan (delayed cord clamping vs. cord milking vs. immediate clamping)?
2. Pre-Resuscitation Team Briefing:
   • Identification of the team leader.
   • Allocation of specific clinical roles and responsibilities (e.g., airway operator, timer/recorder, medication/circulation nurse, equipment monitor).
   • Discussion of potential clinical scenarios and anticipation of specialized interventions (e.g., immediate thermal wrap, early CPAP, surfactant administration, umbilical venous catheterization).
   • Review of communication protocol (closed-loop communication and flat hierarchy for safety concerns).
3. Equipment Checklist (Standard Functional Categories):
   • Warmth: Radiant warmer pre-warmed to $100\%$ manual mode, warm blankets/towels, plastic wrap/polyethylene bag, chemical thermal warming mattress, servo-probe, pre-warmed hat.
   • Airway: Suction apparatus set to $80–100\text{ mmHg}$, $8\text{F}, 10\text{F}, 12\text{F}$ suction catheters, meconium aspirator, bulb syringe, shoulder roll.
   • Breathing: T-piece resuscitator (or self-inflating bag with reservoir) connected to piped medical air and oxygen blender; manometer checked (PIP set at $20–25\text{ cmH}_2\text{O}$, PEEP set at $5\text{ cmH}_2\text{O}$, gas flow at $10\text{ L/min}$); term and preterm masks; pulse oximeter with neonatal sensor; 3-lead ECG monitor; appropriate laryngoscope blades (Size 0 and 00) with bright lights; uncuffed ETTs (sizes $2.5, 3.0, 3.5\text{ mm}$); stylet; colorimetric $\text{CO}_2$ detector.
   • Circulation: 1:10,000 ($0.1\text{ mg/mL}$) Epinephrine ampoules, normal saline flush ($0.9\%$), umbilical venous catheter (UVC) tray ($3.5\text{F}$ and $5\text{F}$ catheters), scalpel, suture, three-way stopcocks.
4. Thermal Specifications for <32 Weeks Gestation:
   • Delivery/Resuscitation Room Ambient Temperature: Maintain between $23^\circ\text{C}\text{ to }25^\circ\text{C}$ ($74^\circ\text{F}–77^\circ\text{F}$).
   • Thermal Adjuncts: Food-grade polyethylene occlusive bag or plastic wrap (placed up to the neck without drying the baby), head covered with a warm cap/hat, and an underlying exothermic thermal mattress to maintain target core temperature between $36.5^\circ\text{C}\text{ and }37.5^\circ\text{C}$.

1. Diagram Identification & Axes:
   • Diagram: Left Ventricular Pressure-Volume (PV) Loop.
   • X-axis: Left Ventricular Volume, measured in milliliters ($\text{mL}$).
   • Y-axis: Left Ventricular Pressure, measured in millimeters of mercury ($\text{mmHg}$).
2. Four Critical Valve Points (Counter-Clockwise Progression):
   • Point A (Bottom-Right corner): Mitral Valve Closure (represents End-Diastolic Volume and Pressure).
   • Point B (Top-Right of vertical line): Aortic Valve Opening (LV pressure exceeds aortic diastolic pressure).
   • Point C (Top-Left corner): Aortic Valve Closure (represents End-Systolic Volume and Pressure).
   • Point D (Bottom-Left corner): Mitral Valve Opening (LV pressure falls below left atrial pressure).
3. Phases of the Ventricular Cycle:
   • Segment A $\rightarrow$ B: Isovolumetric Contraction (all valves closed, volume constant, rapid pressure rise).
   • Segment B $\rightarrow$ C: Ventricular Ejection (rapid followed by reduced ejection of blood into the aorta).
   • Segment C $\rightarrow$ D: Isovolumetric Relaxation (all valves closed, volume constant, rapid pressure decline).
   • Segment D $\rightarrow$ A: Ventricular Filling (early rapid passive filling, diastasis, and atrial contraction).
4. Mathematical Calculations:
   $$ > \begin{aligned} > \text{Stroke Volume (SV)} &= \text{EDV} - \text{ESV} \\ > &= 125\text{ mL} - 75\text{ mL} \\ > &= \mathbf{50\text{ mL}} \quad (\text{Normal pediatric value varies by BSA; reference SV: } 40–60\text{ mL}) \\[1em] > \text{Ejection Fraction (EF)} &= \left( \frac{\text{SV}}{\text{EDV}} \right) \times 100 \\ > &= \left( \frac{50}{125} \right) \times 100 \\ > &= \mathbf{40\%} \quad (\text{Depressed; normal reference range: } 55\%–70\%) \\[1em] > \text{LVSW (Approximated)} &= \text{SV} \times (\text{Mean Systolic Pressure} - \text{LV End-Diastolic Pressure}) \times 0.0136 \\ > &= 50\text{ mL} \times 90\text{ mmHg} \times 0.0136\text{ g}\cdot\text{m/mmHg}\cdot\text{mL} \\ > &= \mathbf{61.2\text{ g}\cdot\text{m/beat}} \quad (\text{or } 50\text{ mL} \times 90\text{ mmHg} = \mathbf{4500\text{ mmHg}\cdot\text{mL}}) > \end{aligned} > $$

1. Thermal Protection Protocol for Preterm Infants ($<32$ Weeks):
   • Maintain delivery room ambient temperature at $23^\circ\text{C}\text{ to }25^\circ\text{C}$.
   • Do not dry the infant's body at birth (drying wipes away heat-retaining vernix and causes evaporative heat loss).
   • Immediately place the infant up to the neck inside a pre-warmed polyethylene wrap or occlusive plastic bag under the radiant warmer.
   • Place a chemical thermal mattress beneath the radiant warmer mattress sheet.
   • Dry the head thoroughly and apply a pre-warmed cap/hat.
   • Attach a servo-controlled skin temperature probe over the right hypochondrium (target skin temperature $36.5^\circ\text{C}–37.5^\circ\text{C}$).
2. Initial Respiratory Support Parameters:
   • Modality: Continuous Positive Airway Pressure (CPAP) initiated via a T-piece resuscitator using an appropriate-sized anatomical mask or binasal prongs.
   • Initial CPAP Pressure: Set at $5\text{ to }6\text{ cmH}_2\text{O}$ (gas flow $8–10\text{ L/min}$).
   • Initial Inspired Oxygen ($\text{FiO}_2$): Initiate at $21\%–30\%$ ($0.21–0.30$) blended with medical air; titrate to preductal $\text{SpO}_2$ targets.
3. NRP 8th Edition Targeted Preductal $\text{SpO}_2$ (Right Hand/Wrist):
   • 1 minute: $60\% - 65\%$
   • 2 minutes: $65\% - 70\%$
   • 3 minutes: $70\% - 75\%$
   • 4 minutes: $75\% - 80\%$
   • 5 minutes: $80\% - 85\%$
   • 10 minutes: $85\% - 95\%$
4. Surfactant Indications, Timing, and Administration Technique:
   • Indications: Preterm infant with clinical signs of respiratory distress syndrome (RDS) requiring $\text{FiO}_2 \ge 0.30$ on CPAP $\ge 6\text{ cmH}_2\text{O}$ to maintain target preductal saturations.
   • Timing: Early administration within the first 2 hours of life is superior to delayed rescue therapy.
   • Preferred Method: LISA (Less Invasive Surfactant Administration) or MIST (Minimally Invasive Surfactant Therapy).
   • Technique: While the infant remains spontaneously breathing on CPAP, direct laryngoscopy is performed to visualize the vocal cords. A thin, flexible vascular catheter (e.g., $16\text{G}–18\text{G}$ angiocath or $4\text{F}–5\text{F}$ feeding tube) is placed $1.5–2.0\text{ cm}$ through the vocal cords. Natural bovine/porcine surfactant (e.g., Poractant alfa $200\text{ mg/kg}$ [$2.5\text{ mL/kg}$] or Beractant $100\text{ mg/kg}$ [$4\text{ mL/kg}$]) is instilled slowly over 1–3 minutes while maintaining continuous CPAP, followed immediately by catheter removal.

1. Definition of Moderate (Conscious) Sedation:
   • A drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation (reflex withdrawal from a painful stimulus is not considered a purposeful response).
2. Moderate Sedation vs. Deep Sedation:
   • Responsiveness: Purposeful response to verbal or light tactile stimuli in moderate sedation; purposeful response only following repeated or painful stimuli in deep sedation.
   • Airway: Patent without intervention in moderate sedation; may require intervention and positioning in deep sedation.
   • Spontaneous Ventilation: Adequate in moderate sedation; may be inadequate or compromised in deep sedation.
   • Cardiovascular Function: Usually maintained and stable in both levels of sedation.
3. Recovery and Discharge Scoring Systems:
   • Modified Aldrete Score.
   • Steward Post-Anesthesia Recovery Score.
4. Dissociative Sedative Agent and Dosing:
   • Drug: Ketamine hydrochloride.
   • Intravenous induction dose: $1\text{ to }2\text{ mg/kg}$ IV slowly over 60 seconds (for this child: $14\text{ to }28\text{ mg}$).
   • Antisialagogue counter-agent: Glycopyrrolate ($5\text{ to }10\text{ }\mu\text{g/kg}$ IV) or Atropine ($0.01\text{ to }0.02\text{ mg/kg}$ IV).
5. Ultra-Short-Acting Opioid:
   • Remifentanil.

1. Mechanism of Action:
   • Positive allosteric modulation and direct activation of $\text{GABA}_\text{A}$ receptor chloride channels, prolonging inhibitory postsynaptic currents.
   • Inhibition of excitatory NMDA ($N\text{-methyl-}D\text{-aspartate}$) glutamate receptors via sodium channel gating modulation.
2. Lipid Emulsion Composition and Caloric Value:
   • Formulation: 1% propofol ($10\text{ mg/mL}$) formulated in an emulsion containing 10% soybean oil, 2.25% glycerol, and 1.2% purified egg phosphatide (egg lecithin).
   • Caloric density: $1.1\text{ kcal/mL}$.
3. Indications:
   • Induction and maintenance of general anesthesia.
   • Procedural sedation for non-invasive (e.g., MRI/CT) and brief invasive diagnostic or therapeutic procedures.
   • Refractory status epilepticus unresponsive to second-line antiepileptic therapy (short-term administration).
4. Advantages:
   • Rapid onset of action ($30\text{ to }45\text{ seconds}$) and short context-sensitive half-time with rapid, clear-headed emergence.
   • Inherent antiemetic properties (reduces postoperative nausea and vomiting).
   • Reduces intracranial pressure (ICP) and cerebral metabolic rate of oxygen consumption ($\text{CMRO}_2$).
5. Contraindications:
   • Known severe hypersensitivity to propofol, egg protein, or soy products (anaphylactic allergy).
   • Prolonged high-dose infusion ($>4\text{ to }5\text{ mg/kg/hour}$ for $>48\text{ hours}$) in children due to the risk of Propofol Infusion Syndrome (PRIS).
   • Mitochondrial disorders / disorders of fatty acid oxidation (relative contraindication due to heightened susceptibility to PRIS).

1. Calculations and Acid-Base Disorder:
   $$ > \begin{aligned} > \text{Serum Anion Gap} &= \text{Na}^+ - (\text{Cl}^- + \text{HCO}_3^-) \\ > &= 138 - (96 + 9.5) \\ > &= \mathbf{32.5\text{ mEq/L}} \quad (\text{Reference: } 8\text{--}12\text{ mEq/L}) > \end{aligned} > $$
   $$ > \begin{aligned} > \text{Calculated Osmolality} &= 2 \times \text{Na}^+ + \frac{\text{Glucose (mg/dL)}}{18} + \frac{\text{BUN (mg/dL)}}{2.8} \\ > &= 2 \times 138 + \frac{90}{18} + \frac{18}{2.8} \\ > &= 276 + 5 + 6.4 = \mathbf{287.4\text{ mOsm/kg}} > \end{aligned} > $$
   $$ > \begin{aligned} > \text{Osmolar Gap} &= \text{Measured Osmolality} - \text{Calculated Osmolality} \\ > &= 325 - 287.4 = \mathbf{37.6\text{ mOsm/kg}} \quad (\text{Reference: } <10\text{ mOsm/kg}) > \end{aligned} > $$
   • Primary diagnosis: High Anion Gap Metabolic Acidosis (HAGMA) with high osmolar gap and secondary hyperlactatemia.
2. Underlying Toxic Etiology:
   • Propylene glycol toxicity secondary to prolonged, high-dose intravenous infusion of solvent-containing benzodiazepines (midazolam/lorazepam).
3. Biochemical Pathophysiology:
   • Propylene glycol is a low-molecular-weight alcohol used as a vehicle/solvent for hydrophobic parenteral medications; its accumulation raises serum osmolality and widens the osmolar gap.
   • It is metabolized in the liver by alcohol dehydrogenase to $D\text{-lactate}$ and $L\text{-lactate}$, and subsequently pyruvate, producing a severe high anion gap metabolic acidosis.
   • Toxicity causes renal proximal tubular injury, worsening acute tubular necrosis, and central nervous system depression.
4. Management Steps:
   • Immediately discontinue or taper the vehicle-containing drug infusion (transition to alternative non-propylene-glycol antiepileptics such as levetiracetam, valproate, or propofol/ketamine).
   • Hemodialysis or continuous renal replacement therapy (CRRT) to clear accumulated propylene glycol, $D\text{-lactate}$, and correct refractory acidemia (and consideration of fomepizole to inhibit alcohol dehydrogenase if severe).

1. Cardiac Arrest Rhythm:
   • Pulseless Electrical Activity (PEA).
2. Reversible Causes (Hs and Ts):
   • Hs:
     • Hypovolemia
     • Hypoxia
     • Hydrogen ion (Acidosis)
     • Hypoglycemia / Hypokalemia / Hyperkalemia / Hypothermia
   • Ts:
     • Tension pneumothorax
     • Tamponade (cardiac)
     • Toxins / Poisoning
     • Thrombosis (pulmonary or coronary)
3. First-Line Pharmacotherapy:
   • Drug: Epinephrine (Adrenaline).
   • Route: Intravenous (IV) or Intraosseous (IO).
   • Concentration & Dose: $0.01\text{ mg/kg}$ ($0.1\text{ mL/kg}$ of $1:10,000$ [$0.1\text{ mg/mL}$] solution).
   • Calculated dose for 22 kg: $0.22\text{ mg}$ ($2.2\text{ mL}$ of $1:10,000$ solution).
   • Frequency: Every $3\text{ to }5\text{ minutes}$ while cardiac arrest persists.
4. Elements of High-Quality CPR:
   • Rate: $100\text{ to }120\text{ compressions/minute}$.
   • Depth: Compress at least one-third the anteroposterior (AP) diameter of the chest (approximately $2\text{ inches [}5\text{ cm]}$ in a child).
   • Chest Recoil & Interruptions: Allow complete chest wall recoil between compressions and minimize interruptions to $<10\text{ seconds}$.

1. Clinical Triad and Significance:
   • Triad: Cushing Triad (Hypertension with widened pulse pressure, Bradycardia, and Irregular/bradypneic respirations).
   • Significance: Indicates life-threatening, critically elevated intracranial pressure (ICP) with impending or ongoing cerebral (transtentorial/uncal) herniation.
2. Clinical Coma Scoring Systems:
   • Pediatric Glasgow Coma Scale (GCS).
   • Full Outline of UnResponsiveness (FOUR) Score.
3. Modality for Monitoring ICP / Cerebral Oxygenation:
   • Intraventricular catheter (External Ventricular Drain - EVD; gold standard for therapeutic CSF drainage and monitoring).
   • Intraparenchymal fiberoptic/piezoelectric transducer catheter (e.g., Camino catheter).
   • Brain tissue oxygenation probe ($\text{PbtO}_2$, e.g., Licox system) or Near-Infrared Spectroscopy (NIRS) for cerebral regional oxygen saturation ($\text{rScO}_2$).
4. Osmotherapy Calculations & Safety Threshold:
   • 20% Mannitol:
     $$ > \begin{aligned} > \text{Dose range} &= 0.5\text{ to }1.0\text{ g/kg IV over } 15\text{--}30\text{ minutes} \\ > \text{For 30 kg child (at } 0.5\text{ g/kg)} &= 15\text{ g} = \mathbf{75\text{ mL of 20\% Mannitol}} \\ > \text{(at } 1.0\text{ g/kg)} &= 30\text{ g} = \mathbf{150\text{ mL of 20\% Mannitol}} > \end{aligned} > $$
   • 3% Hypertonic Saline (HTS):
     $$ > \begin{aligned} > \text{Dose range} &= 2\text{ to }5\text{ mL/kg IV over } 10\text{--}20\text{ minutes} \\ > \text{For 30 kg child} &= \mathbf{60\text{ to }150\text{ mL of 3\% NaCl IV}} > \end{aligned} > $$
   • Target Serum Osmolality Threshold: Withhold mannitol if measured serum osmolality exceeds $320\text{ mOsm/kg}$ to prevent renal failure.

1. The 7 Ps of Rapid Sequence Intubation (RSI):

   • Preparation ($T - 10\text{ min}$): Assemble SOAPME equipment (Suction, Oxygen, Airway gear [laryngoscope blades, ETT sizes, stylet, video laryngoscope], Pharmacy [induction/paralytic/resuscitation drugs], Monitors [ECG, NIBP, pulse oximetry, end-tidal $\text{CO}_2$], End-tidal $\text{CO}_2$ detector).
   • Preoxygenation ($T - 5\text{ min}$): Administer 100% $\text{FiO}_2$ via non-rebreather mask (NRBM) or high-flow nasal cannula for 3–5 minutes to wash out alveolar nitrogen.
   • Pretreatment / Optimization ($T - 3\text{ min}$): Hemodynamic stabilization (fluid bolus, vasopressor readiness) and optional pharmacotherapy (e.g., atropine $0.02\text{ mg/kg}$ in infants $<1$ year to prevent reflex bradycardia).
   • Paralysis with Induction ($T = 0$): Rapid IV/IO push of a potent sedative-hypnotic induction agent followed immediately by a rapid-acting neuromuscular blocking agent.
   • Positioning and Protection ($T + 20\text{ to }30\text{ s}$): Position head in "sniffing" position (neutral position with shoulder roll if $<2$ years); avoid positive pressure bag-mask ventilation unless desaturating.
   • Placement with Proof ($T + 45\text{ to }60\text{ s}$): Direct or video laryngoscopy, passage of ETT under direct vocal cord visualization, followed by clinical confirmation (bilateral breath sounds, chest rise) and quantitative continuous waveform capnography ($\text{EtCO}_2$).
   • Post-intubation Management ($T + 1\text{ to }2\text{ min}$): Secure ETT, obtain chest radiograph to verify tip position, titrate mechanical ventilation, and initiate continuous post-intubation analgosedation.

2. Induction Agents and Neuromuscular Blockers:

   • Induction Agents:
     • Ketamine: $1.5\text{–}2\text{ mg/kg}$ IV/IO. Contraindicated in severe hypersensitivity; use with caution in catecholamine-depleted shock.
     • Etomidate: $0.3\text{ mg/kg}$ IV/IO. Relative contraindication in septic shock (adrenal suppression).
     • Propofol: $1.5\text{–}3\text{ mg/kg}$ IV/IO. Absolute contraindication in egg/soybean allergy, hemodynamic instability/hypotension.
   • Neuromuscular Blocking Agents:
     • Succinylcholine (Depolarizing): $1.5\text{–}2\text{ mg/kg}$ IV/IO ($2\text{ mg/kg}$ if $<1$ year, $1.5\text{ mg/kg}$ if $>1$ year). Contraindicated in malignant hyperthermia history, acute denervation syndromes/myopathies, hyperkalemia, and crush/burn injuries $>48\text{ hours}$ old.
     • Rocuronium (Non-depolarizing): $0.9\text{–}1.2\text{ mg/kg}$ IV/IO. Reversible with Sugammadex ($16\text{ mg/kg}$ for immediate rescue reversal).

3. Mathematical Derivations for Endotracheal Tube Dimensions:
   

   $$ > \begin{aligned} > \text{Uncuffed ETT ID (mm)} &= \frac{\text{Age (years)}}{4} + 4 \\ > &= \frac{6}{4} + 4 = \mathbf{5.5\text{ mm ID}} \\ > \text{Cuffed ETT ID (mm)} &= \frac{\text{Age (years)}}{4} + 3.5 \\ > &= \frac{6}{4} + 3.5 = \mathbf{5.0\text{ mm ID}} \\ > \text{Depth of Insertion at Lip (cm)} &= \text{Cuffed ID} \times 3 = 5.0 \times 3 = \mathbf{15\text{ cm}} \\ > \text{Alternative Formula} &= \frac{\text{Age (years)}}{2} + 12 = \frac{6}{2} + 12 = \mathbf{15\text{ cm}} > \end{aligned} > $$

4. Preoxygenation Rationale and Target Parameters:

   • Mechanism: Replaces the nitrogen gas resident within the child's functional residual capacity (FRC) with 100% pure oxygen (nitrogen washout/denitrogenation). Because children have a metabolic oxygen consumption rate twice that of adults ($6\text{–}8\text{ mL/kg/min}$ vs $3\text{–}4\text{ mL/kg/min}$) and a small FRC, this intrapulmonary oxygen reservoir delays critical arterial desaturation during the apneic period of intubation.
   • Target Parameter: End-tidal oxygen concentration ($\text{EtO}_2$) $>85\text{–}90\%$ (or 3 minutes of quiet tidal breathing / 8 vital-capacity breaths on $100\%\ \text{FiO}_2$).

1. Clinical Localization Matrix of Pediatric Respiratory Distress:

   • Extrathoracic Upper Airway (e.g., Croup, Foreign Body):
     • Respiratory Rate: Increased (bradypnea if near exhaustion).
     • Retractions: Predominantly suprasternal and supraclavicular retractions.
     • I:E Ratio: Prolonged inspiration ($I > E$).
     • Audible Sounds: Inspiratory stridor, stertor, barking cough.
   • Intrathoracic Lower Airway (e.g., Bronchiolitis, Acute Asthma):
     • Respiratory Rate: Significantly elevated (tachypnea).
     • Retractions: Intercostal and subcostal indrawing.
     • I:E Ratio: Prolonged expiration with active abdominal push ($E \gg I$).
     • Audible Sounds: Expiratory wheezing, prolonged expiration.
   • Lung Parenchymal Disease (e.g., Pneumonia, ARDS):
     • Respiratory Rate: Marked tachypnea.
     • Retractions: Subcostal, intercostal, sternal retractions with nasal flaring.
     • I:E Ratio: Normal or balanced ($I = E$).
     • Audible Sounds: Expiratory grunting (auto-PEEPing), fine/coarse crackles, bronchial breath sounds.
   • Extrapulmonary / Chest Wall / Neuromuscular:
     • Respiratory Rate: Shallow tachypnea or bradypnea/hypopnea.
     • Retractions: Paradoxical (seesaw) breathing, minimal or absent retractions despite severe weakness.
     • I:E Ratio: Variable; shallow tidal volume.
     • Audible Sounds: Absent breath sounds, faint cry, no adventitious sounds.

2. Systemic Non-Pulmonary Etiologies of Respiratory Distress:

   • Diabetic Ketoacidosis (Kussmaul deep breathing secondary to metabolic acidosis).
   • Inborn Errors of Metabolism / Organic Acidemias (lactic acidosis, hyperammonemia).
   • Congestive Heart Failure / Congenital Heart Disease (pulmonary venous congestion).
   • Severe Anemia (tissue hypoxia leading to compensatory tachypnea).
   • Salicylate Toxicity (direct stimulation of the medullary respiratory center causing primary respiratory alkalosis followed by metabolic acidosis).

3. Calculation of the Oxygenation Index (OI):
   

   $$ > \begin{aligned} > \text{Oxygenation Index (OI)} &= \frac{\text{FiO}_2 \times \text{MAP} (\text{cmH}_2\text{O}) \times 100}{\text{PaO}_2 (\text{mmHg})} \\ > &= \frac{0.60 \times 15 \times 100}{75} \\ > &= \frac{900}{75} = \mathbf{12} > \end{aligned} > $$
   • Interpretation: $\text{OI} = 12$ indicates moderate Pediatric Acute Respiratory Distress Syndrome (PARDS) per PALICC criteria (Mild: $4 \le \text{OI} < 8$; Moderate: $8 \le \text{OI} < 16$; Severe: $\text{OI} \ge 16$).

4. Classification of Respiratory Failure:

   • Type 1 (Hypoxemic Respiratory Failure): $\text{PaO}_2 < 60\text{ mmHg}$ on room air with normal or low $\text{PaCO}_2$ ($<45\text{ mmHg}$); caused by V/Q mismatch or intrapulmonary shunt (e.g., severe pneumonia, ARDS, pulmonary edema).
   • Type 2 (Hypercapnic Respiratory Failure): $\text{PaCO}_2 > 50\text{ mmHg}$ with associated respiratory acidosis ($\text{pH} < 7.35$); caused by alveolar hypoventilation or respiratory muscle fatigue (e.g., status asthmaticus exhaustion, Guillain-Barré syndrome, central respiratory depression).

1. Pharmacological Class and Mechanisms of Action:

   • Class & Target: Genetically engineered chimeric murine/human monoclonal IgG1-kappa antibody directed specifically against the human CD20 transmembrane surface antigen expressed on pre-B and mature B lymphocytes.
   • Mechanisms of Action:
     • Complement-Dependent Cytotoxicity (CDC): Binds CD20, recruits C1q, and triggers the complement cascade, forming the membrane attack complex (MAC) leading to cell lysis.
     • Antibody-Dependent Cellular Cytotoxicity (ADCC): The Fc portion binds Fc$\gamma$RIII receptors on natural killer (NK) cells and macrophages, initiating directed cytolysis.
     • Induction of Apoptosis: Cross-linking of CD20 activates intracellular caspase cascades and downregulates cell-survival signaling pathways.

2. Four Pediatric Indications Outside Nephrotic Syndrome:

   • Refractory Immune Thrombocytopenia (ITP).
   • Severe refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis.
   • Autoimmune Hemolytic Anemia (AIHA) / Evans Syndrome.
   • Post-Transplant Lymphoproliferative Disorder (PTLD) or CD20+ B-cell Non-Hodgkin Lymphoma.

3. Pre-treatment Screening and Pre-medication Protocol:

   • Infectious Disease Screening Checklist:
     • Hepatitis B serology: HBsAg, Anti-HBc total, Anti-HBs (high risk of fulminant viral reactivation).
     • Hepatitis C antibody and HIV I/II serology.
     • Latent tuberculosis screening: Mantoux (TST) or Interferon-Gamma Release Assay (IGRA) plus chest radiograph.
     • Baseline quantitative serum immunoglobulins (IgG, IgA, IgM) and absolute CD19/CD20 B-cell counts.
   • Pre-medication Protocol (30–60 minutes prior):
     • Antipyretic: Oral Paracetamol $15\text{ mg/kg}$ (max $1000\text{ mg}$).
     • Antihistamine: IV Pheniramine maleate $0.5\text{ mg/kg}$ or Diphenhydramine $1\text{ mg/kg}$.
     • Corticosteroid: IV Hydrocortisone $2\text{–}4\text{ mg/kg}$ or Methylprednisolone $1\text{ mg/kg}$.

4. Dosing, Titration, and Severe Adverse Reactions:

   • Dose & Route: $375\text{ mg/m}^2$ IV infusion once weekly for 1 to 2 doses (or single dose followed by monitoring for CD19 B-cell reconstitution $<1\%$). For this patient ($0.92\text{ m}^2$): $375 \times 0.92 = \mathbf{345\text{ mg}}$ IV.
   • Infusion Rate Titration:
     • Initiate at $50\text{ mg/hour}$ for the first 60 minutes.
     • In the absence of infusion-related reactions, escalate by $50\text{ mg/hour}$ every 30 minutes to a maximum rate of $400\text{ mg/hour}$.
   • Severe / Black-Box Adverse Reactions:
     • Severe Infusion-Related Reactions / Cytokine Release Syndrome: Acute anaphylaxis, bronchospasm, hypoxia, and cardiogenic shock (typically within 30–120 minutes of first infusion).
     • Progressive Multifocal Leukoencephalopathy (PML): Opportunistic JC polyomavirus reactivation causing fatal demyelinating brain disease.
     • Hepatitis B Reactivation: Fulminant hepatic failure.
     • Severe Late-Onset Neutropenia and Hypogammaglobulinemia: Predisposing to life-threatening bacterial and fungal sepsis.

1. Five Essential Steps of Routine Care at Birth:

   • Provide Warmth: Place the infant directly prone on the mother's bare chest/abdomen in continuous skin-to-skin contact (KMC) and cover with a warm, dry pre-warmed towel/blanket and cap.
   • Dry and Discard: Thoroughly dry the infant's skin immediately to prevent evaporative heat loss; discard wet linen and replace with dry blankets.
   • Airway Clearance (if needed): Wipe secretions from the face, mouth, and nose; avoid routine, vigorous or deep oropharyngeal suctioning in a vigorous baby.
   • Ongoing Assessment: Continuously evaluate tone, breathing/crying, and color while remaining with the mother.
   • Early Breastfeeding: Facilitate and initiate exclusive breastfeeding within the first hour of life while maintaining thermal protection.

2. Delayed Cord Clamping (DCC) Guidelines:

   • Duration: Delay umbilical cord clamping for at least 60 seconds (range: 60 to 180 seconds) after birth in vigorous term and preterm infants.
   • Physiological Benefits:
     • Term Infants: Enhances iron stores at 4–6 months of age, reducing infantile iron deficiency anemia and improving long-term neurodevelopment.
     • Preterm Infants: Increases systemic blood pressure and cerebral perfusion, reduces the incidence of intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), and neonatal mortality.
   • Contraindications:
     • Hemodynamically unstable neonate requiring immediate resuscitation where equipment cannot be brought to the mother.
     • Maternal hemodynamic instability / severe postpartum hemorrhage, placental abruption, placenta previa, or cord avulsion.
     • Known severe fetal hydrops, severe maternal-fetal Rh alloimmunization (relative), or monochorionic twins with twin-to-twin transfusion syndrome (TTTS).

3. Universal Prophylactic Medications:

   • Vitamin K1 (Phytomenadione):
     • Dose & Route: $1.0\text{ mg}$ IM single dose into the anterolateral thigh (vastus lateralis) for term infants ($0.5\text{ mg}$ if birth weight $<1500\text{ g}$).
     • Rationale: Prevention of early, classic, and late Vitamin K Deficiency Bleeding (VKDB) / Hemorrhagic Disease of the Newborn.
   • Ophthalmic Prophylaxis (Erythromycin 0.5% or Tetracycline 1% or Povidone-Iodine 2.5%):
     • Dose & Route: A $1\text{-cm}$ ribbon of $0.5\%$ Erythromycin ophthalmic ointment instilled into each lower conjunctival sac within 1 hour of birth.
     • Rationale: Prevention of ophthalmia neonatorum caused by Neisseria gonorrhoeae.
   • Hepatitis B Vaccine (Birth Dose):
     • Dose & Route: $0.5\text{ mL}$ ($10\ \mu\text{g}$) IM in the contralateral anterolateral thigh within 24 hours of birth.
     • Rationale: Prevention of vertical mother-to-child transmission of Hepatitis B virus and carrier state development.

4. Normal Physiological Vital Sign Ranges (First 2 Hours of Life):

   • Axillary Temperature: $36.5^\circ\text{C}$ to $37.5^\circ\text{C}$ ($97.7^\circ\text{F}$ to $99.5^\circ\text{F}$).
   • Heart Rate: $120\text{–}160\text{ beats/min}$ (transiently $160\text{–}180\text{ bpm}$ in the first 15–30 minutes during the initial period of reactivity; may drop to $100\text{–}120\text{ bpm}$ during sleep).
   • Respiratory Rate: $40\text{–}60\text{ breaths/min}$ (regular or transiently periodic without significant subcostal indrawing or grunting).

1. Most Likely Clinical Diagnosis:
   • Severe red scorpion sting envenomation (Mesobuthus tamulus envenomation with autonomic storm).
2. Pathophysiology of Autonomic Storm:
   • Cholinergic phase (Parasympathetic stimulation): Initial transient massive acetylcholine release via venom-mediated delay in sodium channel inactivation and blockade of voltage-gated potassium channels, manifesting as hypersalivation, vomiting, diaphoresis, bradycardia, priapism, and bronchospasm.
   • Adrenergic phase (Sympathetic storm): Profound endogenous catecholamine release (norepinephrine and epinephrine) from adrenal medulla and sympathetic nerve endings causing severe systemic vasoconstriction, systemic hypertension, myocardial strain, transient left ventricular dysfunction, pulmonary edema, and peripheral hypoperfusion.
3. Characteristic ECG Findings:
   • Tall, peaked "tented" T waves or deep T-wave inversions.
   • ST-segment elevations or depressions (mimicking acute myocardial infarction).
   • Prolonged corrected QT interval ($QT_c$).
   • Transient conduction abnormalities (sinus tachycardia, supraventricular tachycardia, ventricular premature complexes, or varying degrees of AV block).
4. Pharmacotherapy and Management:
   • Prazosin (First-line therapeutic agent):
     • Mechanism of Action: Selective post-synaptic $\alpha_1$-adrenergic receptor antagonist; decreases systemic vascular resistance (afterload reduction) and enhances cardiac index without reflex tachycardia; also suppresses phosphodiesterase.
     • Dose & Regimen: $30\ \mu\text{g/kg/dose}$ orally (or via nasogastric tube) immediately (Hour 0), repeated at 3 hours, then every 6 hours until peripheral vasoconstriction resolves and extremities become warm with normal capillary refill time. For this 10 kg child: $300\ \mu\text{g}$ ($0.3\ \text{mg}$) per dose.
   • Scorpion Antivenom (SAV):
     • Specific monovalent or polyvalent equine $F(ab')_2$ fragments given early (within 2–4 hours of sting) to neutralize circulating free venom.
     • Dose: 30 to 50 mL (typically 1 to 2 vials reconstituted in normal saline) administered intravenously over 30 minutes, combined alongside prazosin therapy.

flowchart TD
    A[Scorpion Venom Inoculation] --> B[Inactivation of Na+ Channels / Blockade of K+ Channels]
    B --> C[Neuronal Depolarization & Autonomic Storm]
    C --> D[Parasympathetic Stimulation]
    C --> E[Massive Sympathetic Stimulation]
    D --> F[Priapism, Salivation, Vomiting, Bradycardia]
    E --> G[Excess Catecholamine Release]
    G --> H[Alpha-1 Vasoconstriction: Cold Peripheries, HTN]
    G --> I[Myocardial Ischemia & Acute LV Dysfunction]
    H --> J[High SVR & Afterload Mismatch]
    I & J --> K[Cardiogenic Pulmonary Edema / Shock]
    K --> L[Treatment: Prazosin Afterload Reduction + SAV]

1. Accidental Hypothermia Classification (Swiss Staging System):
   • Stage I (Mild): Core temp $32^\circ\text{C} - 35^\circ\text{C}$; conscious, shivering vigorously, normal to elevated vitals.
   • Stage II (Moderate): Core temp $28^\circ\text{C} - 32^\circ\text{C}$; impaired consciousness, loss of shivering reflex, bradycardia.
   • Stage III (Severe): Core temp $24^\circ\text{C} - 28^\circ\text{C}$; unconscious/comatose, profound bradycardia/hypotension, ventricular arrhythmias.
   • Stage IV (Apparent death/Cardiac arrest): Core temp $< 24^\circ\text{C}$ (or $< 28^\circ\text{C}$ with asystole/VF); absent vital signs.
2. Mechanism of Hematologic Derangements:
   • Severe hypothermia causes thrombocytopenia secondary to:
     • Acute splenic and hepatic sequestration of circulating platelets.
     • Direct cold-induced bone marrow suppression and inhibition of megakaryopoiesis.
     • Coexisting consumptive coagulopathy / disseminated intravascular coagulation (DIC).
   • Platelet dysfunction also occurs due to reduced temperature-dependent synthesis of thromboxane $A_2$ and impaired glycoprotein Ib-IX-V/vWF interaction, resulting in a marked bleeding diathesis despite hemoconcentration.
3. Pathognomonic ECG Finding:
   • Osborn wave (J wave): An extra positive deflection occurring at the J-point (junction between the terminal QRS complex and the beginning of the ST segment), whose height correlates directly with the depth of hypothermia.
4. Rewarming Protocols & Target Rate:
   • Active Internal Core Rewarming:
     • Administration of warmed IV fluids ($38^\circ\text{C} - 42^\circ\text{C}$).
     • Humidified warmed inhaled oxygen via endotracheal tube ($40^\circ\text{C} - 42^\circ\text{C}$).
     • Cavitary lavage (pleural, peritoneal, or bladder irrigation) with warm isotonic saline ($38^\circ\text{C} - 40^\circ\text{C}$) or Extracorporeal Life Support (ECLS / VA-ECMO / CPB) if refractory arrest or severe hemodynamic instability.
   • Active External Rewarming:
     • Forced-air warming blankets (e.g., Bair Hugger) focused on the trunk/core first (to prevent peripheral vasodilation-induced "core temperature afterdrop" and "rewarming shock").
   • Target Rewarming Rate:
     • Rewarm at $0.5^\circ\text{C} \text{ to } 1.0^\circ\text{C}$ per hour to prevent sudden peripheral vasodilatory collapse, severe electrolyte shifts, and rebound hyperkalemia.

1. Clinical Interpretation of Signs:
   • Effortless tachypnea: Represents respiratory compensation (Kussmaul-type breathing) for underlying severe metabolic acidosis (blowing off carbon dioxide to lower $PaCO_2$), in the absence of primary pulmonary parenchymal or airway pathology.
   • Earliest sign of circulatory compromise: Sinus tachycardia (heart rate: 168/min), representing sympathetic compensation to preserve cardiac output in compensated hypovolemia.
2. Mechanisms of Metabolic Acidosis in Diarrheal Dehydration:
   • Direct gastrointestinal loss of sodium bicarbonate ($HCO_3^-$) in copious alkaline watery stools.
   • Prerenal azotemia / acute renal hypoperfusion leading to impaired renal tubular excretion of fixed hydrogen ions ($H^+$) and decreased phosphate/sulfate clearance.
   • Lactic acidosis secondary to tissue hypoperfusion and anaerobic metabolism in hypovolemia.
3. WHO Plan C Resuscitation Protocol (Age $\ge$ 12 months, Weight: 10 kg):
   • Fluid of choice: Ringer's Lactate (Hartmann's Solution) or Normal Saline ($0.9\%\ \text{NaCl}$) if Ringer's Lactate is unavailable.
   • Total Volume: $100\ \text{mL/kg} = 100 \times 10\ \text{kg} = 1000\ \text{mL}$.
   • Infusion Schedule (for children $\ge 1$ year of age):
     • First Step ($30\ \text{mL/kg}$): $300\ \text{mL}$ given rapidly over 30 minutes.
     • Second Step ($70\ \text{mL/kg}$): $700\ \text{mL}$ given slowly over 2.5 hours.
   • Monitoring: Reassess hydration status every 15–30 minutes until strong radial pulse returns, then every hour.
4. Vascular Thrombotic Complication:
   • Renal vein thrombosis (RVT).

1. Equations for Oxygen Content and Delivery:
   $$CaO_2 = (\text{Hemoglobin [g/dL]} \times 1.34 \times SaO_2) + (PaO_2 \times 0.0031)$$
   $$DO_2 = Cardiac\ Output\ (CO\ [\text{L/min}]) \times CaO_2\ (\text{mL/dL}) \times 10$$
2. Mathematical Calculations:
   $$ > \begin{aligned} > CaO_2 &= (10 \times 1.34 \times 0.95) + (80 \times 0.0031) \\ > &= 12.73 + 0.248 \\ > &= \mathbf{12.98\ \text{mL/dL}} \quad (\text{Reference Range: } 16 - 20\ \text{mL/dL}) > \end{aligned} > $$
   $$ > \begin{aligned} > DO_2 &= 2.0\ \text{L/min} \times 12.98\ \text{mL/dL} \times 10 \\ > &= \mathbf{259.6\ \text{mL/min}} > \end{aligned} > $$
   (Indexed $DO_2I$: For $BSA \approx 0.65\ \text{m}^2$, $DO_2I = 399.4\ \text{mL/min/m}^2$; Reference Range: $400 - 600\ \text{mL/min/m}^2$)
3. Dynamic Parameters for Fluid Responsiveness:
   • Stroke Volume Variation ($SVV > 10 - 13\%$).
   • Pulse Pressure Variation ($PPV > 13\%$).
   • Inferior Vena Cava (IVC) Distensibility Index ($> 18\%$ in mechanically ventilated patients).
   • Aortic blood flow velocity peak variation ($\Delta Vpeak > 12\%$).
4. Resuscitation Monitoring Endpoints:
   • Microcirculatory / Clinical Endpoints:
     • Capillary refill time $\le 2$ seconds.
     • Peripheral skin temperature / peripheral-to-core temperature difference ($\Delta T < 2^\circ\text{C}$).
     • Adequate urine output ($\ge 1\ \text{mL/kg/hr}$).
   • Global Biochemical Endpoints:
     • Central venous oxygen saturation ($ScvO_2 \ge 70\%$).
     • Normalization of blood lactate ($< 2\ \text{mmol/L}$) or lactate clearance $> 10 - 20\%$ over 2 hours.

1. "RIGHT" First-Aid Protocol:
   • R: Reassure the patient (panic and agitation accelerate venom absorption through tachycardia and lymphatic pumping).
   • I: Immobilize the bitten limb using a splint or sling (keep movement to a minimum; do NOT apply tight arterial tourniquets, do not incise, suction, or apply potassium permanganate/herbal pastes).
   • G: Get to the hospital immediately (rapid transport to an emergency facility where antivenom and resuscitation are available).
   • H: Hospital arrival confirmation (avoid traditional healers or alternative delay tactics).
   • T: Tell the healthcare provider about all systemic symptoms, changes in urine color, eyelid drooping, or bleeding tendencies.
2. 20-Minute Whole Blood Clotting Test (20WBCT):
   • Procedure:
     • Collect $2 - 3\ \text{mL}$ of fresh venous blood via an aseptic venipuncture using a clean, dry, silicone-free glass test tube (plastic tubes must NEVER be used).
     • Leave the tube completely undisturbed at ambient room temperature in an upright position for exactly 20 minutes.
     • At 20 minutes, gently tilt the tube to nearly $90^\circ$ (horizontal) to inspect for clot formation.
3. Interpretation & Frequency:
   • Abnormal (Positive) Test: The blood remains completely liquid / fails to form a solid clot when tilted, indicating venom-induced consumptive coagulopathy (fibrinogen depletion caused by prothrombin activators or thrombin-like enzymes).
   • Repeating Frequency:
     • On arrival: Perform immediately.
     • If negative initially: Repeat every 30 minutes for the first 2 hours, then hourly for at least 6 to 12 hours.
     • Post-ASV administration: Repeat every 6 hours after the completion of the ASV infusion (takes 6 hours for liver to resynthesize clotting factors).
4. Polyvalent ASV Protocol in Children:
   • Initial Dose: 10 vials (pediatric patients receive the exact same dose as adults, as snakes inject the absolute same quantity of venom regardless of patient body mass).
   • Reconstitution & Dilution: Reconstitute 10 vials in $5 - 10\ \text{mL}$ of sterile water per vial; dilute the total reconstituted solution in $5 - 10\ \text{mL/kg}$ (up to $100 - 250\ \text{mL}$) of Normal Saline ($0.9\%$) or $5\%$ Dextrose.
   • Infusion Rate: Infuse slowly at $1\ \text{mL/min}$ for the first 10–15 minutes while vigilantly monitoring for early anaphylactoid reactions; if no adverse reactions develop, run the remainder over 60 minutes.

1. Test Name and Principle:
   • Test: Fast-flush test / Square-wave test.
   • Principle: Rapid flushing delivers a high-pressure square wave into the closed transducer system. Releasing the flush induces resonant oscillations, allowing assessment of the dynamic response characteristics—specifically the natural frequency ($f_n$) and damping coefficient ($\zeta$) of the fluid-filled monitoring circuit.
2. Waveform Interpretation:
   • Waveform A (Adequate / Optimal Damping): Demonstrates 1.5 to 2 oscillations below and above the baseline with a rapid return to the physiological arterial waveform; dynamic response is optimal.
   • Waveform B (Underdamped / Ringing): Demonstrates $>2$ excessive, sharp oscillations with high resonant frequency before returning to baseline.
   • Waveform C (Overdamped): Demonstrates $<1.5$ oscillations (sluggish upstroke, rounded peak, loss of dicrotic notch) returning slowly to baseline.
3. Effect on Measured Blood Pressure Values:
   • Underdamping:
     • SBP: Falsely elevated (overestimated) due to overshoot.
     • DBP: Falsely decreased (underestimated).
     • MAP: Remains largely accurate (unaffected).
   • Overdamping:
     • SBP: Falsely decreased (underestimated).
     • DBP: Falsely elevated (overestimated).
     • MAP: Remains largely accurate (unaffected).
4. Causes of Overdamping and Corrective Measures:
   • Causes: Air bubbles within the tubing or transducer dome, blood clot or fibrin at the catheter tip, loose or compliant extension tubing, kinking of the catheter or tubing, or pressure bag deflation ($<300\text{ mmHg}$).
   • Bedside Corrective Measures:
     • Check and purge all air bubbles from the transducer dome and rigid tubing.
     • Aspirate (do not flush) to check for and clear intraluminal thrombi; if unobstructed, flush gently.
     • Ensure pressure bag is inflated to $300\text{ mmHg}$.
     • Eliminate compliant connectors, redundant stopcocks, and long extension lines; straighten any kinks.

graph TD
    A[Arterial Line Waveform Inaccuracy] --> B[Perform Fast-Flush Square-Wave Test]
    B --> C{Number of Post-Flush Oscillations}
    C -->|1.5 to 2 Oscillations| D[Optimal Damping: Values Reliable]
    C -->|>2 Oscillations / High Peak| E[Underdamped System]
    C -->|<1.5 Oscillations / Sluggish| F[Overdamped System]
    E --> G[Insert Resonator / Damping Device; Remove Extra Tubing]
    F --> H[Check Pressure Bag 300 mmHg; Purge Air Bubbles; Aspirate Clots]

1. Clinical Definition:
   • Status Asthmaticus (Acute Severe Asthma Refractory to Standard Therapy): A severe, life-threatening exacerbation of asthma characterized by progressive bronchospasm, airway inflammation, and mucus plugging that fails to respond adequately to initial repetitive doses of inhaled short-acting $\beta_2$-agonists and systemic corticosteroids.
2. Oxygen Therapy Goal & Hazard:
   • Target $\text{SpO}_2$: Maintain oxygen saturation between $94\%\text{--}98\%$ using humidified high-flow oxygen via nasal cannula or non-rebreather mask.
   • Physiological Hazard: Excessive, uncontrolled hyperoxia ($\text{PaO}_2 > 100\text{ mmHg}$) worsens ventilation-perfusion ($\dot{V}/\dot{Q}$) mismatch by abolishing compensatory hypoxic pulmonary vasoconstriction in poorly ventilated lung units, leading to increased dead space ventilation and progressive hypercapnia.
3. Pulmonary Air-Leak Complications:
   • Tension pneumothorax.
   • Pneumomediastinum (with or without subcutaneous emphysema).
4. Emergency Pharmacological Regimen:
   • Systemic Corticosteroids:
     • Intravenous Methylprednisolone: $1\text{--}2\text{ mg/kg}$ IV bolus (or Hydrocortisone $4\text{ mg/kg}$ IV every 6 hours; maximum initial methylprednisolone dose $60\text{ mg}$).
   • Inhaled Anticholinergic Therapy:
     • Ipratropium bromide: $250\text{ }\mu\text{g}$ via jet nebulizer combined with Salbutamol ($2.5\text{ mg}$) every 20 minutes for 3 doses, then every 2 to 4 hours.
   • Intravenous Magnesium Sulfate:
     • Dose: $50\text{ mg/kg}$ IV (maximum $2\text{ g}$) infused over 20 to 30 minutes with continuous ECG and blood pressure monitoring.
   • Continuous $\beta_2$-Agonist Infusion (if refractory to above):
     • Intravenous Terbutaline: Loading dose $2\text{--}10\text{ }\mu\text{g/kg}$ IV over 10 minutes, followed by continuous infusion at $0.1\text{--}4\text{ }\mu\text{g/kg/min}$, OR continuous nebulized salbutamol at $0.5\text{ mg/kg/hour}$ (maximum $15\text{ mg/hour}$).

1. Cardiac Rhythm:
   • Severe / Symptomatic Sinus Bradycardia (with progression toward cardiopulmonary failure / pre-arrest rhythm).
2. Reversible Contributing Factors ("Hs" and "Ts"):
   • Hypoxia / Hypoxemia (the most common trigger in infants).
   • Hypovolemia / Shock.
   • Hypothermia.
   • Hydrogen ion excess (Acidosis) or Hyperkalemia / Hypokalemia.
   • Tension pneumothorax or Tamponade (Cardiac).
3. Immediate Management & Resuscitation Threshold:
   • First-line step: Support airway, provide immediate positive pressure ventilation (PPV) with $100\%\text{ O}_2$ using a bag-valve-mask, and ensure adequate oxygenation.
   • Chest Compression Threshold: Initiate cardiopulmonary resuscitation (CPR) with chest compressions if the heart rate remains $<60\text{ beats/minute}$ with signs of poor systemic perfusion despite at least 30 seconds of effective ventilation and oxygenation.
4. Primary Pharmacotherapy:
   • Drug: Epinephrine (Adrenaline).
   • Route: Intravenous (IV) or Intraosseous (IO).
   • Dose: $0.01\text{ mg/kg}$ ($0.1\text{ mL/kg}$ of $1:10,000$ concentration [0.1 mg/mL]); maximum single dose $1\text{ mg}$. Repeat every 3 to 5 minutes if bradycardia and poor perfusion persist.
   • (Note: Atropine $0.02\text{ mg/kg}$ [minimum $0.1\text{ mg}$, maximum $0.5\text{ mg}$] is reserved for suspected increased vagal tone, primary AV block, or organophosphate poisoning).

graph TD
    A[Symptomatic Bradycardia with Poor Perfusion: HR < 60/min] --> B[Support Airway, 100% Oxygen, Bag-Mask Ventilation]
    B --> C{HR remains < 60/min despite adequate oxygenation/ventilation?}
    C -->|No| D[Continue ventilation, monitor, evaluate etiology]
    C -->|Yes| E[Initiate Chest Compressions + CPR]
    E --> F[Obtain IV/IO Access]
    F --> G[Epinephrine: 0.01 mg/kg IV/IO 1:10,000 every 3-5 min]
    G --> H{Suspected Vagal Tone or AV Block?}
    H -->|Yes| I[Atropine: 0.02 mg/kg IV/IO; min 0.1 mg, max 0.5 mg]
    H -->|No| J[Identify & Treat Hs and Ts: Hypoxia, Hypothermia, Acidosis, Hypovolemia]

1. Diagnosis and Shock Subtype:
   • Primary Diagnosis: Right-sided Tension Pneumothorax.
   • Physiological Subtype of Shock: Obstructive Shock (caused by severe reduction in venous return from vena caval compression and mediastinal shift).
2. Immediate Procedural Intervention:
   • Procedure: Emergency Needle Thoracocentesis / Needle Decompression.
   • Anatomical Landmarks (ATLS 10th edition / PALS):
     • Primary / Preferred Site: 2nd intercostal space in the midclavicular line (just superior to the 3rd rib to avoid the neurovascular bundle) on the affected (right) side.
     • Alternative Site: 4th or 5th intercostal space anterior to the midaxillary line on the affected side.
   • Equipment: Large-bore over-the-needle catheter (14-gauge or 16-gauge) attached to a 10-mL syringe partially filled with sterile saline to visualize air bubbles during aspiration.
3. Definitive Management:
   • Tube Thoracostomy (Intercostal Chest Drain Insertion):
     • Insertion of a sterile, dedicated chest tube (size 20–24 Fr for a 6-year-old child) positioned at the "triangle of safety" in the 5th intercostal space anterior to the midaxillary line, directed apically and posteriorly.
     • Connect catheter to an underwater seal drainage system with continuous negative pressure suction ($-10\text{ to } -20\text{ cmH}_2\text{O}$).
4. Signs Confirming Successful Decompression:
   • Audible rush of pressurized air exiting through the needle/cannula.
   • Immediate rise in systemic blood pressure and deceleration of tachycardia.
   • Rapid improvement in oxygen saturation ($\text{SpO}_2$) and clearing of cyanosis.
   • Symmetrical chest excursion and return of audible vesicular breath sounds on the affected hemithorax.

1. UAC Position Levels and Hazard of Intermediate Zone:
   • High UAC Position: Thoracic vertebral levels T6 to T9 (above the origin of the celiac trunk and superior mesenteric artery; safely below the ductus arteriosus).
   • Low UAC Position: Lumbar vertebral levels L3 to L5 (below the origin of the inferior mesenteric artery and above the aortic bifurcation).
   • Hazard of Intermediate Zone (T10 to L2): Avoided because it houses the visceral arterial branches—celiac axis (T12), superior mesenteric artery (L1), and renal arteries (L1–L2). Catheter tip location here causes renovascular thrombosis, acute renal infarction, hypertension, and necrotizing enterocolitis.
2. UVC Radiographic Landmark and Anatomical Pathway:
   • Ideal Position: At the junction of the inferior vena cava (IVC) and right atrium (radiographically corresponding to the level of the diaphragm or T8–T9 vertebral bodies).
   • Anatomical Course: Umbilical ring $\rightarrow$ Umbilical vein $\rightarrow$ Left branch of the portal vein $\rightarrow$ Ductus venosus $\rightarrow$ Middle/left hepatic vein $\rightarrow$ Inferior vena cava.
3. Calculation of UAC Insertion Depth:
   $$ > \begin{aligned} > \text{High UAC Depth (Morphometric formula)} &= (\text{Shoulder-to-Umbilicus Distance in cm} \times 0.77) + 3.0\text{ cm} \\ > \text{High UAC Depth (Weight-based Shukla formula)} &= [\text{Birth Weight (kg)} \times 3] + 9\text{ cm} \\ > &= (1.050 \times 3) + 9 \\ > &= 3.15 + 9 = \mathbf{12.15\text{ cm}} \quad (\text{Target: } 12.0\text{--}12.5\text{ cm}) > \end{aligned} > $$
4. Management of Lower Extremity Blanching / Vasospasm:
   • Step 1: Apply a warm, moist compress to the contralateral uncompromised lower limb (reflex vasodilation). Do not place hot packs directly onto the ischemic limb.
   • Step 2: Inspect catheter for tight fixation sutures, excessive tension, or kinking; reposition or loosen if identified.
   • Step 3: If blanching fails to resolve within 15 to 30 minutes, or if limb ischemia progresses, immediately remove the umbilical arterial catheter under aseptic technique and re-site elsewhere.

1. CT Thorax Findings:
   • Severe extrinsic circumferential or posterior compression of the mid-to-lower trachea resulting in slit-like luminal narrowing.
   • Presence of an encircling or aberrant vascular structure compressing both the trachea and the esophagus.
2. Definitive Diagnosis & Etiologies:
   • Diagnosis: Complete Vascular Ring (causing extrinsic tracheoesophageal compression).
   • Etiologies:
     • Double Aortic Arch (most common complete vascular ring, typically with a dominant right arch).
     • Right Aortic Arch with aberrant left subclavian artery and persistent left ligamentum arteriosum.
     • Pulmonary Artery Sling (aberrant left pulmonary artery originating from right pulmonary artery).
3. Airway Dynamics Comparison:
   • Extrathoracic Airway Obstruction: Transmural pressure becomes negative during inspiration, causing dynamic airway collapse and predominantly inspiratory stridor.
   • Intrathoracic Airway Obstruction: Pleural pressure becomes positive during forced expiration relative to luminal pressure, causing dynamic collapse and predominantly expiratory stridor / wheezing.
   • Fixed Vascular Compression: Complete rings produce a non-compliant fixed ring, causing biphasic stridor unaltered by respiratory phases.
4. Management & Preoperative Workup:
   • Definitive Management: Surgical division of the non-dominant/hypoplastic aortic arch or ligamentum arteriosum through a left posterolateral thoracotomy (or median sternotomy for pulmonary artery sling reimplantation).
   • Essential Preoperative Investigations:
     • Echocardiography: To delineate intracardiac anatomy, arch sidedness, and branching patterns.
     • Flexible/Rigid Bronchoscopy: To assess severity of tracheomalacia, evaluate vocal cord mobility, and exclude complete tracheal cartilaginous rings.

graph TD
    A[Suspected Vascular Ring / Sling] --> B[Echocardiography]
    B --> C[CT Angiography / MR Angiography]
    C --> D{Anatomy Defined}
    D -->|Double Aortic Arch| E[Divide Non-Dominant Arch + Ligamentum]
    D -->|Right Arch + Aberrant LSCA| F[Divide Ligamentum Arteriosum]
    D -->|Pulmonary Artery Sling| G[Reimplant Left PA onto MPA]
    C --> H[Bronchoscopy to Exclude Associated Tracheomalacia]

1. Cardiac Events:
   • Point A: Mitral valve closure (marking the onset of isovolumetric ventricular contraction / end-diastole).
   • Point B: Aortic valve opening (marking the end of isovolumetric contraction and onset of ventricular ejection).
2. Segment BC Dynamics:
   • Phase: Ventricular ejection phase (rapid and reduced ejection).
   • Effect of Increased Afterload:
     • Point B shifts upward (higher pressure required to open aortic valve).
     • Peak systolic pressure increases.
     • Segment BC shortens horizontally because End-Systolic Volume (ESV) increases, leading to a reduced stroke volume.
3. Therapeutic Strategies:
   • Afterload Reduction (Inodilators / Vasodilators): Infusion of Milrinone (0.25–0.75 mcg/kg/min IV) or Sodium Nitroprusside (0.5–3 mcg/kg/min IV) lowers systemic vascular resistance, shifting the end-systolic PV relationship leftward and expanding width of the loop.
   • Preload Optimization: Controlled volume expansion increases End-Diastolic Volume (EDV), shifting Point A rightward along the EDPVR curve to augment stroke volume via the Frank-Starling mechanism.
4. Mathematical Derivation:
   $$ > \begin{aligned} > \text{Stroke Volume (SV)} &= \text{EDV} - \text{ESV} \\ > &= 60\text{ mL} - 24\text{ mL} \\ > &= \mathbf{36\text{ mL}} \\[10pt] > \text{Ejection Fraction (EF)} &= \frac{\text{SV}}{\text{EDV}} \times 100 \\ > &= \frac{36}{60} \times 100 \\ > &= \mathbf{60\%} \quad (\text{Normal: } 55\text{--}70\%) \\[10pt] > \text{Left Ventricular Stroke Work (LVSW)} &\approx \text{SV} \times \text{MAP} \\ > &= 36\text{ mL} \times 65\text{ mmHg} \\ > &= \mathbf{2340\text{ mmHg}\cdot\text{mL}} \quad (\text{or } 2340 \times 0.0136 = \mathbf{31.8\text{ g}\cdot\text{m}}) > \end{aligned} > $$

1. Device Identification & Mechanism:
   • Devices: Linear Peristaltic Volumetric Infusion Pump (large volume) and Syringe Micro-Infusion Driver.
   • Mechanical Difference:
     • Volumetric pump: Uses peristaltic rollers or linear finger cassettes compressing specialized IV tubing to propel fluid; ideal for moderate-to-high hourly delivery volumes (>10 mL/hr).
     • Syringe driver: Uses an electric stepper motor driving a precision lead screw to advance the plunger of a prefilled syringe; delivers highly accurate, pulseless micro-infusions at low rates (0.1–10 mL/hr).
2. Mandatory High-Alert Indications:
   • Continuous inotrope/vasopressor infusions (e.g., epinephrine, norepinephrine, dopamine).
   • Concentrated electrolyte infusions (e.g., 3% Sodium Chloride, Potassium Chloride).
   • Continuous intravenous insulin therapy for diabetic ketoacidosis.
   • Continuous intravenous sedatives, opioids, or neuromuscular blocking agents.
3. Built-in Safety Alarm Mechanisms:
   • Upstream / Downstream Occlusion Alarm: Triggered by piezoelectric pressure sensors detecting line kink, cannula thrombosis, or closed stopcocks exceeding preset psi thresholds.
   • Air-in-Line Ultrasonic Alarm: Piezoelectric ultrasonic crystals detect micro air bubbles within the tubing cassette to prevent air embolism.
   • Free-Flow Protection Mechanism: Mechanical clamp automatically engages upon opening the pump door to prevent gravitational free-flow.
4. Mathematical Derivation:
   $$ > \begin{aligned} > \text{Patient Dose Rate} &= 0.15\text{ mcg/kg/min} \times 8\text{ kg} = 1.2\text{ mcg/min} \\ > \text{Hourly Dose} &= 1.2\text{ mcg/min} \times 60\text{ min/hr} = \mathbf{72\text{ mcg/hr}} \\[10pt] > \text{Concentration of Solution} &= \frac{4\text{ mg}}{50\text{ mL}} = \frac{4000\text{ mcg}}{50\text{ mL}} = \mathbf{80\text{ mcg/mL}} \\[10pt] > \text{Pump Delivery Rate} &= \frac{\text{Hourly Dose}}{\text{Concentration}} \\ > &= \frac{72\text{ mcg/hr}}{80\text{ mcg/mL}} \\ > &= \mathbf{0.9\text{ mL/hr}} > \end{aligned} > $$

1. Hallmark ECG Features:
   • Short PR interval: <120 ms in adolescents (or <lower limit of normal for age).
   • Delta wave: Slurred, slow upstroke of the initial portion of the QRS complex.
   • QRS prolongation: Widened QRS complex duration (>100–120 ms) with secondary ST-T wave discordance.
2. Electrophysiological Basis:
   • Diagnosis: Wolff-Parkinson-White (WPW) Pattern / Syndrome.
   • Substrate: Congenital accessory atrioventricular bypass tract (Bundle of Kent) that bridges atrial and ventricular myocardium, bypassing the physiological conduction delay of the AV node (causing pre-excitation).
3. Contraindicated Drugs & Hazard:
   • Contraindicated Drugs: Digoxin, Verapamil, Diltiazem, beta-blockers, and intravenous Adenosine (during pre-excited atrial fibrillation).
   • Pathophysiological Hazard: AV-nodal blocking agents selectively prolong the refractory period of the AV node without slowing accessory pathway conduction. Impulses conduct preferentially down the bypass tract, which has a shorter refractory period, accelerating ventricular rates (>250–300 bpm) and provoking degeneration into Ventricular Fibrillation (VF) and cardiac arrest.
4. Emergency Pharmacotherapy & Defibrillation:
   • Stable Orthodromic AVRT:
     • Non-pharmacological: Vagal maneuvers (ice water bag applied to face for 15–20 seconds or modified Valsalva maneuver).
     • Pharmacological: Rapid IV push Adenosine via a large-bore proximal vein: Initial dose 0.1 mg/kg (maximum 6 mg), followed immediately by a rapid 5–10 mL saline flush. If unsuccessful after 1–2 minutes, administer a second dose of 0.2 mg/kg (maximum 12 mg).
   • Hemodynamically Unstable Tachycardia:
     • Synchronized DC Cardioversion: Initial energy dose of 0.5 to 1 J/kg. If ineffective, escalate to 2 J/kg with procedural sedation if perfusion permits.

graph TD
    A[Symptomatic WPW Tachycardia] --> B{Hemodynamically Stable?}
    B -->|No: Hypotension / Shock| C[Synchronized DC Cardioversion 0.5-1 J/kg]
    B -->|Yes| D{ECG Morphology}
    D -->|Narrow QRS: Orthodromic AVRT| E[Vagal Maneuvers -> IV Adenosine 0.1 mg/kg]
    D -->|Wide QRS: Pre-excited AF / Antidromic| F[Avoid AV Nodal Blockers!]
    F --> G[IV Procainamide 15 mg/kg or DC Cardioversion]